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ABSTRACT 
Identifying and communicating a disease diagnosis has historically been 
the center of the medical encounter. Recent advances in molecular biology and 
genetics have increased the amount of care devoted to disease screening and 
risk assessment. In this era of prevention, risk itself has become a ‘problem’ 
requiring intervention where once such problems were left unidentified. Treating 
risk as a diagnosis itself allows it be treated in a familiar manner, but 
marginalizes the patient experience. It is important to understand how adopting a 
biomedical view of risk and prevention influences participation in care and patient 
willingness to engage with the medical system, despite a lack of manifest 
disease. This is a critical gap in knowledge at a time when there is increased 
emphasis on preventive medicine. 
This dissertation contains three chapters that seek to characterize how 
identifying, labeling, and developing interventions for patients ‘at risk’ affects 
service provision and use. Study 1, Explanatory Models of Risk: The Role of 
Social Context in Breast Cancer Risk Perception and Decision-Making, sought to 
characterize explanatory models of risk among women at risk for developing 
vii 
breast cancer. Qualitative interviews demonstrated the importance of perceptions 
of risk and control in combination with elements of explanatory models and social 
context in their decision-making. 
Study 2, Associations between Breast Cancer Risk and General Health 
Service Use, considered the possibility that patterns of health service utilization 
may change following a medical finding that is often perceived as increased risk. 
Results showed a greater increase in the rate of outpatient visits and referrals in 
the year following a false positive mammogram, suggesting such utilization is 
driven by both patients and providers.  
Study 3, An Assessment of Patient Navigator Activities in Breast Cancer 
Patient Navigation Programs Using a Nine-Principle Framework, described 
similarities and differences in the execution of patient navigation programs 
designed to increase engagement in care among individuals who have been 
labeled as ‘at risk’ upon having an abnormal mammogram. Activities conducted 
by navigators where shown to vary according to the local context and population 
of women that they served. 
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CHAPTER 1 : INTRODUCTION 
Increases in breast cancer screening and detection options combined with 
advances in genetics and risk assessment tools have led to clinician use of 
personalized risk estimations in order to tailor screening, prevention, and 
treatment recommendations. In this era of disease risk assessment, risk itself 
has become a ‘problem’ requiring intervention where once such problems were 
left unidentified. This dissertation examines two distinct, but related processes of 
care in the setting of breast cancer prevention. The first process is the screening 
of otherwise healthy individuals, which aims to identify potential disease at early 
stages to improve treatment outcomes. Screenings for the early detection of 
cancer have become ingrained as part of routine quality care in the United 
States, are widely adopted, and in fact rewarded (Centers for Disease Control 
and Prevention, 2012). 
The second process addressed is the use of risk assessment to engage 
‘at risk’ women in prevention. These ‘at risk’ individuals are drawn into medical 
care, labeled as patients, and often undergo medical testing and interventions.  
During this process of patient engagement, estimated individual probabilities of 
the chances of developing cancer are utilized to guide physicians in counseling 
about risk and encourage the adoption of behavioral and medical preventive 
actions. The main focus of this dissertation is on those women who have been 
identified as ‘at risk’ through either the process of screening or risk assessment. 
The broad effects of these approaches to screening and prevention have yet to 
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be studied at the individual, provider, and health system level. This is a critical 
gap in knowledge at a time when there is increased emphasis on preventive 
medicine.  
This chapter will provide a broad overview of the conceptual basis for 
studying patients who engage in screening and/or have been identified as at risk 
and how they interact with the medical system. The subsequent three chapters 
represent separate studies that seek to characterize how identifying, labeling, 
and developing interventions for patients ‘at risk’ affects service provision and 
use. The first study, Explanatory Models of Risk: The Role of Social Context in 
Breast Cancer Risk Perception and Decision-Making, characterizes explanatory 
models of risk and how perceptions of risk and control contribute to risk-reduction 
behaviors in women who are at high risk of developing breast cancer. The 
second study, Associations between Breast Cancer Risk and General Health 
Service Use, considers the possibility that patterns of health service utilization 
may change following a medical finding that could be perceived as increased 
risk. Finally, An Assessment of Patient Navigator Activities in Breast Cancer 
Patient Navigation Programs Using a Nine-Principle Framework, describes 
similarities and differences in the execution of patient navigation programs that 
are designed to increase engagement in care among minority and hard-to-reach 
individuals who have been labeled as ‘at risk’ upon having an abnormal 
mammogram.  
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Biomedical Views of Risk and Prevention 
Identifying and communicating a disease diagnosis has historically been 
the center of the medical encounter (Christakis, 1997). Providing a diagnosis 
allows the patient and doctor to work towards a resolution within a defined 
framework. The import given to the diagnosis process renders the concept of 
prevention more difficult to manage within a medical encounter, as it doesn’t fit 
the framework of diagnosing and subsequently treating identified disease. 
Further, a focus on risk for developing disease introduces an element of 
diagnostic uncertainty in that it represents a state without experienced symptoms 
or disease classification.  Some argue that extended periods of uncertainty 
require significant interpretive work by patients and providers to maintain a state 
between health and disease with efforts expended to try and resolve it 
(Timmermans & Buchbinder, 2010). One way that this uncertainty has been 
managed is through the creation of a new category of diagnosis, that of being ‘at 
risk’ for disease development. Treating risk as a diagnosis allows the assignment 
of a category with associated actions that can be initiated, fitting within the 
existing process of diagnosis and treatment.  
  It is important to understand how adopting a biomedical view of risk and 
prevention influences participation in care and patient willingness to engage with 
the medical system, despite a lack of manifest disease. In particular, the focus on 
molecular changes in human biology as indicators of disease neglects the patient 
experience of risk and disease. Understanding how these perspectives are 
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integrated may help elucidate how individuals interpret medical information and 
make decisions about prevention under conditions of being ‘at risk’.  
  
Conceptual Model 
In order to understand the complex multilevel relationships that promote 
individual engagement in health services, a conceptual framework based on the 
Behavioral Model (Andersen, 1995) was developed to guide this research.  The 
model can be seen in Figure 1.1. First, I will discuss the three contexts represented 
in the model (shaded in gray): the health system context, the social and cultural 
context, and public discourse. Subsequently each element of the model will be 
described, beginning with predisposing characteristics and enabling factors, 
followed by perception of individual risk, perception of individual need, provider 
recommendations, and medical events. 
 
Figure 1.1: Modeling Influences on Risk Perceptions and Health Service Use 
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Contexts 
I begin with a discussion of 3 salient contexts represented in this model: the 
health system context, the individual’s social and cultural context, and public 
discourse, as these three interact to influence most other domains, which are 
described in further detail below. There are several levels of context that affect 
decision making in a risk setting. This model demonstrates that the processes 
driving perception and use are taking place at the intersection of social/cultural, 
health system, and public discourse contexts.  Beliefs, appraisals, and feelings are 
modified over time within each context and through participation in health care 
and experiences with illness outside of the healthcare system. There is relatively 
little understanding on how the health system’s focus on treating risk and disease 
integrates with the patient experience of being ‘at risk’ as situated in their own 
social and cultural context.  With a diagnosis in place, a set of experiences, 
identities, life strategies, and medical actions are initiated by the patient that 
represents both the social and biological aspects of health. Some qualitative 
studies have characterized patients who become engaged in care without 
manifest disease as ‘partial patients’ (Greaves, 2000), ‘patients-in-waiting’ 
(Timmermans & Buchbinder, 2010), or the experience as ‘measured vulnerability’ 
(Gillespie, 2012). These studies highlight one of the challenges for patients ‘at 
risk’: to take population-level risk estimates and integrate them with personal 
information in order to form a perception of personal risk. This is inherently 
difficult, and is influenced by predisposing and enabling factors as well as social 
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and health system contexts.  
Experiences in each of these contexts generate heuristics, which are 
patterns of beliefs and knowledge based on experience that simplify the complex 
task of prediction to a simpler judgmental operation (Tversky & Kahneman, 
1974). Individuals draw upon these heuristics to make decisions and it is 
therefore important to examine the contexts in which they are formed. Because 
probability has no equivalent experience on a personal level, these perceptions 
and reliance on simple heuristics often result in a determination of being either 
healthy or not healthy (Olin-Lauritzen & Sachs, 2001). Producing a healthy/not 
healthy dichotomous determination may result in heightened perceptions of risk 
for disease (Loewenstein, Weber, Hsee, & Welch, 2001).  
 
Health System Context 
Providers bring their experiences within the health system context to bear 
in clinical decisions. Being embedded in a health systems context affects 
recommendations to patients at risk through policies and incentives including 
organizational features, economic incentives, malpractice experience, and 
system advocacy (Kaczorowski et al., 2013). This context in which providers 
operate likewise produces a set of heuristics by which providers make judgments 
and decisions for individual patients.   
One of the major features of the health system context that influences 
providers’ management of ‘at risk’ patients is the previously discussed biomedical 
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focus on risk as a disease. Individuals are no longer required to be afflicted with 
a disease to engage with providers, but are instead encouraged to attend visits 
under healthy conditions. One mechanism by which healthy individuals engage in 
care is through annual ‘well’ visits. A recent meta-analysis found that the use of 
these visits lead to an increased number of new diagnoses, yet did not have any 
effect on morbidity and mortality (Krogsbøll, Jørgensen, Grønhøj Larsen, & 
Gøtzsche, 2012). However, ‘well’ visits provide opportunities for providers to 
identify otherwise healthy individuals as ‘at risk’ for a variety of conditions and 
counsel patients on managing this risk. In establishing risk as a diagnosis in 
itself, the medical enterprise has developed processes for keeping ‘at-risk’ 
individuals engaged in care through surveillance, which itself implies some notion 
of risk or threat (Olin-Lauritzen & Sachs, 2001).  
Once identified as ‘at risk’, providers counsel patients to adopt lifestyle 
changes, engage in disease screenings, take medications or undergo risk-
reduction procedures. These activities parallel the experience of treating for 
disease, yet without the accompanying illness experience of the patient. While 
there is the presumption that these preventive activities are beneficial in terms of 
reducing morbidity and mortality, there is insufficient evidence to demonstrate 
this, particularly once harms of overtreatment, over-diagnosis, and risks of 
interventions are accounted for (Krogsbøll et al., 2012). For example, breast 
cancer screening in the United States has an estimated rate of over-diagnosis of 
approximately 31%, with screening producing little effect on mortality from breast 
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cancer (Bleyer & Welch, 2012; Miller et al., 2014). Nonetheless, providers are 
working within a setting where screening, risk assessment, and prevention are 
encouraged through cultural framing of disease and/or organizational incentives 
for treating ‘at risk’ patients. This perspective focuses on the goals of medicine at 
the expense of the patient experience, where patients themselves may feel 
healthy and prefer not to seek such care. The focus of Chapter 4 is on how one 
particular health care delivery intervention, patient navigation, is utilized by 
hospitals and clinics to engage those defined as ‘at risk’ to further instantiate 
them as patients to receive perceived needed care.  
 
Social and Cultural Contexts 
Understanding the broader social and cultural contexts in which people of 
different social groups and ethnicities conceptualize ‘being at risk’ and the 
meaning they attribute to cancer is important. An individual’s social and cultural 
context may influence decisions through interpretations of broad media 
messages about cancer, health, and risk, local community beliefs, and personal 
experiences with family and friends that create biases of representativeness or 
availability. There are many examples of how particular risks may become 
amplified or attenuated at the individual level based on what people acquire from 
the social world around them (Pidgeon, Kasperson, & Slovic, 2003). Social and 
cultural processes shape how individuals perceive threats and define a range of 
possibilities for action. 
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The everyday lived context of the individual is important because it is the 
context in which individuals make sense of and find meaning in risk.  In the case 
of breast cancer where heredity is strongly associated with risk of breast cancer, 
family ties and social support may provide support for adopting a risk identity. It 
has been well documented that risk perceptions are influenced by the health 
experiences of families and other social contexts and that women make 
associations based on family history differently than do medical providers (Davis, 
Stewart, & Bloom, 2004; Haber, Ahmed, & Pekovic, 2012; Lim & Hewison, 2014). 
Likewise, women with mothers, sisters, or other family members who have had a 
diagnosis of breast cancer can be influenced by the experience of being in close 
contact with their family member’s illness experience.  Women also look for 
similarity between themselves and others in both assessing risk and whether or 
not to undergo screening regimens (Pfeffer, 2004). Other factors such as 
fatalistic beliefs that are prevalent in particular cultural contexts influence 
engagement in certain types of care, such as screening or genetic counseling for 
risk (Mayo, Ureda, & Parker, 2001; Parrott, Silk, & Condit, 2003). The individual 
social contexts here contribute to the salience of breast cancer risk within a 
woman’s life, affecting personal assessments about risk and the acceptability of 
engaging with the medical system to prevent future disease. 
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Public Discourse 
A third context influencing both patients and providers’ social contexts is 
the public discourse.  An examination of the public rhetoric on breast cancer 
describes a narrative that constructs “an idealized patient identity that serves a 
prescriptive function for women and situates all women as being “at risk” for 
breast cancer” (Davis, 2008). This discourse has established a model version of 
how to behave as someone at risk for breast cancer and what may be expected 
of medical providers. This narrative plays out in public discourse and is an 
example of a bias that may influence patient and provider decisions about 
preventive treatment. For example, once individuals are provided with the 
knowledge that they are ‘at risk’, there is an underlying assumption that each will 
take the proposed steps to maintain health and prevent disease (Koch & Nordahl 
Svendsen, 2005). When individuals do not follow the prescribed ‘treatment’, there 
may be a tendency to blame those who develop disease for their own choices or 
inability to prevent its occurrence. Thus a moral imperative for prevention has 
been established (Koch & Nordahl Svendsen, 2005), with public health 
messaging reinforcing its importance (i.e. “Early detection saves lives”). In this 
era of patient-centered care, an examination of public messaging around cancer 
screenings is warranted, especially in light of low rates of engagement in certain 
preventive behaviors (Waters, Cronin, Graubard, Han, & Freedman, 2010) and 
screening rates not meeting Healthy People 2020 targets (Centers for Disease 
Control and Prevention, 2012).  
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Together, these three contexts create an environment in which individual 
perceptions are formed and decisions are made about participation in prevention. 
The health system context’s influence on providers more explicitly encourages 
particular behaviors through incentives built into organizations that reward 
providers for adopting a focus on prevention and screening. Elements of this 
health system context are examined in Chapters 3 and 4 by focusing on how 
abnormal mammograms can generate provider referrals and how the use of lay 
health navigators can promote engagement in the screening process among at 
risk populations. The social and cultural context of the patient brings together a 
diverse set of influences and experiences and is unique to each individual. While 
it poses challenges for research in this area, it is nonetheless important to 
identify contextual factors that impact both perceptions and subsequent 
behaviors. This is the focus of Chapters 2 in which women’s risk perceptions and 
decision-making processes related to risk reduction therapy are studied. Finally, 
the public discourse context is an underlying element that while not examined in 
this dissertation, disseminates powerful messages that define boundaries for 
acceptable prevention strategies and behaviors for both patients and providers.  
 
Enabling Factors and Predisposing Characteristics 
The Behavioral Model (Andersen, 1995) suggests that predisposing and 
enabling factors drive the utilization of health services in concert with both 
perceived and evaluated needs. Predisposing factors such as race, ethnicity, 
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genetics, and lifestyle are seen as important predictors of use, but relatively 
immutable. Genetics is a particularly important predisposing factor in this context, 
given the emphasis on the genetic component of breast cancer and its subsequent 
influence on both evaluated and perceived need. Enabling resources represent 
generally more mutable characteristics of the individual, as well as community 
attributes and include factors such as social support, income, health status, and 
education. Both pre-disposing factors and enabling resources influence the 
individual’s perception of need as situated in particular social and cultural contexts 
unique to each individual. For example, low-income minority women presenting for 
care in a community health center may face barriers to access in obtaining 
screening, risk assessment and/or risk-reduction interventions due to limited 
resources in these settings, lack of insurance coverage, or competing health 
demands (Anderson & Hoskins, 2012). Alternatively, these women may hold 
personal values and beliefs about risk and breast cancer that influence perceptions 
of their own risk and their perceived need for screening and/or preventive services. 
These beliefs or perceptions may not align with provider recommendations and 
therefore these women may be less likely to engage in health services related to 
risk, even if the medical system has determined risk and a need for intervention. 
This model provides a framework for evaluating the varied factors that predispose 
one to access care associated with risk assessment and treatment. Chapter 3 
specifically examines some of these predisposing factors and enabling resources 
as they relate to the screening of women and their use of health services. 
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Perception of Individual Risk 
Risk perception is the subjective assessment of the probability of an 
accident or event happening and how concerned one is with the consequences. 
Risk perceptions include evaluations of the probability of the event along with the 
consequences of a negative outcome (Sjoberg, Moen, & Rundmo, 2004). This 
conceptual model integrates the complex relationships and mechanisms that 
produce individual risk perceptions.  These include health and illness beliefs, 
cognitive evaluation of risk, affective processing, salience and personal 
vulnerability, and prior health system experience. These factors form the foundation 
upon which individuals use heuristics and judgments to form risk perceptions 
(Tversky & Kahneman, 1974).  
Historically, risk perceptions have been conceptualized as generated 
through a set of internal activities that occur when people are exposed to new 
information, using a predominantly psychological framework (Slovic, 1987).  Both 
cognitive and affective processes have been shown to be at work in producing 
perceptions (Loewenstein et al., 2001; Slovic, Finucane, Peters, & MacGregor, 
2004). Some research has shown that affective responses to the event for which 
one is at risk creates a bias in making judgments about risk, framed as the affect 
heuristic (Slovic & Peters, 2006). For example, strong feelings of dread related to 
having cancer may cause women to have a heightened sense of risk, despite 
having a low probability of developing the disease (Loewenstein et al., 2001). To 
date the literature has generally focused on individual cognitive plus affective 
  14
processing using a psychological perspective and does not explicitly address how 
individuals construct risk within a social context. Producing risk perceptions 
represents an important process where medical information, health care 
experience, and social experiences are integrated at the individual level to 
produce varying determinations of risk. Perspectives that incorporate social 
influences on affective and cognitive biases may help develop a more nuanced 
understanding of their roles on decision-making and the meaning risk holds for 
individuals.  
In addition, the manner in which risk perception has been measured has 
been narrowly focused on evaluated risk as determined by medical markers. 
Discrete forms of cancer risk are often measured in relation to a limited set of 
outcomes. Risk has been determined by markers such as family history, genetic 
testing, or abnormal screening tests and related to utilization of mammography 
(Aro, Pilvikki Absetz, van Elderen, van der Ploeg, & van der Kamp, 2000; Brewer, 
Salz, & Lillie, 2007; Haber et al., 2012; Larouche et al., 2012; Wainberg & 
Husted, 2004) or a limited set of psychosocial outcomes such as anxiety and 
worry (Bennett et al., 2010; Hay, McCaul, & Magnan, 2006; Schwartz, Woloshin, 
Sox, Fischhoff, & Welch, 2000). This focus is limited and a broader 
understanding of how individuals apply risk information to their personal situation 
to produce behaviors is warranted. In adopting a broad approach, multi-level 
methods to studying risk including perspectives of both patients and providers 
are needed and lacking in the current literature. Chapter 2 begins to explore this 
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in describing how women conceptualize their own risk using an explanatory 
model framework and relating these to decision-making about participation in 
risk-reduction. 
 
Individual Need 
Within the social and cultural context, predisposing factors, enabling 
resources, and risk perceptions predict individuals’ perceived need for a particular 
health service. In a risk context, however, the medical (evaluated) need for 
treatment is relatively uncertain. Andersen’s conceptual model has thus been 
amended in this application to highlight the prominent role of perceived need.  In 
the absence of overt illness, otherwise healthy individuals may rely less on the 
medical definition of risk and more heavily on their own interpretation of risk to 
determine need, which is produced within their own social context. Evidence has 
supported this theory, demonstrating that women often overestimate their risk for 
breast cancer (Black, Nease, & Tosteson, 1995; Quillin, Fries, McClish, 
deParedes, & Bodurtha, 2004). One study indicated that while communicating 
numerical risk estimates to women improves the numerical accuracy of 
perceptions, women continue to qualitatively describe their risk as higher than 
indicated (Quillin et al., 2004).  
Despite holding perceptions of high risk, women have tended not to 
engage in medical interventions that reduce breast cancer risk (Freedman et al., 
2003; Waters et al., 2010). Current approaches to managing risk acknowledge 
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some uncertainty in evaluated need by ensuring patient preferences and values 
are incorporated into decision making about risk reduction interventions 
(Sheridan, Harris, & Woolf, 2004). One of the reasons for low levels of 
participation in prevention activities could be a gap between professional 
evaluations of need for preventive interventions and the individual’s perception of 
risk, the need for prevention, and/or the costs and harms of preventive activities. 
This further supports the need to explore the lay conceptions of risk and 
prevention and how these integrate with other aspects of social and medical 
environments that produce behaviors. 
 
Provider Recommendations  
Provider recommendations are one area where the health system context 
influences patient behaviors. Distinct from individual decisions regarding 
participation in care are a set of processes initiated by physician 
recommendations for care. Recommended medical interventions support patient 
illness identities whereby the individual becomes an object of medical 
surveillance, subject to intervention and increasingly bringing life under 
professional control.  The influence of providers in this model is adapted from 
Andersen’s model where providers are included implicitly as the agents of 
evaluated need.  Here a more complex relationship between provider 
recommendations, medical events, personal beliefs and evaluation is 
represented. Research has demonstrated that lay and expert evaluations differ 
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and influence behavior in different ways (Adelsward & Sachs, 1996; Galesic & 
Garcia-Retamero, 2011; Sjoberg, 2000). This model therefore incorporates the 
influence of providers on both perceptions and health services use. 
In order for screening and prevention to improve the quality of life at the 
population level, risk-reduction interventions need to be adopted among the 
subset of the population that would most benefit. Identifying such women and 
assisting women in making, evidence-based, informed decisions about 
prevention that align with their values should be the goal of breast cancer 
prevention. Previous research has identified several barriers for providers in 
effectively implementing prevention strategies. Providers, especially those in 
primary care, face significant time constraints within a clinical encounter, limiting 
time for discussion about complex issues such as risk. Incomplete and conflicting 
data along with rapidly changing evidence and guidelines complicate the 
process. Further, breast cancer-specific barriers to providing care include: 
clinician problems and lack of confidence in conducting risk assessments, 
patients’ misperceptions of their own risk, and lack of knowledge and/or 
awareness of the risks and benefits of breast cancer prevention interventions on 
the part of both patient and providers (Kaplan, Haas, Pérez-Stable, Des Jarlais, 
& Gregorich, 2005). This study’s findings point to the importance of both patient 
and provider roles in decisions about health care use.  
In addition to screening for breast cancer using imaging modalities, there 
are several other recommendations that physicians may make in regards to risk. 
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Physicians commonly counsel women of all risk levels to maintain a healthy 
lifestyle, including moderating alcohol intake, exercising, not smoking, and eating 
a healthy, low-fat diet. All of these behaviors are intended to target specific risk 
factors for breast cancer (Chen, Rosner, Hankinson, Colditz, & Willett, 2011; 
Eliassen, Hankinson, Rosner, Holmes, & Willett, 2010; Gaudet et al., 2013; 
Petrelli, Calle, Rodriguez, & Thun, 2002). In addition to these behaviors, there 
are two main modalities that actively intervene to reduce risk. The first is 
chemoprevention with the use of tamoxifen or raloxifene. These two drugs are 
associated with 50% reduction in breast cancer risk, although they are reserved 
for women who have a predicted risk of developing breast cancer of 1.66% or 
higher over the next five years (Vogel, Costantino, Wickerham, & et al., 2006). A 
surgical option is available only to women at the highest risk, usually with a 
documented genetic mutation, and involves undergoing a prophylactic 
mastectomy and/or oophorectomy (Rebbeck et al., 2004). However, these 
medical approaches to breast cancer prevention, particularly prophylactic 
mastectomy and chemoprevention, are seldom adopted by patients (Freedman 
et al., 2003; Waters et al., 2010). While it is clear that there are several 
recommendations available for those ‘at risk’ for developing cancer, the reasons 
for why these interventions are underutilized is not well understood. It is not yet 
apparent whether these approaches are not offered by physicians during 
counseling or whether they are refused by patients. 
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Medical Events 
One aspect of engagement in care is participation in monitoring, testing, or 
procedures that give rise to medical events. Medical events are described in the 
model as manifest symptoms, tests, or abnormal findings. Medical events may 
produce new provider recommendations and/or influence an individual’s 
perception of their own risk. A classic example related to breast cancer risk is the 
presence of breast pain. Breast pain may both trigger a heightened risk 
perception for developing breast cancer and has also been shown to result in 
provider referrals for additional testing, despite the low likelihood of finding 
cancer (Howard, Battaglia, Prout, & Freund, 2012). The interpretation of medical 
events such as these is influenced by the social and health care contexts with 
divergent perspectives negotiated during medical encounters. 
Screening to improve early detection using mammography is the primary 
tool promoted to aid in breast cancer early detection efforts. The use of 
technologies such as digital screening mammography, tomosynthesis and MRI 
are becoming more prevalent across the United States. From 2001 to 2009, use 
of digital screening mammography increased from 2% to 29.8% among Medicare 
beneficiaries, resulting in a 296 million dollar increase in Medicare spending, 
despite no significant change in the detection rate of early-stage tumors (Killelea 
et al.). These surveillance techniques are expensive and may give rise to a 
variety of medical events, such as false positives that require further testing, or 
may be interpreted as medical events themselves. They impact both provider 
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recommendations, but also independently influence individual perceptions of risk. 
It has been shown that abnormal findings on mammograms lead to an increased 
perception of risk, despite no corresponding increase in clinical evaluation 
(Lindberg, Svendsen, Domgaard, & Brodersen, 2013). Findings such as this 
show that it is important to think broadly about what constitutes a medical event 
in realizing the multiple factors that can change provider recommendations or 
influence patient perceptions of their own risk. Chapter 3 addresses this question 
by studying how having a mammogram affects women’s use of a variety of 
health services generated by either physician recommendations or patient 
perceived need for care. 
 
Summary 
Broadly understanding the process by which ‘at risk’ individuals become 
patients is necessary to understand how patients utilize health services to 
prevent disease. For example, patients may be self-produced when they equate 
risk with disease and seek care despite no overt signs of illness. Alternatively, 
patients may be system-produced whereby more care is generated through 
referrals and follow-up testing once the system has identified the individual as ‘at 
risk’. This dissertation seeks to examine these issues to understand how patients 
become engaged in care when perceived to be at risk for developing breast 
cancer.  
Returning to Figure 1.1, predisposing characteristics and enabling factors 
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are viewed as driving perceptions of risk, which are formed within the social and 
cultural context. Chapter 2 focuses closely on these risk perceptions in studying 
how women construct explanatory models of risk and their influence on 
engagement in risk reduction behaviors. Perceptions of risk are also influenced 
by the health system context through provider recommendations and by medical 
events. Chapter 3 examines how an abnormal mammogram, acting as a 
precipitating medical event, can influence utilization both through provider 
recommentations or through perceptions of individual risk and need. Finally, 
Chapter 4 studies how the health care system can intervene through patient 
navigation to take those defined as at risk and frame them as patients to receive 
care that is perceived to be needed from a medical perspective. Together these 
studies begin to elucidate how screening and risk assessment activities work to 
produce engagement in health services through multiple realms of influence at 
the patient, provider, and health system levels. 
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CHAPTER 2 : EXPLORING EXPLANATORY MODELS OF RISK IN BREAST 
CANCER RISK COUNSELING DISCUSSIONS 
Background 
Medically-defined risk refers to the incidence of disease in a population 
over a specific time period. Using population-level estimates of incidence, 
probabilities of disease for individuals can be calculated. When these scientific, 
statistical estimates are provided to patients, it implies that their own personal 
risk is objective and easily measured. However, these estimates are far from 
precise or certain. Nonetheless, tools that predict disease based on patient 
characteristics prior to the emergence of manifest disease are still used routinely 
by physicians and scientists for clinical purposes. Developments in risk 
assessment technologies have increased the number of individuals who are 
identified as ‘at risk’, but do not have a disease. This has created a new category 
of patient, one who is ‘at risk’ for disease development.  This is distinct from other 
conditions where a diagnosis is in place despite no outward symptoms, yet an 
individual is at risk for poor future outcomes (i.e. diabetes, hypertension). ‘At risk’ 
patients now must make decisions about first, whether to intervene to lower their 
risk; and second, how to do so. Making treatment decisions under conditions of 
risk may differ from making similar decisions while experiencing illness, in part 
because the immediacy of ill health is removed. Also, being ‘at risk’ carries 
inherent uncertainties about the likelihood of future disease that complicate such 
decisions. Using probabilistic risk estimates to counsel individuals is challenging 
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for these reasons. Ultimately, there exists a disconnect between the statistical 
concept of risk and lay interpretations of risk as an external threat (Ewald, 1991). 
This extends to differences between lay constructions of risk that differ from 
epidemiologic models (Charles, Whelan, Gafni, Reyno, & Redko, 1998). 
Research in other domains suggests that perceptions of increased risk are 
predictive of participation in care (Brewer, Chapman, et al., 2007). Risk 
assessment is intended to provide patient information in order to make informed 
decisions about treatment options, in a process analogous to patients given a 
diagnosis. However, evidence suggests that for breast cancer, women do not 
respond to risk assessment information in such a straightforward manner. 
Decision-making based on probabilistic risk estimates is particularly pervasive in 
this population, and yet it is unclear how and when women incorporate this risk 
information in to the decisions they make about treatment. Further, current 
medical approaches to breast cancer risk reduction, such as prophylactic 
mastectomy and chemoprevention, are seldom adopted by patients for whom 
these interventions would provide risk-reduction benefits (Freedman et al., 2003; 
Waters et al., 2010).   One study estimates that 4.9% of women in the United 
States could benefit from use of tamoxifen based on their risk for developing 
cancer and the overall risk/benefit ratio (Freedman et al., 2003), yet less than 1% 
actually use tamoxifen for prevention. Research on how patients and providers 
discuss and negotiate behavioral and medical options in a risk context is 
warranted given what little we know about these medical encounters and 
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decision-making processes. Understanding the process by which ‘at risk’ 
individuals adopt the patient role is necessary to elucidate the broader patient 
experience of being at risk for disease development.  
Physicians often identify ‘at risk’ individuals through screening activities 
which include formal genetic testing for BRCA1/BRCA2 mutations, the use of risk 
prediction algorithms (Barlow et al., 2006; Gail et al., 1989; Tice et al., 2008; 
Tyrer, Duffy, & Cuzick, 2004), and less formal means of assessment (i.e. 
inquiring about family history of disease). In addition, there are clinical findings 
that indicate risk, such as biopsy results indicating Atypical Lobular Hyperplasia 
(ALH), Atypical Ductal Hyperplasia (ADH) or Lobular Carcinoma in Situ (LCIS). 
These tools assist clinicians in identifying individuals for whom breast cancer 
may be more likely, enabling them to make recommendations for enhanced 
screening, behavior changes, or risk-reduction therapies. One of the most 
commonly used tools to predict risk is the Gail model (Gail et al., 1989; Gail et 
al., 2007). Clinicians collect information about women’s current age, age at 
menarche, age of first birth, number of first degree relatives with breast cancer, 
biopsy history, and race/ethnicity (Gail et al., 1989) to predict 5-year and lifetime 
risk. Based on the Gail Model, women are considered to have an increased risk 
for breast cancer if their 5-year predicted risk is 1.66%.  The National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) data places the 
average risk for breast cancer at 12.4% over one’s lifetime, while a 40 year-old 
white woman has an average risk of 1.47% over the next 10 years (Kohler et al., 
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2015).The 1.66% threshold represents the 5-year risk posed to an average 60 
year old white woman and has been used consistently as a marker for increased 
risk in clinical trials where it is believed that this is the point at which the benefits 
of chemoprevention outweigh the serious risks.  
While 1.66% is the consensus standard clinical marker for increased risk 
and eligibility for risk reduction therapies, there has been no systematic 
investigation supporting the appropriateness of this threshold (Visvanathan et al., 
2009). Moreover, using medical thresholds to communicate increased risk may 
not align with women’s conceptions about their own chances of developing 
cancer. Several studies have documented that women overestimate their risk for 
breast cancer (Black et al., 1995; Davidson, Liao, & Magee, 2011; Quillin et al., 
2004). One study has shown that while communicating Gail model estimates to 
women improves the numerical accuracy of perceptions, women still qualitatively 
describe their risk as higher than indicated by absolute 5-year and lifetime 
estimates (Quillin et al., 2004). Despite holding perceptions of high risk, women 
have tended not to engage in medical interventions that reduce breast cancer 
risk, as described above. This indicates a need to explore the disconnect 
between medical and lay conceptions of risk and its treatment. 
 
Lay Perceptions of Risk 
It is critical to understand how individuals formulate perceptions of risk 
given that women overestimate their risk of developing breast cancer in 
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comparison to professional estimates of risk using available risk assessment 
tools. Reasons for the gap between patient and provider estimations of breast 
cancer risk can be understood in part by examining the literature on risk 
perception. Risk perceptions have been conceptualized as generated through a set 
of internal cognitive and affective activities that occur when people are exposed to 
new information.  Some risk theories have tended to represent the process by 
which perceptions are formed as a two dimensional process (Slovic et al., 2004). 
One dimension represents the analytical, logical, and probabilistic processing that 
produces perceptions. The other dimension is experiential; this is, it is intuitive, 
unconscious, and automatic (Loewenstein et al., 2001). This approach focuses on 
the cognitive, internal, psychological work that individuals undergo in producing risk 
perceptions. 
Together these two systems produce perceptions of risk upon which 
individuals can act. This set of evaluative processes represents an important 
domain where medical information and experience are integrated at the 
individual level to produce varying determinations of risk. The experiential 
dimension is often comprised of representations of affect, which is simplified as an 
affect heuristic. The affect heuristic is characterized as the positive or negative 
feelings about the topic at hand and how judgments are altered by these feelings 
(Slovic & Peters, 2006). In this formulation of affect, there is a disproportionate 
emphasis on strongly negative consequences and associated feelings (Slovic & 
Peters, 2006), with less focus on how context might mediate or moderate affective 
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responses to risk. While this framework of risk perception may reference social 
elements of perceptions, it does not fully address how women construct risk 
within their social context. It marginalizes other socially-based dimensions such 
as complex interplay of health and illness beliefs, salience and personal 
vulnerability, and prior health system experience that also contribute to risk 
perceptions. These factors form the foundation upon which individuals use 
heuristics and judgments to form risk perceptions (Tversky & Kahneman, 1974). 
Less attention has been given to these dimensions related to how women form 
perceptions of breast cancer risk and subsequently make decisions regarding 
preventive behaviors. Alternative approaches that explicitly incorporate the social 
dimensions of perceptions are imperative to understanding how and why women 
chose certain preventive interventions over others given the gaps between lay and 
professional perceptions of breast cancer risk and related risk reduction behaviors. 
 
Explanatory Models: An Alternative Approach  
Patient explanatory models offer a more comprehensive approach than do 
traditional risk theories by integrating cognitive, affective, and social factors that 
influence perceptions. Explanatory models recognize that illness is experienced 
through perceptions rooted in our explanations of sickness, social positions, and 
systems of meaning (Kleinman, Eisenberg, & Good, 1978). Explanatory models 
represent patient understandings of the etiology, pathophysiology, course of 
illness, symptoms, and treatments for a given condition. Patients and providers 
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each bring their own explanatory models into the medical encounter, where they 
negotiate a clinical reality based on often discrepant goals, expectations and 
therapeutic values (Kleinman et al., 1978). This framework offers an opportunity 
to identify values and beliefs along these dimensions that are inconsistent 
between patient and provider and propose solutions that enhance shared 
decision-making. 
To date explanatory models have been examined among patients who 
have experienced manifest disease (Bokhour et al., 2012; Bokhour et al., 2008; 
Cohen, Tripp-Reimer, Smith, Sorofman, & Lively, 1994). Little attention has been 
given to how explanatory models of risk are employed in the decision-making 
process once patients are labeled as ‘at risk’. Understanding women’s 
perspectives and explanations for risk and the degree to which patient 
explanatory models are accounted for in risk-focused medical encounters could 
impact the development of more acceptable approaches to managing risk from 
the patient perspective. Therefore, this study aimed to characterize explanatory 
models of risk within a sample of women at risk for breast cancer and understand 
how they come to participate in risk-reduction interventions.  
 
Study Aims 
This study sought to answer the question, ‘How do patients’ explanatory 
models of risk inform their perceptions of breast cancer risk and how do they 
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account for their decisions about engaging in behaviors to reduce risk?’ To this 
end, the following aims guided analysis: 
Aim 1: To elucidate what constitutes an explanatory model of risk. 
Aim 2: To describe the explanatory models of risk held by women 
identified to be at an increased risk for developing breast cancer. 
Aim 3: To characterize perceptions of risk and control to describe how 
women account for their decisions about participation in risk reduction 
behaviors. 
Figure 2.1 highlights the conceptual domains addressed in this study. The 
model is a modification of the Behavioral Model (Andersen, 1995), developed in 
order to guide this research aiming to understand the complex multilevel 
relationships that promote individual engagement in health services.  For this 
study, four aspects of the model were the focus. Aims 1 and 2 focused closely on 
individuals’ perceptions of breast cancer risk and the social and cultural context 
in which these perceptions were formed. This helped to characterize patient 
explanatory models and develop an understanding of the links between social 
and cultural context and perception of risk. Secondly, women’s perceptions of 
individual risk and control in light of their decisions about what actions they feel 
empowered to take following provider recommendations for prevention were 
examined. Individual need, viewed as women’s intentions for participating in 
preventive care, was studied in Aim 3, as engagement in health services was not 
explicitly examined. 
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Figure 2.1: Conceptual Model Domains Explored in Chapter 2 
Methods 
 Thirty qualitative semi-structured interviews were conducted with a subset 
of women participating in a large mixed methods National Surgical Adjuvant 
Breast and Bowel Project (NSABP) study of the social and psychological factors 
involved in making decisions about breast cancer risk reduction strategies. 
Qualitative data consist of video recordings of risk discussions between patients 
and their providers and semi-structured, in-depth interviews with patients. 
Institutional Review Board approval was received from both sites where 
interviews were conducted. The principal investigator, Christine Holmberg, and 
the study team at the NSABP were responsible for the overall sampling design 
and strategy. The site team, consisting of Tracy Battaglia (site principal 
investigator), Christine Gunn, and Barbara Bokhour, implemented the protocol 
and designed the analysis plan described below in conjunction with Dr. 
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Holmberg. Interviews at the second site were conducted by a clinical 
psychologist trained to conduct qualitative interviews. 
 
Participants  
A convenience sample of women was recruited from two sites for the 
qualitative analysis: one safety-net academic medical center and a larger 
comprehensive cancer center. Sites were purposely selected to elicit a diverse 
sample with representation from racial and ethnic minorities. Participants who 
were at least 35 years of age, English-speaking, identified as being at increased 
risk for breast cancer by the health care provider, and had discussed breast 
cancer risk and use of SERMs for risk reduction during their counseling session 
with the provider were invited to participate. Women who previously had invasive 
breast cancer, prior Ductal Carcinoma in Situ (DCIS), previous LCIS if treated 
with mastectomy, radiation therapy, or endocrine therapy, or any previous or 
current use of tamoxifen, raloxifene, or other SERM therapy for any reason were 
excluded. Women were also excluded if participating in any other cancer or 
osteoporosis prevention studies involving pharmacologic interventions. 
Thirty women who met the criteria listed above were interviewed. The 
sample size was determined a priori by the study investigators. This sample was 
expected to generate enough data to reach theoretical saturation, defined by no 
new themes arising from the interview data. Other qualitative investigations have 
reached saturation in under thirty interviews when conducting thematic analyses 
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using similar techniques (Ando, Cousins, & Young, 2014; Guest, Bunce, & 
Johnson, 2006).   
 
Data Collection 
  Data were collected over 11 months, from September 2012 through 
August 2013. Women who agreed to the qualitative interview were consented 
prior to their scheduled clinic visit. First, clinical encounters in which women were 
counseled by health care providers regarding their individual risk of developing 
breast cancer and options for prevention were video recorded. A small video 
camera was placed in the clinic room and captured both the health care provider 
and patient on camera for the duration of their counseling session. The video 
material was then uploaded to a secure NSABP server for review by the principal 
investigator and her team.  
Within one month following the counseling session, the participants 
returned for a qualitative in-depth interview. With permission from the 
participants, all interviews were audio-recorded. Interviewers asked participants 
about issues discussed during the counseling session, the participant’s 
experience of being at risk for breast cancer, influences on risk perception, social 
support, and personal approaches to decision-making, both in general and 
specific to the risk reduction therapies discussed. A sample interview guide is 
provided in Appendix A. The semi-structured interview guides were used flexibly, 
allowing a conversational flow to the interview, while ensuring all relevant topics 
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to the research questions were covered. The interview guide was developed 
collaboratively by the research team at the NSABP and both local sites, an 
interdisciplinary group of providers and social scientists, and sought to explore 
breast cancer risk perceptions and approaches to decision-making. The interview 
also included a viewing of the participant’s counseling session with her provider 
and the participant was asked to comment on her actions and thoughts during 
the session.  
All audio data were uploaded securely through the NSABP data portal. 
Each interview was transcribed verbatim by the principal investigator’s staff. 
Participant identifiers were removed from the transcripts for distribution to the site 
researchers conducting analyses. In addition to transcripts, supplemental study 
materials such as printed documents given to patients by providers, examples of 
Gail Model risk calculators, and all video and interview summaries were 
distributed by the Dr. Holmberg’s staff. All analytic materials were uploaded into 
MaxQDA qualitative coding software (version 11, Foxit Software Company) in 
preparation for analysis.  
 
Analysis: Aims 1 & 2 
 This analysis focused specifically on the portion of the interview related to 
perceptions and beliefs about risk. Interview data were analyzed to examine the 
explanatory models of patients in a risk context and how their own conceptions of 
risk integrated with information provided during risk counseling discussions. 
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Coding began with identifying aspects of women’s explanatory models related to 
breast cancer risk, aligned with the aim of describing what constitutes an 
explanatory model of risk (Aim 1). A priori codes were developed, comprised of 
the domains of explanatory models as developed by Kleinman and colleagues: 
Etiology, Pathophysiology, Onset of Symptoms, Course of Illness, and Treatment 
(Kleinman et al., 1978). Iterative amendments were made to definitions through 
reflection and discussion of participant data. Analysis of the first seven interviews 
focused closely on developing the codebook, and sought to capture all 
meaningful phrases. These interviews were co-coded by Christine Gunn (CG) 
and Dr. Bokhour in order to develop and refine initial coding categories. Within 
each domain, a grounded thematic approach (Charmaz, 2006; Strauss, 1987) 
was used to understand participants’ explanatory models related to breast cancer 
risk. Through this process new concepts not covered by the explanatory model 
framework were identified (Aim 2) that represented participant narratives. Based 
on these codes, higher-level themes were developed to capture broader 
concepts developed in the interview text. After the first seven interviews, further 
coding was conducted by one investigator (CG) and was reviewed by Dr. 
Bokhour, with new emergent codes discussed and refined. Thematic saturation 
was reached after 20 interviews, where no new themes were identified by the 
primary coder. The remaining ten interviews were coded to ensure no new 
themes would emerge. These codes and themes comprised the basis for 
analysis of Aims 1 and 2.  
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Analysis: Aim 3 
As perceptions of risk in Aims 1 and 2 were examined, issues of control 
were identified as central to the idea of risk on a personal level.  Therefore, the 
third aim of the analysis asked, how do perceptions of risk and control relate to 
women’s decision-making about risk reduction strategies?  Initial iterative coding 
indicated that both these elements were salient to women’s decision-making. In 
order to describe how risk and control work together to influence decisions about 
risk reduction, the narratives of the participants were studied to understand the 
trajectories related to risk and decision-making. The narratives guided the 
formation of an analytic process model, which identified relevant points of 
evaluation from risk perception to the decision to adopt or not adopt particular 
interventions for risk. The process model was intended to help categorize and 
compare participants based on what might be important to the decision-making 
process. The model was then applied to identify which patients saw themselves 
at high vs. low risk and high vs. low control. It was expected that patient 
explanatory model domains could influence how these groupings arose, and this 
was explored throughout the analytic process.  
First, the explanatory model domains codes for “Course to Illness”, 
“Symptoms”, “Etiology”, “Treatment” and “Social Comparisons” were used to 
characterize whether participants 1) Expressed high or low concern regarding 
risk of developing breast cancer; and 2) Expressed high or low levels of control 
over the stated level of risk. Twelve transcripts were coded independently by CG 
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and Dr. Bokhour before comparisons were made. For risk, nine of 12 transcripts 
were coded concordantly on the risk dimension (75% inter-rater reliability). For 
the control dimension, 10 of 12 participants had concordant codes, representing 
83.3% inter-rater reliability. Through discussion, 100% consensus on the risk and 
control codes was achieved. The remaining 18 transcripts were reviewed by CG 
following the same process. For cases where it was difficult to classify risk and/or 
control, Dr. Bokhour independently reviewed transcripts and confirmed coding 
through discussion. Four such cases were reviewed and consensus was 
reached.  
The remainder of the analysis focused on describing how risk and control 
together were represented in narratives related to decisions about risk reduction 
behaviors. The final stage of analysis categorized women into groups based on 
their perceptions of risk and control to identify commonalities and differences 
within and between groups as they relate to risk perception and the adoption of 
preventive behaviors. After grouping participants into four categories, themes 
related to narratives about behaviors and decision-making regarding risk 
reduction were examined. These groups facilitated the characterization of 
patterns in how women described their experience and behaviors related to 
breast cancer risk. 
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Results 
Participants 
 The purposeful site selection was successful in recruiting a sample with a 
wide range of ethnicities, experiences, and ages. A total of 30 women completed 
the interview process: 16 from Site A and 14 from Site B. Table 2.1 displays the 
demographics and risk characteristics of participants. Notably, although eligibility 
criteria mandated that women must be at increased risk for developing breast 
cancer as determined by a provider, a range of Gail Model clinical risk estimates 
was observed in the sample. Two individuals were not eligible for SERM use 
based on their Gail Model 5-year risk, although their relative risk was slightly 
increased over that of the general population. Thirty-three percent had a 5-year 
risk less than 3%, with only 5 individuals with a more than 5% risk. Finally, seven 
women did not have Gail Model scores available. The reason these women did 
not have estimates was due to the presence of a diagnosis of LCIS that rendered 
the use of the Gail Model inappropriate. All of these women had lifetime risk 
estimates of greater than 20%. 
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Table 2.1: Study Participant Characteristics 
 N (%) 
Age (mean, SD) 50.9 (9.3) 
Race/Ethnicity                                 Non-Hispanic White 19 (63%) 
Hispanic White 2 (7%) 
Hispanic unknown 2 (7%) 
African American 6 (20%) 
Mixed Race 1 (3%) 
Marital Status  
Married/Living as Married 19 (63%) 
Widowed 2 (7%) 
Divorced 4 (13%) 
Never Married 5 (17%) 
Insurance                                                          Medicare 3 (10%) 
Medicaid 1 (3%) 
Private 24 (80%) 
Self-Pay/Uninsured 2 (7%) 
Highest Grade Of Schooling Completed  
High School/Ged 6 (20%) 
Vocational/Technical/Associates Degree 3 (10%) 
Some College 5 (17%) 
College 9 (30%) 
Graduate/Professional Degree 7 (23%) 
Income                                                             < $30,000 4 (13%) 
$30,000 - $50,000 4 (13%) 
$50,000 - $80,000 3 (10%) 
> $80,000 16 (53%) 
Missing 3 (10%) 
5-Year Gail Model Risk                                     < 1.66% 2 (7%) 
1.7 – 3% 10 (33%) 
3 – 5% 6 (20%) 
> 5% 5 (17%) 
N/A (LCIS/Biopsy Finding) 7 (23%) 
 
Aims 1 & 2: The Meaning of an Explanatory Model of Risk 
 One of the main goals of this work is to elucidate what it means to have an 
explanatory model of risk, given that to date research has focused mainly on 
explanatory models of illness. Kleinman and colleagues detailed five concepts 
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based on anthropologic studies that they believed formed the basis of both 
patient and physician tacit explanatory models of illness (Kleinman et al., 1978). 
We identified key amendments to these concepts in the context of risk based on 
our analysis of each domain in the women’s narratives. Table 2.2 displays both 
these concept definitions and the amendments made as a result of this analysis. 
Results for each domain are explored in greater detail below as described by 
women who are at increased risk for developing breast cancer.  
Table 2.2: Brief Descriptions of Explanatory Model Domains 
  Original Definition Amended Definition 
Etiology Why am I ill? Why do I have this? Why am I likely to get that? 
Onset of 
Symptoms What am I feeling? Are there ‘signs’ of my risk? 
Pathophysiology What is happening in my body? Not described in risk context 
Course of Illness 
What will happen to me? 
How serious is this illness? 
Is it acute, chronic, or will I 
be impaired? 
How will my risk turn into a disease? 
What are my chances of actually becoming 
ill? Am I able to control my level of risk? 
This was re-labeled as Course to 
Illness 
Treatment 
What can I take or do to 
resolve my illness? How 
acceptable are my options? 
What can I take or do to lower my 
chances of becoming ill? How acceptable 
are these different options? 
Social 
Comparisons 
Not described in illness 
context 
What is it about people that causes them 
to be at risk? How am I like or unlike people 
who get this? 
 
Overall Adaptation of Explanatory Model Framework 
 We found evidence that many of Kleinman’s concepts related to 
explanatory models were relevant to the context of breast cancer risk. While 
there were commonalities between several of the concepts, some changes to 
concept definitions were necessary, as displayed in Table 2.2. Overall, four of the 
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five original concepts were represented in women’s explanatory models of risk 
for breast cancer: Etiology, Symptoms, Course of Illness, and Treatment. The 
fidelity of the Etiology and Treatment domains to the original definitions was 
maintained. The Symptom and Course of Illness domains shared similar themes, 
but required some conceptual re-definition as related to risk. There was a lack of 
evidence in the data that Pathophysiology played a role in developing 
explanatory models of risk. Risk was not described as changing bodily function or 
something that was necessarily sensed.  
We identified an additional dimension that not accounted for by 
Kleinman’s concepts: Social Comparisons. The Social Comparison element 
captures the phenomenon that risk is consistently thought of and evaluated in 
comparison to others’ experience in the social world. This concept will be fully 
explicated below. 
   
Etiology 
 Etiology encompasses what patients perceive to be the causes of risk or 
illness. The concept of etiology of risk was very closely aligned with etiology as 
represented in explanatory models of illness. Women described a broad range of 
causes of breast cancer risk, with most describing a multi-modal etiology. One 
participant describes this multifactorial exposure perspective:  
“I just feel like it's just it's not all genetics. I just- who knows? 
It could be a little cocktail of environmental exposure, a little 
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bit of genetic mixed up... it's just something that just- it 
happens and you only have so much control. I call it gravity. 
You just have so much control over that gravity and then the 
rest is just, you know…” (1005B)  
Although many women described the idea that causes of breast cancer risk are 
multifactorial, they also described individual causes of risk. The most commonly 
described cause of being at high risk was family. This presented itself in two 
ways: First, women described genetics or hereditary components of risk. For 
example: “I know enough that this is a genetic disease and hereditary and there's 
definitely links so I- I just assumed that I probably was at a greater risk now” 
(0839B). Others described risk as a more general familial trait that isn’t traced 
scientifically to genetics: “My mom's a breast cancer survivor. She has one 
breast… cancer runs in my family so I get more worried or paranoid than 
anything else because I know what I come from” (0551B). This woman’s 
perspective is broader than that of the biomedical model in that she describes an 
amorphous sense of family linkage. Other common explanations for why women 
felt they were at risk included: age, lifestyle, environment, biology, stress, or that 
being at risk was “up to God”.  Representative examples of each of these 
explanations are displayed in Table 2.3. 
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Table 2.3: Participant descriptors of the etiology of breast cancer risk 
Etiology 
descriptor Quote 
Participa
nt 
Age 
“I feel like, you know, um it is kind of an older, 
someone, an older person’s disease or you're at a 
higher risk.” 
0839B 
Lifestyle 
“All we know is fried, greasy [food], you know what I 
mean? So until everybody starts saying oh ho this 
isn't good for you, you can't be doing this… we did it. 
And we still do it, you know, knowing that the risks 
and everything are there we still do it because that's 
the way we was brought up, that's what we know... so 
you're gonna make yourself even more at risk.” 
0551B 
Environme
nt 
“I think a lot of times your environment, uh, where 
you live, the atmosphere was heavily industrialized 
with smog and chemicals floating throughout the air. I 
lived there myself when I was going to school.” 
0532B 
Biology “I'm at a high risk because I have it, it's there … [ADH is] a lesion, it's a lesion.” 0442A 
Stress 
“It was surprising that it even was a high risk but then 
reading about it, you know… I said well maybe 
because I'm just so always spazzed out, I'm just 
stressed all the time. I said, you know, I don't feel 
stressed but maybe because the life I live, you know, 
hustle and bustle, I'm just always been running and 
doing things. I said well maybe I'm just stressing 
myself out, maybe that's causing it so.” 
0664A 
Up to God “If God thinks it's alright to have it I guess he'll give it to me. I mean he did this.” 0935A 
 
These explanations of the cause of breast cancer risk were used by 
women to make sense of the information that was provided to them in 
consultations. While some of these causes were explicitly addressed by 
providers, others were more reflective of the patients’ experience outside of the 
medical realm.  
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Treatment 
 Treatment encompasses the types of interventions that patients and 
providers believe can be received to manage risk. Treatment, like etiology, 
displayed more commonality than divergence with explanatory models of illness. 
In both illness and risk, individuals formulated and described actions that could 
ameliorate or reduce illness or risk. Amongst these participants, three broad 
categories of ‘treatments’ for risk were described: Monitoring, Preventive Health 
Behaviors, and Medical Interventions. 
 
Monitoring 
Monitoring risk encompassed two distinct phenomena: self-monitoring and 
screening strategies. The first was self-monitoring, with many women describing 
being ‘at risk’ as generating a personal responsibility to be aware of bodily 
changes. For example, one woman described her approach:  
“I think that's one of the better preventative methods… being 
cognizant and aware of your own body. If you don't identify certain 
changes or aren't aware of things, you might be missed and it can be 
easily missed in a physical if you don't bring something to the 
attention of your physician.” (0435B) 
The second component of monitoring that women described was the use 
of screening strategies such as mammography, ultrasound, clinical breast 
exams, or other means of tracking risk and bodily changes. One woman 
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described the urgency she felt to get a mammogram after her mother was 
diagnosed with cancer:  
“I had never had a mammogram, and I was under forty… [I] said, you 
know, I don't need to see my doctor, but can he send me for a 
mammogram? They're like 'no you don't need one' and I was like 
'yeah' and it took a lot of convincing to go get a mammogram.” 
(1025A) 
While many of the women felt participation in mammogram screening was 
beneficial and especially important given an elevated risk of breast cancer, 
others felt additional screening measures were too aggressive.  In regards to 
supplementing mammograms with MRIs, one woman stated, “I mean that just 
seems… it seems like overkill” (0839B). Despite some reservations about 
supplemental screening tests, the idea of monitoring was the most widely 
recognized and accepted method of reducing risk. Routine screening brought 
about a cycle of reassurance that risk was not increasing and cancer had not yet 
developed. As one woman stated, she’ll be “less worried for another year” 
(0987B). 
 
Preventive Health Behaviors 
 Preventive health behaviors included interventions such as diet changes, 
stress reduction, exercise, weight loss, limiting alcohol intake, and quitting 
smoking as means to reduce risk. Preventive health behaviors were not 
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universally recognized as a method to reduce breast cancer risk, but they were 
regarded as important for staying generally healthy. Once these women 
underwent counseling regarding breast cancer risk, there were mixed reactions 
to the acceptability and effectiveness of behavior change in reducing breast 
cancer risk. Table 2.4 displays the range of participant understanding and 
acceptability regarding the use of preventive health behaviors. 
Table 2.4: Descriptions of Preventive Health Behavior as a Treatment for Risk 
Perspective Quote Participant 
Elevated 
importance 
of behavior 
change 
“So I’m consciously trying to work on things with 
even hearing about the breast cancer and seeing 
my sister...I’m trying to see what physically I could 
possibly do as far as changing, a change in my diet, 
I’m doing even more exercises than I was before, 
I’m conscious of things now.” 
1026B 
“I mean as far as just conventional wisdom I think I 
knew, you know, the healthy lifestyle and exercising 
and, you know, moderation of, you know, alcohol 
and caffeine and things like that, which more or less 
we try to follow. But now it, you know, seems to be 
more important now given the situation.” 
0607A 
Understandin
g benefits 
without 
action 
It's like I’m a slave to my cigarettes … It makes me 
feel like I should be doing what she's saying for 
me to do to help myself. I feel like I should do what 
I can do to reduce my risk of any cancer so, you 
know, not smoking.” 
0404B 
“So exercise is probably beneficial I guess to 
prevent, you know, breast cancer too, along with, 
you know, lowering your risk of heart attack, stroke 
whatever. No I’m not really exercising. I know I 
should but... I try to walk a little bit but it's not 
enough and uh it's so hot outside.”  
0407A 
Skepticism 
about 
benefits of 
behavior 
change 
“Just like a friend called me just yesterday… and 
said all you gotta do is just go on this garden of 
eden diet…and it will cure anything in your body, 
cancer, arthritis... don't do anything just do this diet. 
That's so tempting to hear that just like gosh all I 
gotta do is just eat salads for a year…But then, you 
0454A 
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know, I come back to… that's taking a big chance 
with your health.” 
“It's in my face. You know, I’m looking at this going, 
she quit smoking almost thirty years ago, she ended 
up getting lung cancer. What's the risk factor, really 
in reality, what are my chances of not getting 
cancer just because I stop smoking? Obviously 
they're not any better than if I’m smoking as 
such. That's all I’m saying.” 
1021B 
 
Medical Intervention 
 Taking medications or undergoing prophylactic surgeries were the two 
treatments mentioned in relation to breast cancer risk reduction by both patients 
and providers. The presence of medical interventions for breast cancer risk was 
largely unknown to women before their risk counseling session. As one woman 
expressed, “I did not know that that was even an option... I thought, honestly, the 
tamoxifen and raloxifene were just for only people who do have the breast 
cancer” (1027A). After being provided with information on the use of medications 
in a risk context, women described reactions to this treatment related to its utility 
and side effects: 
“I feel like I should do what I can do to reduce my risk of any cancer 
so, you know, not smoking and even taking the drug, you know. 
Knowing the side effects and the way she explained them, the side 
effects, they are small… So I just watch and if something happens 
then I'll jump on it.” (407A)    
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 “I feel like I’m playing Russian roulette with my life, like I said. ‘Cause 
either way, you know, either way I’m just taking a risk. Not taking it, 
having the treatment for breast cancer and going through all of that 
and possibly losing my life that way or losing my life with the blood 
clots so I’m in between.” (1026B) 
 
“So that was a little bit alarming of the possibility of the side effects 
of the drugs, you know, especially at my age and also with me having 
a stiff heart muscle that could possibly have a stroke, you know. I 
don't know which I would prefer- cancer or the stroke. I think probably 
cancer because a stroke, I mean that just renders you, you know, not 
able to function pretty much in a lot of cases.” (0532B) 
In terms of prophylactic surgery to reduce risk, most women found this intervention 
extreme. One woman who was considering surgery described her perspective: 
“I’m leaning towards the mastectomy not because I want to be cut on 
or take the risk of surgery, which I understand there's a risk, but 
because in the long run all those, all that tissue where the LCIS and 
DCIS could be will be gone. And I understand that I'll be down to like 
a three percent chance I can still get cancer and the pills would do 
that too. But also had a really good friend in high school that her 
mother died from blood clots and it was due to the- taking the pill. I 
don't want to go have my breasts removed. Who in their right mind 
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would want to do that? I just felt like a fifty percent chance I’m kind 
of like a ticking bomb. It's like flipping a coin, when is it going to land 
on heads?” (0454A) 
Descriptions of treatments for risk seem to present tradeoffs: the severity of risk 
and chances of getting cancer, versus the risks of the treatments themselves. 
While behavioral ‘treatments’ posed few risks, descriptions of the risks of 
supplemental screening and medical treatments highlighted the importance of 
what women understand and interpret about benefits and risks of treatments in 
their decision-making process. 
 
Symptoms 
 In explanatory models of illness, the definition of ‘onset of symptoms’ 
relates to why patients think illness started when it did, and the experience of 
bodily symptoms. In risk, there is generally a lack of experienced bodily 
symptoms. We thus defined symptoms as what women experience as risk. In 
particular, we identified ‘signs’ that women felt were related to their level of risk. 
They aided women in understanding what risk is and contributed to their 
perceptions of their own level of risk. These signs often were the result of 
screening activities and included mammogram findings, biopsy findings, benign 
lumps, and breast pain. Table 2.5 presents the types of signs that women 
identified as related to breast cancer risk. 
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Table 2.5: Patient Descriptions of ‘Signs’ of Breast Cancer Risk 
Type Quote Participant 
Mammogram 
Finding 
“I didn't know until I had that- the mammogram. I 
had no idea I would be at risk for breast cancer 
‘cause there's no breast cancer in my family.”    
0294A 
Breast Pain 
“They don't know why women have pain- you know, 
but it was a pain that I’ve never had experienced- it 
was like, like, like somebody like stabbing me, it 
was, it was just wild.” 
1027A 
Atypical Cells 
on Biopsy 
“The LCIS will never turn into the cancer itself, 
even though it is cancer. It's a stage zero cancer 
that's encapsulated is the way they described it to 
me but because you have that with the 
precancerous growth, that increases your odds of 
getting cancer. You're at a great risk of getting 
cancer” 
0454A 
Benign Breast 
Lumps 
“I did see a doctor and she said no I don't even feel 
anything. And that's what the doctor said to me, but 
the ultrasound showed something different and, 
you know, being dense in the breast they said well 
we're gonna go in there and look because it seems 
like something’s there. And there was. They called 
it a lesion.” 
0442A 
Gail Model 
Risk Estimate 
“I think actually going over my individual risk level, 
a number, I mean unfortunately that's what the 
world is made of. Numbers kind of give you an idea 
of like where you think you- although it's just a 
statistic and we know that that's just basically an 
idea. It's not like you are now exactly at this risk 
level but I think it's helpful.” 
0940B 
 
Not all of these are considered risk factors for breast cancer by medical experts. 
Nonetheless, they were interpreted as indicators of risk by patients. As women 
rely on perceived signs of risk, it becomes apparent how information provided by 
physicians and medical personnel can greatly impact their interpretation of 
findings. This in turn has implications for what women interpret as signs of risk. 
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This is clear in many of the descriptions above, particularly related to 
mammogram findings and the discovery of atypical cells on biopsies. 
Pathophysiology 
 Pathophysiology was defined by Kleinman and colleagues as what illness 
does to the body and how it operates to make one experience illness. This 
concept had no identified corollary in the setting of risk. We identified few 
descriptions of pathophysiology, but these were solely related to cancer itself, 
and not to cancer risk. For example, one woman described breast cancer as 
follows:  
“It seems like it really progresses and you can see how it just eats 
away at the tissue in your breast and just how ugly it really gets 
inside.” (0532B) 
Although there were some descriptions of pathophysiology related to cancer, it 
appears that patients do not identify a pathophysiology of risk in their 
constructions of personal risk and decision-making. The nature of risk may not be 
conducive to thinking about bodily changes in the absence of an illness 
experience. This is a particular area of divergence in explanatory models of risk 
and illness. Based on our data, we suggest that removing pathophysiology from 
the concepts included in the construction of explanatory models of risk. 
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Course of Illness 
 The course of illness in explanatory model research has focused on 
several inter-related concepts: the trajectory, seriousness, and severity of illness. 
Trajectory encompasses the expected path that an illness will take as well as the 
chronicity. Seriousness and severity represent perceptions of the threat of illness 
to daily life. In examining explanatory models of breast cancer risk, we identified 
some key departures from these definitions. Based on our findings, Course of 
Illness was re-conceptualized as Course to Illness.  
 Course to illness was framed around assessing the chances of actually 
becoming ill as a result of personal risk. It was described through reflections on 
how and when risk will turn into disease and whether women felt control over 
their own level of risk. There was also some element of assessing the severity of 
being at risk: it was minimized by some and elevated to disease status by others. 
Each element comprising the course to illness domain was identified, with 
exemplars displayed in Table 2.6.  
 
Table 2.6: Patient Descriptions of the Course to Breast Cancer 
Course to 
Illness 
Concept 
Quote Participant 
Path or 
Timeline to 
Illness 
“If I did not follow up on it and I let it go for another 
five years it could've been DCIS, it could have been 
invasive, who knows?... Right but I’m not thinking 
about what's going to happen to me now. I’m 
thinking about what's going to happen to me in 
ten or twenty years.”  
1021B 
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“Well I mean as you get older you're getting more 
increase for any type of illness so and then 
obviously, you know, it's like a kind of like a 
trajectory of, you know, what an older generation 
might have it a year usually you think, you know, ok 
well I could be susceptible around that age or 
maybe even younger and so forth.”             
0940B 
Chances of 
Risk 
Turning to 
Illness 
“You don't know, it's a roll of the dice.” 1018A 
“The seventy five percent of not getting the cancer, 
you know, to me that sounds good. I, you know, I 
don't know how with - it just sounds good, you know. 
I mean it's not a hundred percent but seventy five 
percent.” 
0553A 
I’m just in the like wait and see period…you know, I 
have to look at where I come from, my family. You 
know, everyone in my family has cancer. …I feel 'oh 
nothing's going to happen to me. That's just them. 
It's going to skip me'. No nothing skips. Sooner or 
later it comes, you know, so I just gotta deal with it.” 
0551B 
Control 
Over Risk 
“Well I mean there's no guarantee that you’re never 
going to develop cancer…maybe I took it for granted 
that I would never have a cancer problem, but, you 
know, you expect the- expect the worst or just be 
prepared.” 
0294A 
“I’m thankful if anything else that uh that, you know, 
the radiologist saw what she saw and the pathologist 
was able to identify what he or she saw and um, you 
know, that I get kind of a heads up or a flag, you 
know, that says hey this might be down the road and 
then also thankful that I have the possibility of 
doing something.” 
0607A 
“I can see that this is not going to happen and I am 
doing the right things to minimize the risk... I will do 
everything that I have to do, improving my eating 
habits, doing exercise, eating healthy or taking the 
medicine, everything to minimize that risk. At the end 
I don't know I’m- I don't know.” 
0887A 
Seriousness 
“Every year you get older that this is- this risk factor- 
this number is going up. It's not going down, it's 
going up… You just don't know how seriously to take 
it. You don't know how seriously to take your risk 
0839B 
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factor. And I know with like with breast cancer it's 
you kind of get it or you don't.” 
“So I am a firm believer if something’s not hurting 
you leave it alone but I don't want a ticking time 
bomb and I’m not taking care of it. So I really felt 
like, you know, I shouldn't just leave it. I should take 
something.” 
0442A 
“I don't want people like to feel sorry for me because 
I’m not labeled with breast cancer, you know, I 
have certain cells. I have certain things that can 
make me- that I probably could get it but it's not a 
hundred percent that I will get so I don't wanna be 
labeled as breast cancer patient I was trying to tell 
my husband. And I don't wanna get that in my mind 
that I’m a breast cancer patient because I’m not.” 
0664A 
 
 
One of the themes expressed throughout all of the course to illness concepts 
was the inherent uncertainty about the potential path to illness. Women often 
articulated this uncertainty, which was unique to discussions of risk versus the 
experience of breast cancer itself. Potential courses were described as a 
combination of three dichotomies: inevitability vs. control, uncertain vs. expected 
trajectory, and risk as an immediate and constant vs. distant threat. Women 
constructed narratives about their expected courses to illness, describing these 
themes as the basis of their assessment. For example, one common narrative 
was that while breast cancer was inevitable since risk would always rise with 
age, it was nothing to worry about until later in life. One woman expresses this 
particular path:  
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“I think right now for me personally given my age, I'm real comfortable kind 
of where we're at now. I think each year we'll talk about this and I'll, you 
know, have to look at it through a different lens cause I'm a bit older and 
my risk factor’s going to continue to increase as it does with age…When 
talking about, you know, potential options in the future to take medication 
that may reduce my risk, you know, that to me is a bit off in the distance. 
I'm young and I don't know how I'll feel in five years or ten years.” (0839B) 
Another common course to illness included risk as an immediate threat with an 
expected path to breast cancer that required action in order to change the 
course. Alternatively, risk was described as uncertain and distant, with no 
expected trajectory, but able to be controlled with actions taken in the present. 
Social Comparisons 
 In addition to the domains previously identified as relevant to individuals’ 
explanatory models of illness, we identified a critical thread that ran through all 
other domains. Assigned the label of ‘social comparisons’, it was identified as the 
process by which individuals produce explanatory models of risk. Explanatory 
models of breast cancer risk represent an understanding of the compilation of 
attributes of breast cancer. These attributes are socially distributed throughout 
the population of all women. Women consider attributes of other people they 
know in the social world who develop cancer to evaluate and personalize their 
own risk. Social comparisons involved an evaluation or understanding of how 
personal risk estimates or signs related to others’ risk, the experience of being at 
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risk, or having cancer. This was viewed an integrative, critical element to 
understanding how women conceptualize risk that informs all the other domains 
of explanatory models. It is clear that perceptions are not based solely on what 
women learn from medical providers or others, but these are negotiated in 
relation to the social world where knowledge and belief systems are formulated. 
This idea reflects the social construction of risk perceptions; that is, we 
understand risk based on what we know from our social world. Women seemed 
to consider questions such as “What is it about people that causes them to be at 
risk? How am I like or unlike people who get this? These questions involve an 
explicit evaluation of the self in relation to others in the social world that has not 
previously been described using data related to illness models. Below are 
examples of how this concept was manifested in the sample of women at risk for 
breast cancer: 
“[The information about risk reduction] was non-biased, but it 
just didn't feel like it was a fit for me. Like those weren't- I wasn't 
reading about myself. That wasn't me.” (1005B) 
 
“I understand the whole cell dividing but I have a very different 
lifestyle than my mother did. And not that she brought that on 
herself but she had many diseases and because she didn't take 
care of herself and she was the total opposite of what I am. So 
I went the other path where I’m just trying to be very healthy and 
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we're different make up as far as uh like I feel like my brother 
took a lot after like her like his physical and make up and just 
stuff that happens to him is almost mirroring her, but I feel like 
I’m mirroring my father as far as what his- that could be very- 
I’m sure it's very naive and there's no scientific correlation.” 
(1005B)  
 
“I know that, it [cancer] could happen. It is so scary that I might 
do the same thing [my grandmother] did because I had a knot 
in my breast in nineteen something and back then, you know, 
everything- you have something and everybody thinks it's 
cancer, it's cancer, it's cancer. I stayed in denial for like two 
years without even going to the doctor so I'm thinking, ‘will I be 
reliving her life now that I'm just sittin' up here?” (0553A) 
 
These quotes demonstrate how women incorporate their knowledge of the social 
world and contextual experience to compare themselves to others as a means of 
ascertaining their own risk.  
 
Aim 3: Relating Perceptions of Risk and Control to Decision-Making 
 Analyzing the narratives of women identified to be at increased risk for 
breast cancer revealed that decisions about participating in risk-reduction 
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strategies incorporated a series of evaluative steps. Figure 2.2 depicts those 
steps identified as critical to the decision to participate in prevention. In addition, 
the explanatory model domains that appeared to be related to each evaluation 
are indicated below. 
 
Figure 2.2: Analytic Process Model 
Based on the model shown above, we further characterized women’s 
perceptions by grouping participants into four categories, representing the 
possible combinations of perceptions of risk and control, the first two evaluative 
steps in the above model (Table 2.7) and the two most relevant concepts related 
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to decision making. Table 2.8 displays illustrative phrases that we identified as 
representing high/low risk and high/low control. Notably, control was sought 
either through personal actions (self-control) or through the medical system. Key 
themes identified within each group are described in greater detail below. 
Table 2.7: Participant Classifications of Risk and Control 
 High Control Low Control 
High Risk 8 7 
Low Risk 9 6 
 
Table 2.8: Participant Indications of Risk and Control 
High 
Risk 
“I think [risk] it's more immediate because … it's just it's there. It's 
in my face.” (1021B) 
“I'm at high risk. It's something I think about very frequently, you 
know.” (0487A) 
Low Risk 
“I took it for granted that I would never have a cancer problem… I 
think [the risk] it’s small, but you know in life there's no guarantee 
of anything.” (0294A) 
“I think my chances, if looking back at my sister and my mother, 
I'm ten years older than what they were when they first was 
diagnosed…all of that's pretty good for me.” (1020B)  
High 
Control 
“I feel like that I can prevent something where somebody else 
couldn't.” (0935A) 
“I'd probably be looking at the whole gamut. I won't just say just 
‘cause my provider said we have a drug called tamoxifen and this 
can prevent breast cancer. I'd want to find out and what other 
people are doing, what are the other options?” (0940B) 
Low 
Control 
“I just think if the cells are going to divide and do there's nothing. I 
mean I know a lot of healthy individuals that just develop cancer … 
it's just a crapshoot.” (1005B) 
“I'm not sure what I could do with the breast cancer risk.” (0407A)   
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High Risk – High Control 
 Eight women expressed high levels of concern over their risk status 
combined with high levels of control in reducing that risk. These women were 
characterized by using language suggesting that risk was a serious 
phenomenon. Notably, seven of these women had risk factors present on biopsy 
(ALH, ADH, or LCIS). The woman who did not have an abnormal biopsy finding 
had an elevated Gail score with a lifetime risk of 20% and a mother who had 
suffered from breast cancer twice.  
 The social comparison domain of explanatory models was very important 
to this group, particularly in relation to their ability to control risk. Women relied 
on social evidence from those around them in accounting for their participation in 
risk-reduction behaviors. The social ties discussed in narratives took a range of 
forms: some looked to familial experiences, faith, other friends, or even physician 
narratives to describe their reasoning for choosing particular preventive 
behaviors.  
All women in this group described either a model of success or model of 
failure that was central to how they thought about controlling their own high levels 
of risk, regardless of what type of risk-reduction method they adopted. We 
describe this as a form of social evidence: social context linked how each woman 
found control (i.e. through lifestyle changes, medications, or monitoring) in 
accomplishing risk-reduction. For instance, one woman used a friend’s cancer 
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experience as a motivator to adopt preventive behaviors, believing that 
monitoring and SERM use together can be used to control high risk:  
“I had a friend that brought me the first day. That is a year breast 
cancer survivor. So it's kind of like, my thing is I get a chance. She 
didn't. She didn't have a chance. She's gone through the chemo, 
she's gone through the radiation, she's gone through the breast 
surgery. You know, she had to have a mastectomy. She's gone 
through all that. So I just felt like that was my chance, since God gave 
me the chance to try to prevent it. To try to say ‘ok maybe I won't get 
cancer down the line with all this’, you know. And so they're gonna 
do a six month regimen on me from now [on].” (0935A)  
This woman describes her friend’s missed opportunity for prevention and her 
subsequent experience with cancer and its treatment as evidence that she 
should take advantage of prevention options available to her.  
 A second woman described why she decided not to take a SERM based 
on the experience of her son. This woman focused on who could provide some 
control over her risk. She believed that she was the only one who could control 
her risk and that the medical system was unable to effectively alter her risk 
status: 
“I just feel like I don't want to take that pill and then I have a personal 
reason for not wanting to take it. My son had Addison’s disease and 
they put him on all kinds of prescriptions for that and when one pill 
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would cause side effects they'd put him on another one. And when 
he died, I think he was on about fifteen to twenty pills a day. Each 
pill treating another symptom of another pill or an ongoing symptom 
of his actual disease. And so I watched that happen and I watched 
the personality changes, the mood swings and all of the things and 
I felt like he got trapped. Not purposefully, just incidentally he got 
trapped in a lot of the things that doctors are trying to do to help 
relieve one thing or another. If I can I want to avoid that.” (0454A) 
This woman saw the medical system fail her son and her perception of treatment 
was influenced by the social evidence of her son’s situation. She relied on a 
social comparison related to prior experience with medical care to inform her 
decision-making about SERM use. Instead of trusting the medical system to 
control her risk, she implies that she herself can control her risk trajectory. She 
reveals a sense of control through focusing on making lifestyle changes related 
to her diet and exercise regimen. These narratives were typical of women in this 
group, who used positive and negative social evidence to describe their 
decisions about risk-reduction behaviors primarily related to whether or not risk 
could be controlled and who could influence risk trajectories.  
 
High Risk – Low Control 
 Seven women were identified as being highly concerned about their risk, 
but expressing that they felt little control over their risk. Similar to participants in 
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the high risk – high control group above, these women described risk as a 
serious phenomenon. Yet, they perceived breast cancer as an inevitable 
outcome of their risk status and felt unable to exert much control over their risk 
trajectories. One woman expressed these feelings of inevitability in saying, “I feel 
'oh nothing's going to happen to me. That's just them. [Cancer’s] going to skip 
me'. No, nothing skips. Sooner or later it comes, you know, so I just gotta deal 
with it” (0551B). 
While women who felt they had high levels of control over their risk 
focused on what they themselves could do to reduce risk, women in this group 
relied more on medical interventions to reduce risk, as they didn’t express 
empowerment to reduce their risk through their own lifestyle and behaviors.  
Decisions appeared to relate to whether women bought into the biomedical 
theory of prevention whereby risk was a treatable condition, amenable to change 
through medical interventions. The explanatory model domain of treatment was 
central in explanations of why women did or did not choose to participate in risk 
reduction interventions. Some women expressed hope that treatment would do 
something good despite remaining skeptical that the medical system could 
produce a change in risk status. Others relied on doctors to exert control where 
they felt ill-equipped to do so, trusting that the doctor’s recommended course of 
action was in their best interest. Regardless of women’s decisions to participate 
in prevention activities or not, this group ceded control to the medical system, 
believing that they did not have the power to alter risk status. 
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The perceived role of medical interventions for high risk was central 
among this group. Some women implied that a change in disease risk status 
should not necessitate medical intervention as illness would. For example, 
participant 0892A alluded to the conditions under which she would find taking a 
medication acceptable:  
“With the way they went out and the reps would sell it to the 
physicians to get the physicians to work with the lower cholesterols 
to- you actually convince a patient they're sick through the 
conversation through the physician because the pharmaceutical 
company has sold this off to the physicians… Fioricet I take for 
migraines because it allows me to function and when I get my 
migraine headaches. I take one and it curbs the headache enough 
that I can continue to work or not be impaired…and the risks just 
aren't the same.”  
This quotation highlights mistrust in the idea that drugs can change the course of 
risk by drawing parallels between cancer risk and high cholesterol as a risk factor 
for heart disease. Her language suggests that she believes medical interventions 
for problems that signal risk (vs. disease) are a conspiracy generated by drug 
companies and physicians. She contrasts risk situations with the illness 
experience of migraines where she feels medications are needed. These 
women’s accounts of decision-making described how general skepticism about 
the medical system and drugs’ potentially negative impacts on health were 
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applied to feelings about SERM use specifically. Women who held reservations 
about the utility of medical treatment for all types of health conditions felt little 
control over their risk for breast cancer and they therefore often chose not to 
adopt medical interventions. 
Women who did choose to use medications as a method of risk reduction 
in this group similarly expressed a lack of control, but instead of avoiding action, 
they followed the doctor’s recommendation as a means of conforming to social 
expectations for treatment. One woman expressed how she deals with her 
mother’s doctors, which is also reflective of her own experience “We have faith in 
her doctors, that they're doing what's best for her. This is the best. Don't second-
guess it” (1018A). Another alluded to her expectations of the physician’s role by 
stating, “When [the doctor] pointed to the medication and said this is the one I 
would say that you should take - that helped. I mean I felt woman to woman 
that's really what I was looking for” (0892A).  Trust that doctors have the patient’s 
best interest in mind was paramount to their own concerns about the utility or 
side effects of medications. Narratives in this group focused around how risk-
reduction options fit in with women’s explanatory models related to treatment, 
with decisions formed around whether or not women bought into social 
expectations for treatment of risk.   
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Low Risk – High Control 
Nine women in the sample felt that they were at low risk for developing 
breast cancer, but were able to manage or control this limited risk. These women 
as a group expressed risk as uncertain and/or something that could become 
serious over time, but wasn’t an immediate threat. Their actions were described 
in relation to their projected course to illness. As one woman said,  
“I feel like I'm doing everything I can to obviously monitor my risk and 
manage it but I just don't feel like I worry about it. I don't really think 
about it for myself. I think it's one of those things that I think, ‘Oh, 
that'll never happen to me.’ Kind of- it could happen, but you know, 
and if it does you deal with it.” (0839B) 
This woman’s approach highlights both her relative low concern about risk itself, 
but also the fact that she is taking action through monitoring to manage whatever 
risk is present. This was a common theme expressed by all women in this group. 
Behavioral or lifestyle changes to manage risk were widely adopted, as was 
monitoring for the early detection of breast cancer.  
Women in this group expressed that they felt generally healthy and sought 
to maintain their own health in order to keep breast cancer risk low.  As a whole, 
this group perceived healthy lifestyles to be good regardless of breast cancer 
risk.  Actions to reduce breast cancer risk therefore aligned with other health 
risks that they managed through behavior. In this way, they expressed feelings of 
empowerment over their own course of risk. For example: 
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“I’m just gonna watch my health, you know, and what I eat, drink and 
try to work it out, you know, and just take care of my body.  And it’s 
like I think I’ll be fine.” (1023A) 
 
“I’ve never smoked, I’ve never drank and like I said I’ve always eaten 
healthy foods. I don't eat a lot of meat, I never did. I don't eat a lot of 
fried foods to have, you know, all the grease and that. So I’m active.” 
(0532B) 
This group of women universally expressed self-efficacy in maintaining current 
health along with the expectation that this course would continue, which was 
described as part of their rationale for adopting behavioral and lifestyle 
mechanisms of risk reduction.  
In conjunction with expressions of self-efficacy in maintaining a health 
trajectory that did not lead to illness, women in this group voiced beliefs that one 
should be ‘aware’ or ‘vigilant’ about current and future health threats. Having a 
personal responsibility to be aware and vigilant was expressed as a requirement 
to maintain health and was central in these narratives. The following are 
examples of how women described this concept: 
“I think obviously in healthcare you have to take care of your own 
health and, you know, you can't just let this up to your gynecologist 
or someone to say ‘Oh by the way, I think you're at increased [risk]- 
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you need to do this or that’. You need to be on top of all these things.” 
(0940B) 
 
 “I would say I’m not hyper vigilant but I’m rather vigilant about what's 
going on in my body. I feel like I’m very aware of changes and 
differences in my body but I’m not overly, you know, concerned about 
any particular funny feeling.” (0607A)  
“So I’m aware and I’m seeing things that I’m trying to see what 
physically I could possibly do as far as changing, a change in my 
diet, I’m doing even more exercises than I was before, I’m conscious 
of things now.” (1026B) 
This group was different than the others in how they described awareness as 
central to their decision-making process and actions they adopted, which is a 
very personally-focused concept rather than a social one. Even those women 
who did choose to take a SERM for risk reduction, accounted for this choice 
using the rationale of being healthy and seeking to maintain this state:  
“I can see that this [breast cancer] is not going to happen and I am 
doing the right things to minimize the risk. Okay, but at the end, you 
know, I will accept the things that I can. I will do everything that I have 
to do, improving my eating habits, doing exercise, eating healthy or 
taking the medicine, everything to minimize that risk. At the end I 
don't know.” (0887A)  
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The other woman who chose to take a SERM described her decision in terms of 
positive attributes about her current state mitigating some of the negative side 
effects of medications that she was informed about:   
“Given my age, that I'm premenopausal, that some of the negative, 
more serious side effects would not necessarily be an issue for me 
just because of my premenopausal status… That's obviously very 
compelling too, you know, when you've got a lot of advantages and 
then the disadvantages are mitigated by my age.” (0607A)  
This focus on maintaining a course that avoided future illness was central to all of 
these narratives, regardless of whether women adopted lifestyle changes, 
enhanced monitoring and early detection practices, or medical interventions to 
reduce risk. Many women in this group viewed breast cancer as one health risk 
among many and spoke about risk-reduction activities as applying to several 
potential threats. The emphasis on the status quo may be linked with the 
uncertain experience of being at risk for disease, combined with individual 
perceptions that risk is not an immediate threat to health and it can be controlled 
by individual actions. 
 
Low Risk – Low Control 
 Six women were categorized as having perceptions of both low risk and 
low levels of control over risk. Three of these women had ‘signs’ of risk such as 
ADH or ALH, with the remaining three having other symptoms such as benign 
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cysts. The explanatory model domain of symptoms, or ‘signs’ of risk were 
important to these women. Consistent with perceptions of low risk, often 
narratives indicated that ‘signs’ of risk were interpreted over time as normal 
resulting in little concern regarding breast cancer risk: 
“I don't feel like I have a concern right now so that's- maybe that's 
why I don't think about it often… It's been like this for probably about 
five years where I, you know, go for a mammogram, you know, go 
for the ultrasound. There's more- they aspirate sometimes, they don't 
aspirate, they fill back up and they've always been just benign cysts. 
So I guess no I’m not concerned right now” (1005B)       
 
“I found the first cluster of cysts and I was panicking at that point 
because my sister had not been deceased for that long. When I had 
the ultrasound and the mammogram and when it was found to be 
cysts I was like ok I can deal with that, you know, but it's always oh I 
found something, panic first then settle down and go through the 
tests and then I’m reassured at the end.” (1006B) 
 
“I didn't worry ‘cause, you know, like I talked to my sisters and we 
prayed over it and everything and yeah so… I was thinking it must 
not be anything if they haven't brought me in before now. Interviewer: 
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So it was kind of reassuring that it wasn't a brand new thing? 
Participant: Yeah” (1020B) 
These women interpreted their own signs of risk as normal in light of 
others in their social context or from cues given by providers. Many of them had 
previous experience with abnormal findings and the fact that abnormalities found 
on mammograms or ultrasounds were ‘not new’ was reassuring. These women 
used their social contexts to normalize their experiences when they found signs 
of risk, suggesting that provider communication about increased risk was not 
concerning to this group. 
The general theme of interpreting medical findings as normal was 
consistent with women’s beliefs about what risk was and whether it could be 
controlled. Women in this group expressed one of two beliefs about risk. First, 
some suggested that that risk is just a chance or possibility: “Everybody's at risk. 
I guess- and I guess I am at a small risk now with the breast cancer, ‘cause I 
think everybody's at risk” (0294A). Alternatively, risk was thought to be theoretical 
or a gray area:  “As far as risk factors, I think getting up in the morning and 
getting out of bed can be a risk and if- to me if there's not some kind of proof” 
(1006B). Here the lack of risk symptoms led to a perception of low risk. Most 
women in this group didn’t buy into the medical paradigm suggesting that risk 
should be intervened upon and was a serious threat to health. Instead, risk was 
consistently expressed to be something that is out of your personal control and 
somewhat abstract.    
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In terms of adopting risk-reduction behaviors, this group unanimously 
voiced the importance of regular screening as part of their activities. Lifestyle 
changes and medical intervention were less commonly adopted to reduce breast 
cancer risk specifically, but those who participated in risk reduction activities did 
so because of broader healthy behaviors. These women described concerns 
about maintaining a healthy trajectory in accounting for their actions.  Their 
rationale was broader in scope than women who felt control over risk and did not 
reflect the notion that these behaviors would minimize risk itself.  As one woman 
stated, “So exercise is probably beneficial I guess to prevent, you know, breast 
cancer too, along with, you know, lowering your risk of heart attack, stroke, 
whatever” (0407A). Women who participated in behavioral efforts saw them as a 
benign way to address a variety of health risks, and were less optimistic about 
what impact these actions would have on breast cancer risk more specifically. 
Unlike women who expressed low levels of risk perception and high levels of 
control, these women did not hold firm beliefs on the utility of behaviors to 
manage risk. 
There were two exceptions to this pattern identified among these women. 
Two women, despite feeling low levels of control over breast cancer risk, did 
choose medical intervention with SERMs to reduce their risk of breast cancer. 
They chose treatment, not because they described their risk as high, nor 
because they felt in control, but because others adopted these interventions. 
They describe their decisions as follows: 
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“Well I think my experience with cancer probably makes me a more 
likely person to take advantage of, you know, taking medication 
because of, you know, seeing other people- because of my relatives’ 
experiences. So it- I probably was a person who had made a decision 
maybe more quickly than somebody else who had not had that 
experience.” (0407A)  
In speaking about her mother’s experience with tamoxifen, this woman also said, 
“I couldn't see anything. I couldn't see any [side] effects in her, or whatever, any 
difference that that made.” The other women described her decision by saying: 
“I was thinking that I’m sixty two and if I take [tamoxifen] for five years, 
I’m there- I’m sixty seven. Okay, but at sixty nine if my risks increase 
again then, you know. You see what I’m saying? So it's like 'I’m 
young' (laughs).  I think just looking at the risk and thinking about my 
mom and that kind of thing and maybe thinking about other things 
that people don't do that they should do, you know. I’m like listen, it's 
wait and watch. If it becomes serious we cut the boob off, I get my 
implants that I’ve always wanted and we call it a day.” (0664A) 
Both of these women who decided to take medication recall the breast cancer 
experiences of their mothers or relatives in relating their reasons for adopting 
medical approaches to risk reduction. They each indicate that they feel 
compelled to adopt all available interventions through a process of social 
comparison, despite their own conflicting perceptions. This underscores the 
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importance of social comparisons as a critical integrative element in how women 
use explanatory models to make decisions related to risk.  
 
Summary 
 Each of these four groups had identifiable, but distinct themes related to 
how women perceived their risk, whether they thought they could control risk, 
who could control risk, and the subsequent risk-reduction behaviors they 
adopted. Understanding the process of decision-making about risk reduction 
behaviors in this context can be linked back to perceptions of risk and control and 
how these together create narratives focused on particular aspects of 
explanatory models. Figure 2.3 depicts how the thematic foci of each group fit 
with our original process model. For example, high risk – high control group’s 
decision-making was focused around social comparisons made at the point of 
evaluating personal risk. Conversely, the low risk – high control group described 
their decisions as based around their anticipated course to illness and self-
efficacy in controlling risk. In sum, the analysis revealed that different aspects of 
explanatory models contribute to women’s perceptions of risk and control at 
different evaluation points throughout the decision-making process.  
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Figure 2.3: Thematic Foci of Risk Control Group Related to Decision Making 
 
Looking more broadly at patterns across groups, those women who perceived 
high levels of control, regardless of risk perception, appeared to account for their 
decisions in similar ways. Behavioral interventions such as diet and exercise 
were common among these women. Their narratives demonstrated self-efficacy 
in participating in risk-reduction behaviors established either through social 
evidence or because behavioral interventions were aligned with broader health 
beliefs and behaviors. Many expressed how behaviors such as losing weight 
would also benefit other aspects of well-being, and such changes brought 
additional benefits related to breast cancer-specific concerns.  
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 Another commonality among the groups was the focus on social context 
or ‘social evidence’. However, distinct patterns emerged related to how social 
context was integrated into decision-making.  The high risk – high control group 
used positive and negative social evidence to model specific behaviors that they 
had seen others adopt (or not adopt).  Women in the high risk – low control group 
made decisions in part based on beliefs about treatment, which were rooted in 
the experiences of those around them. The low risk – low control group 
interpreted signs of risk found during the screening process as part of the normal 
continuum of bodily changes when compared to those in their social realm in 
describing their own low levels of concern regarding risk. Finally, the low risk – 
high control group had few identifiable links between social evidence and risk 
reduction behaviors. This group instead focused on their ability to manage and 
maintain their current health trajectory through a variety of methods. These 
patterns may be useful in identifying targeted strategies that address the social 
context related to both risk perceptions and beliefs about control. 
 
Discussion 
 Understanding women’s perceptions of risk is critical in a time where we 
increasingly screen for undetected disease and propose treatments and actions 
to prevent disease from occurring. In order to engage women in prevention 
activities, it is necessary for them to first acknowledge that disease is a real 
possibility before beginning to explore potential interventions to mitigate risk.  
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The Role of Explanatory Models in Breast Cancer Risk  
The application of the explanatory model framework to breast cancer risk 
perception proved useful in identifying areas of overlap and divergence between 
conceptions of risk versus disease. We found that domains of treatment and 
etiology remained similar in a risk context; while course of illness, symptoms, and 
pathophysiology differed. We identified a new concept relative to explanatory 
models of risk, social comparisons, that perhaps becomes more dominant in a 
risk context due to the lack of physical experiences associated with being ‘at 
risk’. Understanding how these domains influence perceptions may help identify 
areas of departure between professional and lay conceptions of risk. 
One area where lay expectations were strikingly different from biomedical 
models was related to familial risk: Most breast cancers are sporadic in nature, 
with only 5-10% associated with specific, known genetic mutations. Risk 
prediction models suggest that only first degree relatives with breast cancer 
actually increase a woman’s chances of developing breast cancer herself 
(Costantino et al., 1999; Gail et al., 1989). However, many women described that 
once any family member is diagnosed with breast cancer, their own risk 
increases significantly either due to genetics or more general family associations. 
This broad view of familial associations related to risk is incongruent with the 
more narrowly-focused, Mendelian genetics view of medicine. This divergence 
has been similarly been noted by others (Lim & Hewison, 2014; Richards, 1993; 
Silverman et al., 2001) and may contribute to the documented heightened 
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perceptions of risk among women. Family history is commonly invoked as a 
signal for breast cancer risk and delineating what ‘family history’ means in both 
lay and professional terms is important for developing shared understandings of 
what factors materially increase risk. 
Similarly, women saw signs of cancer risk in testing results or in 
experienced symptoms such as breast pain. Yet clinical evidence does not 
suggest that experiencing breast pain signals an increased risk of having breast 
cancer (Duijm, Guit, Hendriks, Zaat, & Mali, 1998; Khan & Apkarian, 2002; 
Lumachi et al., 2002). Likewise, women who had a false positive mammogram 
suggested that this alone signaled heightened risk, despite the common 
occurrence of false positives not resulting in a breast cancer diagnosis. In fact, 
over a ten-year period, the cumulative risk of a false positive may be as high as 
49% (Christiansen et al., 2000; Elmore et al., 1998). Our data suggest that some 
women interpret the message of an abnormal test as risk itself. These signs of 
risk were sought to provide a sense of control over risk trajectories. Alternatively, 
negative screening tests often bring reassurance to patients that they are 
disease-free and this could be interpreted as being at low risk for cancer. As 
Kenen states (p.1547), “Many Americans receive a diagnostic invitation 
presented as a ‘gift’ of knowing. Patients are told that with this knowledge they 
can take steps towards the prevention of serious health problems” (Kenen, 
1996). However, having an abnormal test does not equate to increased risk from 
a medical perspective and patients may not be directly empowered to change 
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risk level through their behaviors following a false positive result, as Kenen 
suggests. Another study on women’s mental models of breast cancer and 
screening found that women interpret benign breast abnormalities as a pre-
cursor to cancer, with progression advancing in a linear fashion from benign 
findings to early cancer to late cancer and eventually death (Silverman et al., 
2001). This idea is inconsistent with the clinical perspective that separates 
benign findings from cancer and characterizes breast cancer as having many 
possible trajectories. This presents challenges for communication about 
screening tests and their interpretation. It is important for physicians to recognize 
that women interpret mammograms as signs of risk in order to gain a sense of 
control over the potential for future disease. Disclosing both negative and positive 
mammogram findings may impact women’s perceptions about participation in 
future screening and risk-reduction behaviors.   
One of the key aspects of explanatory models of risk that we identified in 
this study was the addition of social comparisons. Social comparisons are a 
means by which women integrate and navigate different ways of thinking and are 
part of broader cultural models. Explanatory models are always formed and 
negotiated within a social context, but the experience of being ‘at risk’ and not ill 
elevated the importance of others’ experiences. Risk’s inherent uncertainty and 
lack of identifiable illness meant that women looked for outside cues and social 
evidence to make meaning of risk rather than focusing on internal bodily 
indicators. Women used others as models to critique and evaluate where they fell 
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along the continuum of risk. Using breast cancer risk as an example, explanatory 
models of risk were formulated and explicitly addressed how social comparisons 
play into risk. This is a departure from current illness explanatory model 
frameworks. The examination of the role of social comparisons in an illness 
context is warranted given these findings.  
This newly described domain of social comparisons is compatible with 
other research in cancer prevention. For example, Pfeffer has described a similar 
concept of ‘candidacy’ for breast cancer to explain why women do or do not 
participate in breast cancer screening programs. Candidacy represents the 
personal characteristics and lifestyles that make some people more/less likely to 
develop a disease. Pfeffer found that in breast cancer screening, women placed 
a lot of emphasis on comparing moral and biographical details of candidates’ 
reproductive histories (Pfeffer, 2004). The concept of social comparisons is 
similar, although establishing ‘candidacy’ is more limited in scope. Here 
candidacy, social evidence, and evaluations of positioning of risk are integrated 
with the social context and other pieces of explanatory models to produce a risk 
identity. 
 
The Integration of Explanatory Models with Perceptions of Risk and Control 
Our analysis also indicated that explanatory models not only contribute to 
the assessment of risk, but also to perceptions of control. Both risk and control 
were important elements that related to the decision to participate in preventive 
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behaviors to reduce risk and were influenced by women’s explanatory models of 
risk. Others have similarly identified these as key features in identifying oneself 
as ‘at-risk’ for disease (Kenen, 1996). While the ‘at risk’ label is presented as 
medical fact, the adoption of a risk identity by any individual is a much more 
complex process. Our findings suggest that there are a series of evaluation steps 
that women described in assessing their own risk and making decisions about 
preventive actions that could be taken. We only interviewed women who were 
given a risk identity through counseling with providers. This likely influences the 
way that they perceive and talk about their own risk, decision-making, and 
intentions for risk-reduction. However, we observed a range of predicted clinical 
risk values amongst our sample. Our findings suggest that even those with 
increased risk may not interpret the risk label as threatening. We suspect that 
women at average or low risk might alternatively feel threatened by breast 
cancer, although further work in the general population is required to confirm how 
risk estimates influence evaluations of personal risk and behaviors. Recognizing 
the various evaluations that women undertake once provided with personalized 
risk information has several implications for clinical practice. 
First, women may or may not feel risk is something to be concerned 
about. This poses a challenge for providers when engaging women in 
discussions about breast cancer risk, screening and prevention. The biomedical 
approach to risk evaluation assumes that providing risk information to individuals 
will lead to increased knowledge and is sufficient for informed decision making 
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about prevention and screening. This may not be true, particularly in underserved 
populations that may have less understanding of the biomedical explanations of 
breast cancer signs, symptoms, treatment options, and screening guidelines 
(Davis et al., 2004; Rauscher et al., 2010). Yet even in educated populations, 
beliefs and skewed perceptions of actual risk exist (Black et al., 1995) and 
remain after providing personalized risk information (Quillin et al., 2004).  
Secondly, patients and providers may hold different ideas about whether 
risk can be controlled and who has the power to alter risk status. Some have 
suggested that women view breast cancer as more preventable than providers 
(Black et al., 1995), and exaggerate the importance of modifiable risk factors 
when determining their own risk (Silverman et al., 2001). Others have 
documented that women adopt more fatalistic approaches to the development of 
breast cancer that prevent them from participating in risk reduction behaviors 
(Niederdeppe & Levy, 2007). We observed similar variation in our study, and 
captured this by examining women who felt they had high versus low control over 
their risk trajectories. The varied associations and perceptions may be in part due 
to the conditions under which risk perceptions and behaviors are being studied. 
Brewer et al. contend that personal risk perceptions are more important for 
relatively diffuse external influences, such as general public health messaging 
about sunscreen use. This is contrasted with strong, directed external 
messaging, such as professional recommendations for cancer screening tests 
where they view risk perceptions as less influential (Brewer, Chapman, et al., 
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2007). However, this assertion overlooks how perceptions of control contribute to 
behaviors, even in the presence of strong physician recommendations. The 
discrepancies in findings highlight the complexity of studying perceptions and 
behaviors. While fatalism as an explanation for behaviors may be too simplistic 
(Flórez et al., 2009), there are likely a combination of internal and external 
evaluations and perceptions that influence decision-making to produce 
behaviors. Our study found that perceptions of control varied among women at 
high risk for breast cancer, and contributed to behaviors in concert with 
perceptions of risk. 
Finally, women in our sample were seen to evaluate who was able to 
control risk: either themselves, the medical system, or some combination of the 
two. A main aspect of this was trust in both medical providers and the system in 
general. Physicians are increasingly tasked with establishing trust by attending to 
patient preferences and values as part of adopting a shared decision-making 
approach. Still, a recent national survey suggested that patient decisional 
processes in cancer screening and medication use were poor, and many patients 
have poor knowledge of benefits and risks of these interventions (Fairfield et al., 
2015). The interventions in this setting, including tamoxifen use, increased 
frequency of screening tests, and/or lifestyle modifications are all long-term 
commitments. The ability of physicians to inform and empower women to commit 
to prevention is essential in promoting adherence to these regimens, which have 
substantial rates of discontinuation (Roetzheim et al., 2015). Physicians require 
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more support in both assessing perceptions of risk and counseling patient about 
available options for prevention (Agoritsas et al., 2015; Collins et al., 2014). Our 
results suggest that finding some shared understanding of risk and the potential 
for treatment may provide a way to increase adoption of risk-reduction behaviors. 
A shift in medical practice to a patient-centered model of shared decisions 
requires that patients and providers work together in decision-making, particularly 
under conditions of uncertainty, as is present in risk communications (Eriksson, 
Nilstun, & Edwards, 2007). 
Attending to patient preferences applies not only to preferences about 
treatment options, but also in regards to informational needs. It is important to 
understand the patient’s desire for decisional responsibility. It has been 
suggested that considering the patient’s informational needs is an ethical 
imperative that is influenced by the approach taken during consultations 
(Eriksson et al., 2007). There are patients who seek full disclosure of all risk 
information and subsequent decisional authority. For example, some women in 
the high risk – high control group felt they alone had the ability to control their 
own risk, and were distrustful that the medical system was acting in their best 
interests to intervene on their risk status. This creates significant challenges for 
providers when making recommendations about risk-reduction strategies. Other 
patients will seek medical advice and adopt interventions for risk proposed by 
physicians as a means to avoid decisional regret (Zeelenberg, 1999). We 
observed evidence of this pattern within the high risk – low control group. Some 
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women adopted a trusting stance towards medical provider recommendations 
potentially as a means of ceding decisional authority and future culpability. They 
gained reassurance from their doctors providing direction, despite feeling overall 
that risk was difficult to control.  
 
Limitations 
 This study assessed women who were identified by clinical providers to be 
at risk for developing breast cancer. The limited sampling frame restricts 
inferences that can be made about the broader population undergoing screening. 
In order to fully explicate what explanatory models of risk look like and their 
influence on decision making, expanding this work to women at all levels of risk 
and into other types of disease is necessary. Further, these women were primed 
to discuss their risk following a medical encounter that specifically involved 
personalized risk counseling. Others who do not undergo these specialized 
services may provide different perspectives that are not accounted for in these 
data.  
 A second limitation is the inability of these qualitative data to explicate the 
role of individual explanatory model domains on risk perceptions. Understanding 
the individual contributions of understandings of etiology, treatment, course to 
illness and ‘signs’ of risk to overall perceptions will be important in determining 
areas where risk communication can target gaps between lay and professional 
perceptions. One area where this may be particularly important is in those who 
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undergo diagnostic tests that reveal some abnormality. These interviews 
indicated that women who have received a diagnosis of atypia on biopsy (ADH, 
ALH, or LCIS) appeared to have particularly heightened perceptions of risk. It 
could be that once something physical is ‘found’, women are more likely to adopt 
the model of risk as a true diagnosis. While beyond the scope of this study, 
differentiating the material causes of cancer and risk (i.e. ADH) from efficient 
causes (i.e. lifestyle or environment) may further our understanding of how 
women construct risk and make decisions about prevention. Future studies are 
required to evaluate the unique contributions of these different facets of 
explanatory models to risk perceptions, as well as further understand the role of 
social comparisons across domains. 
 
Conclusions 
Methods of designing more effective risk communications within the 
patient-provider relationship have been proposed. There is a large body of work 
on creating visual representations of risk and numerical data that are 
comprehensible to lay individuals (Cuite, Weinstein, Emmons, & Colditz, 2008; 
Fagerlin, Zikmund-Fisher, & Ubel, 2011; Zikmund-Fisher et al., 2008). These 
address issues of comprehension, but not acceptability of interventions for risk or 
the emotional component of risk perception (Zikmund-Fisher, Fagerlin, & Ubel, 
2010). Others take a more multi-faceted and interpersonal approach to changing 
communication, as in Fischhoff and colleagues’ three step model (Morgan, 
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Fischhoff, Bostrom, & Atman, 2000). Their proposed steps to improving 
communication include: 1) Summarizing available scientific evidence from the 
expert perspective; 2) Conducting non-directive interviews to elicit the 
perspective of the target audience; and 3) Comparing mental models of these 
two groups to identify contradictory mental models and misunderstandings to be 
addressed in subsequent communication (Morgan et al., 2000). The framework 
for this model is appealing, but may find its impact limited by its requirements for 
information gathering and by the lack of attention to social context. In undertaking 
one such evaluation in breast cancer screening, Silverman and colleagues noted 
that societal messages around ‘early detection saves lives’ were pervasive and 
lead to potential victim blaming when cancer was diagnosed (Silverman et al., 
2001). We not only need to understand women’s mental models of cancer and 
risk, but also understand the context in which messaging is received outside of 
clinical encounters that comprises social norms. There is a call for researchers to 
explore ways of supporting better processes of care by re-designing 
communication channels and patient workflows both within and outside of the 
medical system (Klein et al., 2014). Multi-level approaches to researching 
decision making in cancer prevention and control are needed to shed light on 
decisional factors such as heuristics, affective processes, and social context that 
influence both patient and provider decisions and communication. Conversations 
that reveal pieces of explanatory models of risk may be a start to addressing 
misconceptions about the power and limitations of breast cancer risk-reduction 
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interventions. Attending to patient perceptions of risk and control to establish 
shared understandings about risk and its treatment are key to developing a 
framework for the care of high risk patients that is evidence-based and sensitive 
to patient preferences. 
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CHAPTER 3 : ASSOCIATIONS BETWEEN BREAST CANCER RISK 
PERCEPTION AND GENERAL HEALTH SERVICE USE 
Background 
 The use of mammography to screen women for breast cancer has been 
widely adopted, with 66.5% of all women over 40 years of age in the United 
States undergoing a mammogram in 2010 (National Center for Health Statistics, 
2014). Among the core group for whom routine screening is recommended under 
the current United States Preventive Services Task Force (USPSTF) guidelines 
(ages 50-74), screening rates are higher at 72.6%. While screening 
recommendations were based on initial randomized trials demonstrating 
improvements in mortality with mammography screening (Marmot et al., 2013; 
Nelson et al., 2009), long term data have recently shown limited mortality benefit 
over time (Miller et al., 2014). Despite these findings, mammography remains 
one of the best tools that physicians have to detect breast cancer early and 
intervene to stop its spread. Some of the limitations and identified harms of 
mammography include the high prevalence of false positives, requirements for 
further imaging and biopsies, the potential for over-diagnosis of breast cancer, 
radiation exposure, and masking bias in dense breast tissue (Nelson et al., 
2009). These issues have received extensive attention in the literature and are 
important concepts for women to understand as they begin screening regimens. 
Individual psychosocial harms such as anxiety, worry and fear resulting 
from false positive findings have garnered particular attention in recent years 
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(Brewer, Salz, et al., 2007; Watson, Henderson, Brett, Bankhead, & Austoker, 
2005).  Multiple studies have shown that anxiety and distress are common 
among those who have a false positive mammogram with effects persisting in the 
months following the test (Aro et al., 2000; Brewer, Salz, et al., 2007), and 
differing among underserved populations (Goldman & Risica, 2004; Jatoi, Zhu, 
Shah, & Lawrence, 2006). Over a 10-year screening period, the cumulative 
probability that a woman will have a false positive mammogram is 42-61%, 
depending on the screening interval (Christiansen et al., 2000; Hubbard et al., 
2011). The prevalence of false positive findings combined with documented 
negative psychosocial outcomes were in part the basis for amending the 
USPSTF guidelines in 2009 for younger women who are more frequently 
affected by these outcomes (United States Preventive Services Task Force, 
2009). These guidelines acknowledge the complex set of benefits and harms that 
require consideration when patients and providers consider initiating cancer 
screening, and therefore promote shared decision-making in this context. 
Although models of shared decision-making recommend a comprehensive 
discussion of benefits and harms and a process-based approach to shared 
decisions, this is an ideal not often realized in clinical practice (Gunn, Soley-Bori, 
Battaglia, Cabral, & Kazis, 2014; Hoffman et al., 2010; Makoul & Clayman, 
2006). Currently, communication at the time of screening initiation fails the 
patient in terms of framing expectations around the longitudinal implications of 
undertaking screening, including the potential for false positive findings and 
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future testing. 
There is some literature indicating that women have concerns about 
screening when they are presented with the opportunity to undergo 
mammograms. One survey suggested that up to 60% of women were 
apprehensive about the possibility of over-diagnosis with mammography 
screening and believed it should be considered when making decisions about 
undergoing a screening regimen (Schwartz et al., 2000). These findings suggest 
that decisions about mammography screening can be informed by understanding 
probabilities for future testing arising from positive results, especially given that 
the serial nature of screening presents more opportunities for these events. It has 
been shown, however, that having a false positive mammogram is associated 
with increases in individuals’ perception of risk, despite no actual change in risk 
or threat to health (Aro et al., 2000; Rosenbaum, 2014). The full impact of false 
positives on attitudes and behaviors has not yet been documented. If, in fact, 
women who experience a false positive finding on mammogram perceive their 
breast cancer risk to be elevated, a question is raised regarding their subsequent 
health care decisions.  In order to promote more informed expectations about the 
meanings and implications of a positive mammogram further study is warranted. 
The potential impact of screening on the individual may be understood in 
part through research on risk and identity. This research shows the tendency for 
lay individuals to interpret probabilities of disease as both a pronouncement of 
current health status in addition to a projection of future ill health (Gillespie, 2012; 
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Timmermans & Buchbinder, 2010). Gillespie qualitatively investigated the impact 
of surveillance medicine related to cholesterol and PSA screening. He concluded 
that undergoing a test that identified one as ‘at risk’ for disease development 
symbolically altered one’s identity, such that uncertainty and anxiety arose from a 
process intended to provide certainty for individuals. He termed this construct 
‘measured vulnerability’ and suggested that testing encouraged the adoption of a 
sick role (Gillespie, 2012). Based on this conclusion, we may anticipate 
heightened risk perceptions and possibly increased health service use in a 
population undergoing regular screening, particularly for those who experience a 
false positive finding, which acts as a designation of risk. One study in the setting 
of breast cancer risk found that 5 years after receiving a false positive 
mammogram result, low risk women continued to feel at constant risk for breast 
cancer and sought additional screening, despite subsequent normal 
mammography results (Lindberg et al., 2013). Another small study in an HMO 
population suggested that both breast-specific and general ambulatory service 
use increased following a false positive mammogram (Barton et al., 2001). 
Greaves similarly suggests that such processes of identifying risk increase 
contact with the medical system through the creation of ‘partial patients’ who, 
while healthy, undergo repeated monitoring on a long term basis thus increasing 
potential opportunities for treating risk status (Greaves, 2000). To date there is 
limited knowledge regarding the various ways in which a screening regimen can 
affect health care use, and by extension, costs to both the patient and the health 
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system. 
The qualitative findings on the effects of risk identification and surveillance 
medicine have not yet been examined through empirical, quantitative 
investigation. Although there is increasing interest in determining the 
multidimensional benefits and harms associated screening and risk 
communication, the effects of designating individuals as ‘at risk’ on broad health 
care utilization measures have yet to be studied. This is a critical gap in 
knowledge at a time when there is increased emphasis on improving cancer 
screening rates as part of payment schemes intended to improve quality 
(Centers for Medicare and Medicaid Innovation, 2015). Physicians and practices 
have financial incentives to promote mammography among all eligible women. 
Yet the process of undergoing a mammogram and receiving either normal or 
abnormal results may itself change the way a woman conceptualizes her own 
health and engages with the medical system. Understanding the impact of these 
tests on how women participate in care over time, along with potential changes in 
provider recommendations is imperative to achieving accountable care.  
This study seeks to examine whether having a finding of an abnormal 
mammogram, acting as a designation for elevated risk, (Aro et al., 2000; 
Lindberg et al., 2013), is associated with greater health services use. Previous 
studies have examined breast-specific health service use in relation to other 
clinical markers of risk status such as genetic markers or family history (Haber et 
al., 2012; Larouche et al., 2012; Wainberg & Husted, 2004). This study expands 
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the measure of health care utilization beyond breast-specific services among a 
broader population of women undergoing mammography. In addition, this study 
examines both provider and patient factors that drive risk perception and health 
care utilization. Thus, findings may help inform future multi-level interventions 
that target the processes of cancer screening.  
 
Study Aims 
This study employed a retrospective design to assess for effects of having a false 
positive mammogram on subsequent health service use. Two specific aims were 
developed to achieve this goal: 
Aim 1: Examine the association between false positive mammogram 
results and provider referrals for health service use.  
Hypothesis 1: Women who have a recent false positive 
mammogram (high risk) will be more likely to have an increase in 
referrals from providers for all health services, compared to those 
women with no false positive (low risk).  
Aim 2: Examine the association between false positive mammogram 
results and patient participation in health services.  
Hypothesis 2: Women who have a recent false positive 
mammogram (high risk) will be more likely to show an increase in 
outpatient visits compared to those women with a former or no false 
positive (intermediate or low risk). 
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Hypothesis 3: Women who have a recent false positive 
mammogram (high risk) will be more likely to show a decrease in 
the rate of missed appointments, compared to those women with a 
former or no false positive (intermediate or low risk). 
 
Figure 3.1 displays the variables and relationships examined in this study. The 
first step of the analytic process examined the occurrence of medical events (i.e. 
false positive mammograms) in this population.  The abnormal finding acted as 
the precipitating event for the outcomes studied in this chapter. Secondly, the 
effects of having a false positive on provider referrals were measured to assess 
how the health system adapts recommendations for care based on test results to 
produce utilization (Aim 1). Lastly, changes in engagement in health services 
resulting from having a false positive mammogram as measured by outpatient 
visits and missed appointments were examined (Aim 2). This may be a direct 
result of provider recommendations (referrals) or may be a product of increases 
in a patient-perceived need for additional care following a medical finding that 
may be interpreted as risk. Understanding changes in general health service use 
produced by both patients and providers will contribute to the literature on the 
benefits and risks of cancer screenings. 
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Figure 3.1: Conceptual Model Domains Explored in Chapter 3 
Methods 
Study Design 
A longitudinal case-control study design compared women with false 
positive mammogram results, a medical finding that may be interpreted as a risk 
designation, to women with normal mammograms in terms of their overall health 
service use. The study examined how the presence/absence and timing of a 
false positive mammogram finding affected subsequent utilization through 
measuring the number of outpatient visits, referrals, and rates of missed 
appointments both in the two years prior to an index mammogram and one year 
following. Participants were divided into 3 groups, representing variable levels of 
risk status: 1) Low risk, intermediate risk, and high risk. In this study having a 
false positive test acted as a proxy for a designation of risk, which is not 
measured directly. Using an abnormal mammogram as a proxy for high risk 
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designation is supported in the literature.  One study found that compared to 
women with normal mammograms, those who had false positive mammograms 
that resolved to normal perceived significantly higher levels of susceptibility to 
breast cancer at both 2 and 12 months post-mammogram (Aro et al., 2000). 
Others have confirmed that heightened perceptions of risk observed following an 
abnormal mammogram persist over time (Brett & Austoker, 2001; Lindberg et al., 
2013; Rosenbaum, 2014). 
A difference-in-difference analysis assessed trends in utilization over time 
to detect differences in utilization between the three groups. Figure 3.2 provides 
an overview of the study design. 
 
Figure 3.2: Study Design and Measurement Variables for Each Time Period 
Including 2 years of data in the pre-index mammogram period allowed for 
adequate exploration of utilization trends existing prior to the index date. This 
provided a more stable measure of utilization prior to the index mammogram, 
allowing for assessment of bias such as selection-maturation effects that may be 
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threats to internal validity in observational studies (Shadish, Cook, & Campbell, 
2002). Models compared average utilization over the two years prior to the index 
mammogram to utilization in the one year post-mammogram. 
 
Participants 
Utilization data for a sample of women from a single, urban, safety-net 
hospital were examined. Subjects were included in the analysis if they were: 1) 
Between 40 and 75 years of age; 2) Received primary care at Boston Medical 
Center (BMC); 3) Had a screening mammogram performed at BMC in calendar 
years 2010 or 2011; and 4) Had their first mammogram at the age of 40 or more. 
Women receiving primary care at BMC typically use the hospital system as their 
main source of care for all conditions, including emergency and specialist care 
(Kapoor et al., 2014). Restricting the sample to this group provided a more 
consistent measure of utilization given that most records were expected to be 
available. Using 2010 and 2011 as the years to identify index mammograms 
provided a sufficient follow up period of at least 1 year. 
The following criteria were cause for exclusion from the study sample: 1) 
Prior history of any cancer, with the exception of skin cancers other than 
melanoma; 2) Receipt of a diagnostic mammogram with no prior screening 
mammogram within the enrollment window; 3) Primary care received outside of 
BMC; 4) No prior visits in the two years preceding the index mammogram; 5) 
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Diagnosis of any cancer during the study period; or 6) Death during the study 
period. 
 
Data Collection 
This study utilized administrative and clinical data. Therefore, no 
recruitment of individual subjects was required and a waiver of consent was 
obtained from the Institutional Review Board. Data were obtained through the 
Clinical Data Warehouse (CDW) at BMC. The CDW is a distinct, comprehensive 
database that consolidates data from multiple electronic medical record systems 
allowing for the automatic capture of many socio-demographic and clinical 
variables. Database developers were consulted to cross reference data from 
multiple clinical systems and to assist researchers. Criteria for inclusion/exclusion 
and variable definitions were reviewed with the CDW personnel prior to the 
production of the final dataset. Using retrospective clinical data provided a 
measure of actual utilization rates, and eliminated bias from self-reported 
utilization data. 
 
Variable Specification 
Independent Variables 
An abnormal mammogram was defined using criteria defined in The 
Breast Imaging Reporting and Data System (BI-RADS), 4th edition. The BI-RADS 
classification scheme was developed collaboratively between several national 
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professional organizations to standardize mammographic reporting and improve 
the quality of patient care (American College of Radiology, 2003). Classifications 
range from 0-6. A normal finding included a mammogram categorized as a 1 or 
2. These classifications indicate negative (normal) or benign findings, 
respectively. A BI-RADS score of 0, 3, 4, or 5 was included in the abnormal 
mammogram group. A score of zero indicates a need for additional imaging 
evaluation or comparison to a previous mammogram. Scores of 3, 4, and 5 
indicate increasing levels of suspicion for a malignant finding, and all require 
short-term follow up or further testing. All BI-RADS 6 scores were excluded as 
they indicate a known cancer. False positives were defined as those abnormal 
findings that did not result in a cancer diagnosis following the index mammogram 
as measured through the tumor registry. 
BI-RADS results of index and prior mammograms were grouped to create 
3 levels of the risk designation variable. Risk designation was categorized as 
follows: 1) High risk: Women experiencing a false positive mammogram at the 
index date; 2) Low risk: Women who had a normal index mammogram result and 
no previous false positive results; and 3) Intermediate risk: Women who had a 
normal mammogram result  at the index date in 2010/2011 with a false positive 
result in the past. 
The demographic variables included in the analysis as covariates were 
age, race, health insurance, education, and primary language. All of these were 
collected and recorded at the index mammogram date. ICD-9 codes from patient 
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problem lists were collected in order to control for co-morbidities experienced by 
women that may increase health service use independent of breast cancer risk 
designation. ICD-9 codes were used as covariates in the final analysis by 
indicating the presence or absence of the 30 key comorbidities represented in 
the Elixhauser index (Elixhauser, Steiner, Harris, & Coffey, 1998; Quan et al., 
2005). The Elixhauser comorbidities were defined for the pre-index mammogram 
period to assess their potential influence on utilization.  
Lastly, 3 variables related to the timing of events were created. One time 
variable defined rates of utilization (visits, referrals, and missed appointments per 
year) over the course of the three years of data: 2 years pre-index visit, 1 year 
pre-index visit, and 1 year post-index visit. This variable aided in the examination 
of trends in utilization over time. A second variable was defined to dichotomize 
time into a pre-index vs. post-index period. This coding was later interacted with 
the risk groups to assess differences over time by group (Dimick & Ryan, 2014). 
This indicator variable averaged utilization over the two years prior to the index. 
Finally, a third variable indicated whether the initial index mammogram took 
place in calendar year 2010 vs. 2011 in order to adjust for potential secular 
practice pattern changes in mammogram utilization. 
 
Dependent Variables 
The primary outcome variable for Aim 1 was the number of referrals, 
which measured provider-initiated orders for health services. A count of provider 
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referrals was totaled for each time point (pre-index year 2, pre-index year 1, and 
follow up year 1). Referrals were captured in the CDW as orders and all types 
(i.e. procedure-based, specialty visits, laboratory) were compiled to measure the 
total count over each time frame. This measure was intended to capture 
provider-driven utilization through recommendations for care following a false 
positive mammogram. 
To test whether women in the high risk group were more likely to have 
increased health service use (Aim 2), the number of outpatient visits attended 
was measured. A count of outpatient visits was calculated for each 12-month 
period. Outpatient visits included all primary care, specialty, emergency room, 
laboratory, and procedure visits attended. Of note, laboratory visits included all 
individual lab tests over one day. For example, if a patient had 6 individual tests 
done at one visit, the coding captured 1 laboratory visit. It was hypothesized that 
the rate of visits would increase following the occurrence of a false positive 
mammogram, as the false positive may be interpreted as a designation of risk. 
Finally, a rate of missed appointments was calculated as the percent of 
scheduled appointments that were classified as “no show” or “cancelled” over the 
total number of visits in the time period. It was hypothesized that the occurrence 
of a false positive (high risk) would reduce the rate of missed appointments in the 
follow up period as women might feel at higher risk and therefore be less likely to 
forgo scheduled appointments. 
 
  102
Statistical Analysis 
Descriptive statistics were performed for all study variables in the sample. 
These statistics included means, standard deviations, and medians for 
continuous variables, and frequency distributions for categorical variables. Bi-
variate analyses by risk group were performed to examine the association 
between independent and dependent variables. T-tests were performed for 
continuous variables and chi-square tests for categorical variables. Correlations 
between independent variables were also assessed for collinerarity that might 
effect estimates in final regression models. Since correlations all remained 
relatively low (well below 0.5), all covariates were included in final models. The 
correlation matrix can be found in Appendix B.  
Analyses utilized a difference-in-differences model to measure the change 
in utilization, between pre-and post-index mammogram, among the high and 
intermediate risk status cohorts compared to the corresponding change among 
the low risk status cohort, controlling for predisposing and enabling factors such 
as race/ethnicity, education, insurance and comorbidities. It was anticipated that 
women who have some test that indicated a potential breast cancer risk 
designation would have an increase in the number of outpatient visits and 
referrals, and a decrease in the rates of missed appointments, compared to the 
group with no or previous mammography-based indicators for high risk. The 
difference-in-difference model (Bertrand, Duflo, & Mullainathan, 2004; Dimick & 
Ryan, 2014) using a Poisson regression framework assessed the effect of a 
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current or previous false positive mammogram on provider referrals (Aim 1), 
outpatient visits, and missed appointments (Aim 2). The unit of observation in this 
analysis was person-years, with three observations per individual; one for the 2 
years pre-index, one for one year pre-index and another for the post-index 
period.  
The primary independent variable of interest in the difference-in-
differences model was the interaction between time and risk designation, which 
compared the average difference in utilization in the pre- versus post-index 
mammogram periods for the high and intermediate risk groups compared to the 
low risk group. Measuring change using a pre-post design allows individuals to 
act as their own controls and provides a more complete estimation of health 
service use in the population of women undergoing breast cancer screening. All 
analyses were perfomed in SAS version 9.3. Models were constructed using 
generalized linear model commands (proc genmod), specified with a Poisson 
distribution and a log link function. A ‘repeated’ statement was included to 
account for lack of independence of observations across the time periods, and a 
Pearson scale option was specified to ensure the model variance was 
appropriate by adjusting for any overdispersion. Estimates were exponentiated 
and are reported here as incidence rate ratios (IRR) with 95% confidence 
intervals. Statistical significance was set at α=0.05 for all models. 
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Sensitivity Analysis 
Because of the potential for false positive rates to be confounded by age 
due to differences in the properties of mammography imaging and the structure 
of breast tissue, we conducted a sensitivity analysis to assess the influence of 
age. Younger women have higher breast tissue density, resulting in a lower 
sensitivity and specificity of mammography for this group (Carney et al., 2003). 
Stratifying the sample into two groups (40-49 and 50-75) to determine possible 
differential effects by age may help control for the confounding of false positive 
rates due to the properties of mammography. Examining age group separately 
also provided the opportunity to run separate analyses on groups more likely to 
be similar in baseline risk status. 
In addition to creating Poisson regression models, which may not 
adequately capture dispersion in outcome measures, models using a negative 
binomial distribution were also constructed. The negative binomial distribution is 
more flexible, but aslo appropriate for use with count data. 
 
Results 
Patient Characteristics 
 A total of 3,920 women met the inclusion criteria and were included in the 
final sample. Table 3.1 displays the demographic characteristics of this group. 
Almost half of the sample (42%) were part of the core group of women for whom 
screening is recommended by the USPSTF, those between 50 and 64 years of 
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age. An additional 43% were between 40 and 49, with 15% betweeen 65 and 75 
years of age. Approximately half of the sample was Black, and 61% spoke 
English as their primary language. The majority of the women had public 
insurance (55%), mostly comprised of Medicare or Medicaid coverage. Finally, 
41% of women had less than a high school education. These demographics are 
consistent with the racially-diverse and low income patients served by BMC. 
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Table 3.1: Demographic and Risk Characteristics of Sample (N=3,920) 
Variable N  (%) High Risk (n=500) 
Intermediate 
Risk (n=594) 
Low Risk 
(n=2,826) 
P-
value 
Age group 0.0002 
< 50 1,678 (43%) 256 (51%) 227 (38%) 1,195 (42%)  
50-64 1,668 (42%) 188 (38%) 280 (47%) 1,200 (42%)  
65-75 574 (15%) 56 (11%) 87 (15%) 431 (15%)  
Race 0.059 
Non-Hispanic White 595 (15%) 90 (18%) 87 (15%) 418 (15%)  
Hispanic 533 (14%) 59 (12%) 99 (17%) 375 (13%)  
Black 2,035 (52%) 257 (51%) 311 (52%) 1,467 (52%)  
Other/Declined 757 (19%) 94 (19%) 97 (16%) 566 (20%)  
Language 0.18 
English 2,410 (61%) 301 (60%) 374 (63%) 1,735 (61%)  
Spanish 381 (10%) 45 (9%) 72 (12%) 264 (9%)  
Haitian Creole 556 (14%) 79 (16%) 73 (12%) 404 (14%)  
Other 573 (15%) 75 (15%) 75 (13%) 423 (15%)  
Primary Insurance 0.37 
Commerical/Private 1,008 (26%) 124 (25%) 156 (26%) 728 (26%)  
Public 2,137 (54%) 270 (54%) 338 (57%) 1,529 (54%)  
Other/Uninsured 775 (20%) 106 (21%) 100 (17%) 569 (20%)  
Education 0.02 
Less than High 
School 1,610 (41%) 213 (43%) 272 (46%) 1,125 (40%)  
High School/GED 1,110 (28%) 132 (26%) 151 (25%) 827 (29%)  
Some 
College/Assoc. 
Degree 
381 (10%) 37 (7%) 65 (11%) 279 (10%)  
College/Postgrad 539 (14%) 79 (16%) 76 (13%) 384 (14%)  
Other/Missing 280 (7%) 39 (8%) 30 (5%) 211 (7%)  
 
Associations between Demographics and Risk Groups 
 Characteristics of the sample were examined to identify the demographic 
correlates with false positive mammogram findings, acting as a proxy for risk 
designation. The high risk group was younger than the intermediate and low risk 
groups (p=0.0002). This difference was expected given the higher prevalence of 
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false positive mammograms in those under 50 years of age (Carney et al., 2003; 
Hubbard et al., 2011). Education (p=0.02) was the only other characteristic 
significantly associated with risk group. For correlations between all demographic 
variables, refer to Appendix B. 
 In terms of comorbidities present prior to the index mammogram, 75.8% of 
the sample had at least one comorbid condition included in the Elixhauser index. 
Three Elixhauser conditions were not represented in this sample due to specified 
exclusion criteria. These were lymphoma, metastatic cancer, and solid tumor 
without metastasis. Additionally, no patients included in the sample were HIV+ 
and none had blood loss anemia. These conditions are therefore not represented 
in Table 3.2 below. The most common conditions among this group of women 
were uncomplicated hypertension (46%), depression (29%), hypothyroidism 
(9%), diabetes (8%), deficiency anemias (7%) and obesity (6%). Examining 
comorbidities across risk groups, there were few differences. Uncomplicated 
hypertension, chronic pulmonary disease, hypothyroidism, and obesity were 
differently represented in the risk groups. The intermediate risk group had the 
highest prevalence of all of these conditions with the exception of obesity, which 
was lowest in this group. The distribution of having one or more comorbidity also 
differed by group, with the intermediate risk group having the highest prevalence 
of comorbidities at 80.3%, while 75.6% of the low risk group had at least one 
comorbidity and 71.4% of the high risk group did. 
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Table 3.2: Prevalence of Comorbidities by Risk Group 
 
Total  
(n=3920) 
High  
(n=500) 
Intermediate 
(n=594) 
Low  
(n=2826) 
P-
value 
Congestive heart 
failure 69 (1.8%) 4 (0.80%) 8 (1.35%) 57 (2.0%) 0.11 
Cardiac 
arrhythmias 96 (2.4%) 11 (2.2%) 14 (2.4%) 71 (2.5%) 0.91 
Valvular disease 50 (1.3%) 3 (0.60%) 4 (0.67%) 43 (1.5%) 0.09 
Pulmonary 
circulation 
disorders 
40 (1.0%) 3 (0.60%) 8 (1.35%) 29 (1.0%) 0.48 
Peripheral 
vascular disorders 71 (1.8%) 7 (1.40%) 17 (2.9%) 47 (1.7%) 0.10 
Hypertension, 
uncomplicated 1801 (45.9%) 182 (36.4%) 314 (52.9%) 1305 (46.2%) <.0001 
Hypertension, 
complicated 17 (0.4%) 2 (0.40%) 1 (0.17%) 14 (0.5%) 0.67 
Paralysis 14 (0.4%) 3 (0.60%) 1 (0.17%) 10 (0.4%) 0.51 
Other neurological 
disorders 85 (2.2%) 10 (2.0%) 16 (2.7%) 59 (2.1%) 0.63 
Chronic 
pulmonary disease 562 (14.3%) 73 (14.6%) 109 (18.4%) 380 (13.4%) 0.008 
Diabetes, 
uncomplicated 152 (3.9%) 19 (3.8%) 31 (5.2%) 102 (3.6%) 0.18 
Diabetes, 
complicated 169 (4.3%) 21 (4.2%) 20 (3.4%) 128 (4.5%) 0.44 
Hypothyroidism 336 (8.6%) 48 (9.6%) 69 (11.6%) 219 (7.7%) 0.006 
Renal failure 68 (1.7%) 6 (1.20%) 12 (2.0%) 50 (1.8%) 0.56 
Liver disease 54 (1.4%) 5 (1.00%) 10 (1.7%) 39 (1.4%) 0.63 
Peptic ulcer 
disease 30 (0.8%) 2 (0.40%) 9 (1.52%) 19 (0.7%) 0.08 
Rheumatoid 
arthritis/collagen 
vascular disorders 
88 (2.2%) 9 (1.80%) 17 (2.9%) 62 (2.2%) 0.47 
Coagulopathy 42 (1.1%) 5 (1.00%) 6 (1.01%) 31 (1.1%) 0.97 
Obesity 228 (5.8%) 31 (6.2%) 20 (3.4%) 177 (6.3%) 0.022 
Weight loss 131 (3.3%) 15 (3.0%) 21 (3.5%) 95 (3.4%) 0.88 
Fluid and 
electrolyte 
disorders 
65 (1.7%) 10 (2.0%) 13 (2.2%) 42 (1.5%) 0.39 
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Deficiency 
anemias 270 (6.9%) 31 (6.2%) 36 (6.1%) 203 (7.2%) 0.50 
Alcohol abuse 91 (2.3%) 9 (1.80%) 11 (1.9%) 71 (2.5%) 0.44 
Drug abuse 194 (4.9%) 30 (6.0%) 31 (5.2%) 133 (4.7%) 0.44 
Psychoses 58 (1.5%) 6 (1.20%) 10 (1.7%) 42 (1.5%) 0.80 
Depression 1140 (29.1%) 133 (26.6%) 195 (32.8%) 812 (28.7%) 0.06 
≥ 1 comorbidity 2971 (75.8%) 357 (71.4%) 477 (80.3%) 2137 (75.6%) 0.003 
* Bolded estimates  are significant at α=0.05 
Secular Utilization Trends  
 Prior to running adjusted models, secular trends in utilization were 
examined for each outcome variable. Tables 3.3-3.5 display the median visit, 
referral, and missed appointment rates with the interquartile ranges in each risk 
group across the three years of data.  
Table 3.3: Median Visit Rates over Time by Risk Group 
 
Visits 2 Years 
Prior* 
Visits 1 Year 
Prior* 
Visits Post-
Mammogram 
High Risk 4 (0, 11) 9 (5, 17) 11 (6, 21) 
Intermediate Risk 12 (7, 20) 12 (7, 21) 10 (5, 19) 
Low Risk 7 (0, 16) 10 (6, 20) 10 (4, 21) 
* Significant difference in visit rates at α=0.05 
Table 3.4: Median Referral Rates over Time by Risk Group 
 
Referrals 2 
Years Prior* 
Referrals 1 Year 
Prior 
Referrals Post-
Mammogram 
High Risk 0 (0, 2) 2 (0, 4) 2 (0, 4) 
Intermediate Risk 2 (0, 4) 2 (0, 4) 2 (0, 4) 
Low Risk 0 (0, 4) 2 (0, 5) 2 (0, 4) 
* Significant difference in visit rates at α=0.05 
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Table 3.5: Median Missed Appointment Rates over Time by Risk Group 
 
Missed 
Appointments 
2 Years Prior* 
Missed 
Appointments 1 
Year Prior* 
Missed 
Appointments 
Post-
Mammogram 
High risk 0 (0, 4) 2 (0, 6) 4 (2, 10) 
Intermediate Risk 4 (2, 8) 4 (2, 8) 4 (2, 10) 
Low Risk 2 (0, 6) 4 (0, 8) 4 (2, 10) 
* Significant difference in visit rates at α=0.05 
 Bi-variate relationships between utilization outcomes and other 
demographic and risk characteristics reveal additional factors associated with 
utilization. Race, language, primary insurance, and education were associated 
with the number of outpatient visits attended through all time periods. Age group 
was significant only in the one year pre-index and post periods. Risk designation 
categories also demonstrated an association with the utilization of outpatient 
services in both pre-index time periods (p< 0.0001, and p=0.03), but not in the 
post-index period (p=0.1695). Pairwise comparisons using the Tukey-Kramer test 
demonstrated that the intermediate risk group had higher numbers of visits two 
year pre-index mammogram relative to the high risk group (µ=16.4 visits vs. 8.5; 
p<0.0001) and the low risk group (µ=11.69 visits; p<0.0001). One year pre-index, 
the intermediate risk women again demonstrated more utilization as measured 
by outpatient visits relative to the high-risk group (µ=16.8 visits vs. 14.2; 
p=0.028), but similar number of visits compared with the low risk group (µ=15.9 
visits; p=0.085) 
 Referrals demonstrated a similar trend: they were significantly associated 
with race, language, primary insurance and education across all time periods. 
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Risk category was associated with referrals only in the two year pre-index time 
period (p<0.001), but not in the one year prior to index mammogram (p=0.245) or 
in the post-index period (0.485). Pairwise comparisons indicate the mean number 
of referrals was again highest in the intermediate risk group (µ=3.14 referrals), 
which was statistically higher than the high-risk group (µ=1.59 referrals; 
p<0.0001) and the low risk group (µ=2.33 referrals; p<0.0001).  
 Finally, rates of missed appointments were significantly associated with 
race, language and education across the three time points. Primary insurance 
was not significant two years prior to the index mammogram (p=0.524), but was 
significant in the one year pre-index and post-index periods (p<0.0001). Missed 
appointments differed by risk designation in the pre-index periods only. 
Intermediate risk women had the highest rates of missed appointments 2 years 
prior to the index mammogram date, with a mean of 21.7%. This was significantly 
higher than both high-risk women (µ=13.4%, p<0.0001) and low risk women 
(µ=16.5%, p=0.003). Within one year pre-index, the intermediate risk group 
differed only from the high-risk group (µ=23.4 vs. 19.8%, p=0.004). 
 
Difference-in-Difference Models 
 Prior to developing models for the three outcomes of interest, the 
distribution of outcomes was examined to ensure planned modeling strategies 
were appropriate. The decision was made to retain all covariates in the models, 
since many showed significant relationships with the outcomes of interest as well 
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as associations between demographics and the independent variable of interest, 
risk designation category. Figures 3.3-3.5 display the distributions of visits, 
referrals and rates of missed appointments across the entire sample. For both 
visits and referrals, the mean roughly equals the variance and the distribution 
looks unimodal with a positive skew. Therefore, the Poisson distribution was 
deemed appropriate for use with these two outcomes. For the rate of missed 
appointments the distribution was similar, but potentially bimodal. Therefore, the 
models were also run with a negative binomial distribution and estimates were 
compared. Because estimates did not differ much from Poisson models, Poisson 
models are reported for all outcomes. Appendix B contains the full results of the 
negative binomial models. Further model specification details for each outcome 
are described below. 
 
Figure 3.3: Distribution of Total Visits (Post-Index) 
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Figure 3.4: Distribution of Referrals (Post-Index) 
 
Figure 3.5: Distribution of Rate of Missed Appointments (Post-Index) 
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Multivariate Models 
Outpatient Visits 
 Table 3.6 displays the incidence rate ratio (IRR) and 95% confidence 
intervals for the adjusted model predicting the total number of outpatient visits. 
The independent variable of interest is the interaction between risk category and 
time (pre vs. post-index), which represents the difference-in-difference estimate. 
The adjusted model indicates that the high-risk group has an increase in the rate 
of visits prior from pre- to post-index relative to the low risk group (IRR=1.36, 
95% CI: 1.22, 1.51). Specifically, women with a false positive mammogram at the 
index visit, had, on average, a 36% greater increase in visits in the year following 
a false positive relative to women in the low risk group with no false positive 
mammograms.  This is consistent with the hypothesis that the high-risk group 
would have a greater increase in visits relative to the low risk group (Hypothesis 
2). 
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Table 3.6: Poisson Model for Total Visit Outcome 
 
 
 IRR* 95% Confidence 
Interval 
Risk Category 
(ref=low risk) 
High  0.93 (0.85, 1.01) 
Intermediate 1.00 (0.92, 1.08) 
Time 
(ref=1 Year Pre-
Index) 
Post-Index 0.98 (0.94, 1.01) 
2 Years Pre-Index 0.73  (0.70, 0.76) 
Risk Category* 
Time 
High x Post-Index 1.36 (1.22, 1.51) 
Intermediate x  Post-Index 0.80 (0.74, 0.87) 
Age Group 
(ref= 50-64) 
<50 1.02 (0.97, 1.08) 
65-75 0.99 (0.92, 1.07) 
Race 
(ref= Non-Hispanic 
white) 
Black 1.07 (0.98, 1.16) 
Hispanic 1.14 (0.99, 1.32) 
Other 1.10 (0.99, 1.22) 
Language 
(ref=English) 
Haitian Creole 0.88 (0.82, 0.95) 
Spanish 0.95 (0.82, 1.10) 
Other 0.96 (0.89, 1.05) 
Education 
 (ref= 
College/postgrad) 
<High school 1.17 (1.07, 1.28) 
High School/GED 1.30 (1.19, 1.43) 
Some College/Assoc. Degree 1.17 (1.05, 1.31) 
Other/missing 0.94 (0.84, 1.07) 
Primary Insurance 
(ref=Private) 
Public 1.28 (1.20, 1.37) 
Other 1.05 (0.97, 1.14) 
Comorbidities Congestive Heart Failure 1.36 (1.15, 1.61) 
Cardiac Arrhythmias 1.49 (1.27, 1.75) 
Valvular Disease 1.06 (0.86, 1.29) 
Pulmonary Circulation Disorders 1.76 (1.45, 2.14) 
Peripheral vascular disorders 1.34 (1.15, 1.56) 
Hypertension, uncomplicated 1.15 (1.09, 1.22) 
Hypertension, complicated 1.23 (0.90, 1.68) 
Paralysis 0.88 (0.69, 1.12) 
Other neurological disorders 1.31 (1.13, 1.53) 
Chronic pulmonary disease 1.21 (1.13, 1.30) 
Diabetes, uncomplicated 1.48 (1.31, 1.66) 
Diabetes, complicated 1.58 (1.43, 1.75) 
Hypothyroidism 1.20 (1.11, 1.31) 
Renal failure 1.67 (1.39, 1.99) 
Liver disease 1.43 (1.18, 1.73) 
Peptic ulcer disease, excluding bleeding 1.13 (0.91, 1.42) 
Rheumatoid arthritis/collagen vascular disorders 1.25 (1.09, 1.44) 
Coagulopathy 1.31 (1.06, 1.63) 
Obesity 1.26 (1.15, 1.38) 
Weight loss 1.09 (0.94, 1.25) 
Fluid and electrolyte disorders 1.34 (1.13, 1.58) 
Deficiency anemias 1.26 (1.15, 1.37) 
Alcohol abuse 1.01 (0.85, 1.20) 
Drug abuse 1.30 (1.16, 1.45) 
Psychoses 1.41 (1.19, 1.68) 
Depression 1.30 (1.23, 1.38) 
Index Date in 2011 2011 Index 0.97 (0.92, 1.02) 
    * Bolded estimates  are significant at α=0.05 
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In addition to the increase in visits seen among the high-risk group, the 
intermediate risk group displayed a significant decrease in visit rates from pre- to 
post-index compared to the low-risk group (IRR= 0.80, 95% CI: 0.74, 0.87). This 
suggests a 20% greater decrease in visits for women after experiencing a normal 
mammogram where previously they had received a false positive result vs. those 
who have never experienced a false positive. This was not expected, as it was 
anticipated that intermediate risk women may have similar visit trends as the low 
risk women, or perhaps slightly elevated rates of utilization stemming from a 
previous risk designation via mammogram. Instead, a greater decrease in 
utilization was seen following a normal mammogram, suggesting women may 
find reassurance in testing and therefore no longer seek care at higher rates. 
Other significant predictors of increases in outpatient visits include having less 
than a college degree and public insurance.  
 
Referrals 
Table 3.7 displays the model with referrals as the dependent variable. It 
was hypothesized that high-risk women would have a larger increase in referrals 
relative to low risk women (Hypothesis 1). This finding was confirmed. Again, 
women in the high risk group saw a greater increase in referral rates from the 
pre-index period to the post-index period relative to low risk women (IRR=1.34, 
95% CI: 1.16, 1.55). The intermediate risk group did not have a significant 
change in referrals relative to the low risk group (IRR= 0.89, 95% CI: 0.79, 1.00), 
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as expected. Black and Hispanic women, those on public insurance and those 
with a high school diploma also showed an increased rate of referrals from the 
pre- to post-index mammogram time points.  
Table 3.7: Poisson Model for Referral Outcome 
 
 IRR* 95% Confidence Interval 
Risk Category 
(ref=low risk) 
High 0.96 (0.86, 1.08) 
Intermediate 0.88 (0.80, 0.98) 
Time 
(ref= 1Year Pre-Index) 
Post 0.83 (0.78, 0.87) 
2 Years Pre-Index 0.72 (0.67, 0.76) 
Risk Category* Time High x Post-Index  1.34 (1.16, 1.55) 
Intermediate x Post-Index 0.89 (0.79, 1.00) 
Age Group 
(ref= 50-64) 
<50 0.96 (0.90, 1.02) 
65-75 0.92 (0.85, 1.01) 
Race 
(ref= Non-Hispanic 
white) 
Black 1.11 (1.02, 1.22) 
Hispanic 1.22 (1.04, 1.44) 
Other 1.11 (0.99, 1.24) 
Language 
(ref=English) 
Haitian Creole 0.83 (0.76, 0.91) 
Spanish 0.94 (0.79, 1.10) 
Other 1.01 (0.92, 1.11) 
Education 
 (ref= 
College/postgrad) 
<High school 1.06 (0.96, 1.16) 
High School/GED 1.20 (1.09, 1.32) 
Some College/Voc./Tech/Assoc 1.06 (0.94, 1.20) 
Other/missing 0.96 (0.85, 1.10) 
Primary Insurance 
(ref=Private) 
Public 1.21 (1.12, 1.30) 
Other 1.05 (0.96, 1.14) 
Comorbidities Congestive Heart Failure 1.00 (0.83, 1.20) 
 Cardiac Arrhythmias 1.01 (0.86, 1.19) 
 Valvular Disease 0.93 (0.75, 1.16) 
 Pulmonary Circulation Disorders 1.42 (1.12, 1.80) 
 Peripheral vascular disorders 1.27 (1.07, 1.52) 
 Hypertension, uncomplicated 1.09 (1.03, 1.16) 
 Hypertension, complicated 0.74 (0.54, 1.01) 
 Paralysis 1.13 (0.85, 1.50) 
 Other neurological disorders 1.34 (1.15, 1.57) 
 Chronic pulmonary disease 1.15 (1.07, 1.24) 
 Diabetes, uncomplicated 1.35 (1.21, 1.51) 
 Diabetes, complicated 1.57 (1.40, 1.76) 
 Hypothyroidism 1.15 (1.06, 1.25) 
 Renal failure 1.20 (1.03, 1.41) 
 Liver disease 1.49 (1.23, 1.80) 
 Peptic ulcer disease, excluding bleeding 0.86 (0.63, 1.16) 
 Rheumatoid arthritis/collagen vascular 
disorders 
1.25 (1.05, 1.48) 
 Coagulopathy 1.31 (1.01, 1.68) 
 Obesity 1.34 (1.20, 1.49) 
 Weight loss 1.12 (0.98, 1.29) 
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 Fluid and electrolyte disorders 1.08 (0.91, 1.27) 
 Deficiency anemias 1.34 (1.22, 1.48) 
 Alcohol abuse 0.92 (0.78, 1.09) 
 Drug abuse 1.16 (1.02, 1.31) 
 Psychoses 0.98 (0.77, 1.24) 
 Depression 1.38 (1.29, 1.47) 
Index Date in 2011 Index Date 2011 0.96 (0.91, 1.02) 
* Bolded estimates  are significant at α=0.05 
 
Rates of Missed Appointments 
 Finally, rates of missed appointments were examined. A decrease in the 
rate of missed appointments among the high risk group compared to the low risk 
group was expected, but not confirmed. There was no significant interaction 
between time and high risk (IRR=1.08, 95% CI: 0.95, 1.23), but the intermediate 
risk group did have a significant decrease in the rate of missed appointments 
over time (IRR=0.81, 95% CI: 0.74, 0.90). Findings show that women with a 
previous false positive missed 19% fewer appointments across time relative to 
the low risk women. Black women and Haitian Creole speakers saw a decrease 
in the rates of missed appointments from the pre-index to post-index periods. On 
the other hand, those on public insurance saw an increase in the rate of missed 
appointments from the pre to post-index periods (IRR=1.11, 95% CI: 1.04, 1.19). 
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Table 3.8: Poisson Model for Rate of Missed Appointment Outcome 
  IRR* 95% Confidence 
Interval 
Risk category 
(ref=low risk) 
High 0.96  (0.87, 1.05) 
Intermediate 1.09  (0.99, 1.19) 
Time 
(ref=1 year pre-index) 
Post-Index 1.23  (1.17, 1.29) 
2 Years Pre-Index 0.81 (0.77, 0.85) 
Risk category* time High x Post-Index 1.08 (0.95, 1.23) 
Intermediate x Post-Index 0.81 (0.74, 0.90) 
Age group 
(ref= 50-64) 
<50 1.04  (0.97, 1.12) 
65-75 0.98  (0.90, 1.07) 
Race 
(ref= non-Hispanic 
white) 
Black 0.90  (0.82, 0.98) 
Hispanic 0.90  (0.79, 1.04) 
Other 0.90  (0.82, 1.00) 
Language 
(ref=English) 
Haitian Creole 0.89  (0.82, 0.96) 
Spanish 0.96  (0.84, 1.09) 
Other 0.97  (0.89, 1.05) 
Education 
 (ref= 
college/postgrad) 
<High school 0.96  (0.88, 1.04) 
High School/GED 1.07  (0.99, 1.16) 
Some College/Assoc. Degree 1.04  (0.93, 1.17) 
Other/missing 1.00  (0.89, 1.11) 
Primary insurance 
(ref=private) 
Public 1.11  (1.04, 1.19) 
Other 0.99  (0.91, 1.09) 
Comorbidities Congestive Heart Failure 1.07  (0.93, 1.23) 
Cardiac Arrhythmias 0.89  (0.79, 1.01) 
Valvular Disease 1.21  (1.06, 1.39) 
Pulmonary Circulation Disorders 0.70  (0.47, 1.04) 
Peripheral vascular disorders 0.97  (0.85, 1.10) 
Hypertension, uncomplicated 1.15  (1.08, 1.22) 
Hypertension, complicated 0.78  (0.46, 1.33) 
Paralysis 1.04  (0.80, 1.36) 
Other neurological disorders 1.04  (0.90, 1.20) 
Chronic pulmonary disease 1.05  (0.97, 1.14) 
Diabetes, uncomplicated 0.82  (0.68, 1.00) 
Diabetes, complicated 0.99  (0.88, 1.11) 
Hypothyroidism 1.09  (0.96, 1.25) 
Renal failure 0.78  (0.64, 0.94) 
Liver disease 0.94  (0.70, 1.27) 
Peptic ulcer disease, excluding bleeding 0.97  (0.78, 1.20) 
Rheumatoid arthritis/collagen vascular 
disorders 
1.34  (1.20, 1.50) 
Coagulopathy 0.93  (0.65, 1.33) 
Obesity 1.14  (1.04, 1.25) 
Weight loss 0.98  (0.85, 1.13) 
Fluid and electrolyte disorders 1.00  (0.85, 1.17) 
Deficiency anemias 1.03  (0.93, 1.14) 
Alcohol abuse 0.83  (0.62, 1.10) 
Drug abuse 1.00  (0.87, 1.16) 
Psychoses 1.02  (0.87, 1.20) 
Depression 1.21  (1.14, 1.29) 
Index date in 2011 2011 Index 1.05  (0.99, 1.11) 
     * Bolded estimates  are significant at α=0.05 
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Sensitivity Analyses 
As described above, a stratified analysis by age was conducted to account 
for younger women having higher breast tissue density, resulting in a lower 
sensitivity and specificity of mammography for younger age groups (Carney et 
al., 2003). The full models by age are included in Appendix B. Below is a 
summary table displaying the relative rates for each outcome for the total sample 
and stratified by age. As shown in Table 3.9, estimates remain generally 
consistent across age groups. The IRR slightly increases from 1.36 to 1.41 for 
older women (ages 50-75) in the high risk group when outpatient visits is the 
dependent variable. A similar increase is seen in the rate of missed appointments 
among the high risk group. The overall trends and significance remains constant 
across groups, indicating that there was no differential effect by age. 
 
Table 3.9: Incident Rate Ratios by Age Group 
 
Difference-in-Difference 
IRR (95% CI) for High Risk 
Difference-in-Difference 
IRR (95% CI) for 
Intermediate Risk 
Outpatient Visits 
Total  1.36 (1.22, 1.51)* 0.81 (0.75, 0.87)* 
< 50 1.34 (1.17, 1.54)* 0.79 (0.71, 0.88)* 
50-75 1.41 (1.20, 1.65)* 0.81 (0.73, 0.90)* 
Referrals 
Total 1.34 (1.16, 1.55)* 0.89 (0.79, 1.00) 
< 50 1.33 (1.09, 1.63)* 0.91 (0.74, 1.12) 
50-75 1.36 (1.10, 1.68)* 0.88 (0.77, 1.02) 
Rate of Missed Appointments 
Total 1.08 (0.95, 1.23) 0.74 (0.68, 0.80)* 
< 50 1.01 (0.85, 1.20) 0.84 (0.74, 0.96)* 
50-75 1.15 (0.98, 1.37) 0.86 (0.80, 0.93)* 
 * Significant at α=0.05 
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 Lastly, models were created using a negative binomial distribution, which 
does not force the mean and variance to be equal as in Poisson regression, and 
is therefore more flexible. Table 3.10 displays the results using negative binomial 
regression. In the high versus low risk comparison, the rate ratios remain similar 
across outcomes, although the rate of missed appointments shows an increased 
rate estimate from 1.08 to 1.14, which becomes significant at α=0.05. For the 
intermediate risk group estimates for outpatient visits and referrals both 
decrease, but increase for the rate of missed appointments. The only change in 
significance is for referrals, which in the Poisson model do not significantly 
increase for the intermediate risk group, but do so in the negative binomial model 
(IRR=0.84, 95%CI: 0.74, 0.90). 
 
Table 3.10: Difference-in-Difference Estimates in Negative Binomial Regressions 
Outcomes Difference-in-Difference IRR (95% CI) for High Risk 
Difference-in-Difference IRR 
(95% CI) for Intermediate 
Risk 
Outpatient Visits  1.38 (1.24, 1.55)* 0.74 (0.68, 0.80)* 
Referrals 1.33 (1.15, 1.54)* 0.84 (0.74, 0.96)* 
Rate of Missed 
Appointments 1.14 (1.03, 1.25)* 0.86 (0.80, 0.93)* 
 
 Overall, it appears that the Poisson regression is appropriately estimating 
parameters and the negative binomial model produces very similar results. 
Further conclusions will be based on the Poisson estimates, which if anything, 
are more conservative than their negative binomial model counterparts. 
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Discussion 
 This study demonstrated that having a false positive mammogram was 
consistently associated with significantly increased rates of health service 
utilization in the year following the test. Specifically, rates of outpatient visits and 
referrals both increased, suggesting that utilization may be driven both by health 
system means (provider referrals) and patient care-seeking. When examining the 
intermediate risk group, that is, those who had a false positive in the past, but a 
normal mammogram at the index visit, utilization appeared to dissipate over time 
as evidenced by decreased rates of visits and referrals following the normal 
mammogram. These findings have important implications for the frequency at 
which women are screened and potential changes in utilization as a result of 
mammography. 
 The observed increase in referrals in the year following a false positive 
mammogram suggests that medical providers play some role in influencing 
utilization. It remains unclear whether this role is through direct referrals for care, 
or through providing recommendations that increase women’s perceptions of risk 
and elevate their demand for care. Other research has indicated that receipt of 
subsequent screening following a false positive mammogram was dependent 
upon provider recommendation (DeFrank et al., 2012). This research 
underscores the important role that providers play in engaging women in care 
following a medical event. Another patient survey suggested that the majority of 
women (84% of those surveyed) prefer that screening decisions be made in 
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concert with medical providers, and that they particularly prefer their primary care 
provider to provide information and guidance regarding mammography and 
potential steps to take following an abnormal result (Nekhlyudov, Li, & Fletcher, 
2005). The findings of the current study do not elucidate the types of referrals or 
providers that generate the increase in utilization following an abnormal 
mammogram, but it nonetheless is suggestive of a provider role in increasing 
utilization. Additional research is required to describe the types of utilization 
produced following a false positive mammogram and the source of these 
referrals. Further, it is important to understand the mechanism by which these 
additional referrals are produced in terms of whether the patient or provider is 
generating additional referrals. 
 One of the most striking findings from this study is the marked increase in 
outpatient visits among women in the high-risk group relative to those in the low 
risk group following an abnormal mammogram. While increased breast-specific 
utilization is expected in order to rule out a cancer diagnosis (Welch & Fisher, 
1998), the reasons for increases in other types of care is less obvious. Our 
findings suggest that women may in fact change their behaviors and be inclined 
to think of themselves as less healthy than prior to receiving some indication that 
they are at risk for breast cancer. It may also indicate an increase in anxiety 
about their health, leading to additional visits that increase reassurance through 
monitoring other aspects of health. It is yet unknown whether these additional 
visits are needed and appropriate, or whether they represent an overuse of care. 
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One other small study found that patient-initiated visits, including use of mental 
health services, increased following the receipt of an abnormal mammogram; 
and women with documented concerns about breast health were more likely to 
have higher intensity follow up services (Barton et al., 2001). This data 
abstraction study, however, was limited by low ability to discern when concerns 
appeared relative to the mammogram. As our study has demonstrated by using 
both current and former false positive groups, the timing of the mammogram may 
be essential in establishing influences on patterns of care. 
Recently enacted state laws require women to be notified if a 
mammogram indicates that they have dense breasts. This policy has the 
potential to further impact subsequent utilization. To date, 22 states have 
enacted these laws since 2009, yet little is known about how notification of breast 
density affects women. Approximately 50% of women have dense breasts, which 
is one of many risk factors for breast cancer (McCormack & dos Santos Silva, 
2006; Tice et al., 2013). These letters may act as another form of false positive 
finding and there is some evidence that they also increase risk perceptions and 
anxiety (Yeh, Schnur, Margolies, & Montgomery, 2015). Many of these letters 
suggest that women contact their primary care provider to discuss results and/or 
undergo supplemental screening. Therefore, the findings of increased visits 
found in this study may become greatly amplified as these policies go into effect 
and are implemented across the United States. Some states have documented 
that awareness of legislation and how to manage these patients is low among 
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primary care providers (Khong, Hargreaves, Aminololama-Shakeri, & Lindfors, 
2015), creating additional challenges for providing appropriate guidance to 
patients who may feel anxious or have heightened risk perceptions following 
notification of an abnormal finding. With the implementation of these policies and 
laws, it is imperative to determine their effects on health care utilization, patient 
outcomes, and health care costs. This study provides support for the idea that 
medical events, such as a false positive, do increase use of many types of care, 
suggesting broader measures of utilization are needed to assess the full impact 
of these policies. 
 One of the unexpected findings of this study is the consistent decrease in 
utilization among the intermediate risk group compared to the low risk group. 
First, women in this group displayed the highest rates of visits and referrals prior 
to the index mammogram, suggesting residual effects on utilization from a 
previous false positive. However, after receiving a normal result at the index 
mammogram, visits significantly decreased. The intermediate risk group was also 
observed to have a slight decrease in the rate of missed appointments following 
the index mammogram. It is possible that this group was reassured of good 
health with the normal mammogram result, thus removing the impetus to 
continue higher rates of visits and testing, yet being encouraged to maintain their 
good health state by attending necessary appointments. Undergoing imaging and 
receiving a normal result has been characterized as a ‘gift of knowing’, providing 
reassurance to those who engage in screening (Kenen, 1996). It is this 
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reassurance that may be driving decreases in utilization among the intermediate 
risk group. Further research is required to more accurately assess how a false 
positive mammogram changes utilization over time in both the short and long 
term, especially under conditions of serial screening.  
 The frequency at which screening occurs is a key factor in understanding 
the implications of this study. Annual screening as recommended by the 
American Cancer Society increases opportunities for false positives, subsequent 
results that may suggest heightened risk, and increases in utilization. The 
USPSTF guidelines alternatively recommend biennial screening, based in part to 
balance the harms incurred with screening with the benefits (United States 
Preventive Services Task Force, 2009). If having a false positive mammogram 
has a broader impact on all types of outpatient service utilization as found here, 
then the costs of screening, including subsequent testing, have been grossly 
underestimated. While effects at the individual level may be small, with 50% of 
women having a false positive mammogram over 10 years (Christiansen et al., 
2000), the cumulative effect of increased utilization may be large. Thinking more 
broadly about the impact of abnormal test results on risk perception, risk identity, 
and participation in care is imperative to understanding the impact of serial 
screening. This must be done in conjunction with an assessment of the utility of 
downstream utilization, ensuring that potential excesses in utilization are 
considered.  
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Limitations 
Precautions were taken to control for potential limitations of using a 
retrospective database design. Patients were only included if they had at least 1 
visit in the baseline period. The exclusion of non-utilizers ensured that those who 
were listed as having primary care at BMC were in fact connected to care. 
Although this study only had the capacity to measure utilization within one 
institution, we expected that few participants would receive a significant amount 
of care outside the institution. The high rates of patients with public or no 
insurance who receive their care at BMC do so exclusively, in part because of its 
safety net status and the comprehensive services it provides. Further, we limited 
our sample to those who receive primary care at the institution, so primarily 
internal referrals were expected. However, using a sample that was by definition 
connected to care may lead to results that differ from those patients who did not 
undergo screening mammograms and/or those who do not seek care on an 
annual basis. Our sampling strategy limited the generalizations that can be made 
in terms of how screening mammography may affect utilization among a less 
well-connected group of patients. 
Using a proxy for risk status presumed that risk designations stemming 
from an abnormal finding resulted in the adoption of a risk identity. It also 
assumed that women who had normal mammograms did not have any 
perception of increased risk. The results may be biased if women are distributed 
throughout both groups in such a way that influences our ability to detect a 
  128
difference. Some precautions were taken to minimize this. By including women 
who have had their first mammogram after the age of 40, those who likely have a 
very high-risk perception due to family history were excluded, as these women 
usually begin screening earlier. However, the study design does not fully 
characterize risk or women’s interpretation of the abnormal finding, and future 
studies are required to describe behavior patterns based on a more sensitive 
measure of risk and risk identity. 
 
Summary 
This study provides further evidence that abnormal screening tests that 
may heighten risk perceptions are associated with increased utilization of health 
services. It goes beyond previous work to include health services beyond breast-
specific follow up testing. However, prospective, mixed methods approaches that 
combine both utilization data and assessment of patient psychosocial outcomes 
is warranted to more accurately represent both patient perceptions and timing of 
events. Current trends in encouraging adherence to mammography and other 
screening tests, along with transparency in reporting any abnormality, such as 
breast density, increase opportunities to designate women as ‘at risk’, which we 
have shown to impact health service use.  Counseling women about potential 
false positives and their meaning prior to screening may mitigate the anxiety and 
increased concern experienced at the time of the abnormal mammogram. 
Further research is needed to better characterize the drivers of increased 
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utilization, the types of visits that increase the most, and the value that additional 
care provides. This will present opportunities for intervention to increase 
appropriate utilization and develop tools for providers in addressing women’s 
concerns while providing evidence-based care. 
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CHAPTER 4 : AN ASSESSMENT OF PATIENT NAVIGATOR ACTIVITIES IN 
BREAST CANCER PATIENT NAVIGATION PROGRAMS USING A NINE-
PRINCIPLE FRAMEWORK 
Background 
Cancer care has long been documented as an arena of racial, ethnic, and 
socioeconomic disparities (Freeman, 1989; Koh, 2009). Disparities in care 
delivery impact patient outcomes (Battaglia, Roloff, Posner, & Freund, 2007). 
One of the emerging health care delivery models designed to reduce cancer care 
disparities is patient navigation. Named in the early 1990s by Harold Freeman, 
patient navigation aims to reduce delays in care for disadvantaged populations 
by addressing barriers to care through one-on-one intervention (Freeman, Muth, 
& Kerner, 1995).  
Since its inception, patient navigation has expanded rapidly and is now 
used in many settings across the cancer care continuum (Freeman, 2012; 
Stanley et al., 2013). By 2003, over 200 navigation programs were documented 
(Hede, 2006). The National Cancer Institute has funded patient navigation 
through a number of programs including the Community Network Programs 
(Braun, 2012) and the NCI Community Cancer Centers Programs (Swanson, 
Strusowski, Mack, & DeGroot, 2012), as well as individually-funded grants. Three 
large-scale national patient navigation programs represent the largest 
coordinated implementation efforts to date: The American Cancer Society’s 
program with 137 navigators, the Centers for Medicare and Medicaid’s Medicare 
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Cancer Prevention and Treatment Demonstration for Racial and Ethnic Minorities 
(Mitchell, Haber, Holden, & Hoover, 2010), and the National Cancer Institute 
Patient Navigation Research Program (Freund et al., 2008). 
 
Conceptual Model 
 The intent of patient navigation programs is to identify those women who 
are at risk for not completing care to engage them in timely follow up. The breast 
cancer screening process is one such venue where navigation has been 
implemented. Women who have an abnormal finding on a screening 
mammogram often are required to return for follow up diagnostic testing or 
repeat procedures. Minority women, those who don’t speak English, and other 
low income populations have historically been at higher risk for not following 
through with care and suffering poor cancer outcomes as a result (Koh, 2009; 
Peek & Han, 2004). Patient navigation was developed as the health system’s 
response to the need to better serve these patients. Figure 4.1 displays 
overarching conceptual model and the aspects studied in this chapter. Patient 
navigation is a product of the health system context and exists to explicitly 
engage women in care. Therefore, this study examined the relationship between 
a health system intervention and subsequent engagement. Rather than 
investigating the outcomes of navigation, which have been documented and are 
described below, this study sought to understand the process by which outcomes 
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are achieved in observing the everyday practice of breast cancer navigation 
programs. 
 
Figure 4.1: Conceptual Model Domains Explored in Chapter 4 
 
Evidence and Implementation of Patient Navigation as a Health Systems 
Intervention 
The NCI Patient Navigation Research Program has reported results 
indicating navigation produced more timely diagnostic resolution following 
abnormal screening (Battaglia et al., 2012; Dudley et al., 2012; Hoffman et al., 
2012; Markossian, Darnell, & Calhoun, 2012; Paskett et al., 2012; Raich, Whitley, 
Thorland, Valverde, & Fairclough, 2012; Wells et al., 2012). Despite this 
demonstrated effectiveness, there is little systematic examination of how 
programs outside of these organizations are implemented (Stanley et al., 2013). 
Patient navigation programs have been shown to vary in terms of navigator 
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training, services provided, outcomes measured, and efficacy (Wells et al., 
2008). This is in part due to the lack of reimbursement for navigation and reliance 
on institutional, foundation, or research grant funding to establish and maintain 
programs. 
The Commission on Cancer has mandated that all accredited cancer 
centers implement patient navigation programs by 2015 (American College of 
Surgeons, 2012) despite the somewhat limited range of systematic program 
evaluation conducted. Given the rapid diffusion of patient navigation as an 
intervention to reduce cancer outcome disparities, there is an identified need to 
clarify the scope of navigation and ascertain commonalities to develop 
comparative evaluations (Esparza & Calhoun, 2011).   
A unifying definition of patient navigation has been hindered by the lack of 
a process to come to consensus around the definition of navigation while 
allowing for variation in local implementation. One existing model for measuring 
the implementation of patient navigation programs is a 9-principle framework 
developed by Harold Freeman and colleagues during a 2010 summit on the 
measurement of patient navigation (Freeman, 2012). The model suggests a set 
of consensus characteristics without explicitly addressing variations in local 
context. This framework was not presented with data from existing programs to 
assess how well it reflects the organization and function of navigation programs. 
Thus, this exploratory study aims to evaluate how closely these principles reflect 
the practice of navigation in self-identified breast cancer patient navigation 
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programs through independent observation of routine navigator activities.  
 
Methods 
Sample 
We used purposive sampling to select 10 programs from a set of 40 
funded by a single foundation, with the intent to capture variation relative to 
program size, geographic location, rural/urban setting, and target population. The 
sampling procedure was evaluated by comparing the 10 chosen sites to the 
sampling frame of 40 programs. Continuous variable comparisons used Wilcoxon 
Rank Sum tests. Categorical variables were examined with Fisher’s Exact Test. 
Differences were statistically significant at α = 0.05.  
 
Data Collection 
Four researchers conducted field observations. Observational procedures 
were based on a previously published protocol developed to elicit comparable 
observations of navigator tasks and the networks utilized to accomplish these 
tasks (Parker et al., 2010). All observers participated in collective training on the 
use of the observation protocol. Observations were reviewed by the lead 
investigators who provided continuous feedback to ensure consistency in regards 
to protocol implementation. The field note data used for this analysis documented 
the content of patient, clinician, and health care team interactions, where they 
occurred, and any explanations offered by the navigator or solicited by the 
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observer.  
Researchers conducted observations during the course of routine 
navigator activities. Observations were non-selective regarding patients or types 
of activities performed during observation to capture the full range of navigator 
duties. We conducted between 4 and 9 navigator observation sessions at each 
site. When applicable, multiple site navigators were observed to capture variation 
in individual navigator practice within programs. A total of 31 navigators 
participated, yielding 179.5 hours of observation (mean hours/site = 17.95).  
 
Analysis 
Codes were based on nine a priori themes derived from the 9-principle 
model of navigation. The intent in using this 9-principle taxonomy was to assess 
the qualitative variance accounted for in these principles. Pilot coding used field 
notes from Site 1, totaling 12% of the total hours of observation and was based 
solely on the a priori coding scheme. Following pilot coding, two primary coders 
refined the code book to operationalize the original model definitions. 
Initial coding was performed by the primary author, with bi-weekly detailed coding 
reviews conducted with the senior author. Individual codes were assessed by 
each coder prior to meeting, and a constant comparative method was used to 
build consensus (Glaser, 1965; Thorne, 2000). Through this process, codes that 
addressed the same construct were collapsed, while additional principles that did 
not fit existing definitions were added as inductive codes. Following the 
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completion of coding, a third author reviewed findings to assess consistency.  
During analysis, observations from each site were compiled and assessed 
for overall concordance with the definition of each principle. When most 
observations at a site were consistent with the definition, a site was categorized 
as concordant. Conversely, when most observations at a site were not consistent 
with the principle definition, the site was documented as discordant. When no site 
observations related to a particular principle definition, the principle was noted as 
‘not observed’ for the site. The number of sites categorized as 
concordant/discordant for each principle is displayed in Table 3, with descriptions 
provided in the discussion of results for each principle. 
 
Results 
Table 4.1 compares the sites selected for observation to the larger 
sampling frame of 40 programs. The ten observed sites were comparable to non-
observed sites relative to geographic distribution, rural/urban setting, location, 
using full or part-time navigators, and number of patients navigated per month. 
Observed sites utilized more volunteer navigators, although this finding is likely 
driven by one site with 17 volunteers. Consistent with recent findings that 
navigation is being conducted across the entire cancer care continuum, sampled 
and non-sampled sites provided analogous services ranging from outreach to 
survivorship. Patient navigator support was offered through multiple modalities 
  137
with a greater proportion of navigators interacting through medical and social 
service appointments compared to sites not observed.  
Table 4.1: Comparison of Site Characteristics 
 Observed Sites Not 
Program Site   
Community-Based 2  (20) 7  (23.3) 
Hospital-Based 8  (80) 23  (76.7) 
Geographic Region   
Northeast 3  (30) 8  (26.7) 
Midwest 1  (10) 4  (13.3) 
South 2  (20) 10  (33.3) 
West 4  (40) 8  (26.7) 
Rural/Urban   
Rural 2  (20) 4  (13.3) 
Urban 8  (80) 26  (86.7) 
Services Offered   
Outreach/Education 10  (100) 29  (96.7) 
Breast Screening 8  (80) 25  (83.3) 
Diagnostic Services 8  (80) 25  (83.3) 
Treatment 6  (60) 23  (76.7) 
Survivorship 9  (90) 22  (73.3) 
Navigator Support    
By Telephone 10  (100) 29  (96.7) 
At Program Site 9  (90) 29  (96.7) 
In Patient Home  3  (30) 8  (26.7) 
At Medical Appointments 10  (100)* 20  (66.7) 
As Social Service 6  (60)** 2  (6.7) 
Other 2  (20) 2  (6.7) 
Navigator Employment Median  Median  (IQR) 
Total Full Time 1.0  (2.0) 1.5  (1.0) 
Total Part Time 0  (1.0) 1.0  (2.0) 
Total Volunteer 0  (1.0)* 0  (0) 
Patients Navigated per Median  Median  (IQR) 
 21  (109.0) 23  (68.0) 
*significant at α=0.05; **significant at α=0.01. 
 
Table 4.2 provides detailed individual site descriptions among the ten 
sampled sites and highlights the significant diversity in patients served per month 
(range: 8 – 1013). The sites observed in this exploratory study were comparable 
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to the 9 National Cancer Institute patient navigation programs in terms of site 
type, number of navigators, and educational requirements (Clark, Parker, 
Battaglia, & Freund, 2013; Parker et al., 2010).  
Table 4.2: Characteristics of Sampled Sites 
Site Area Region Program Type 
Pts/ 
month 
Full/Part/ 
Vol PNs 
Navigator 
Degree 
# PNs 
observed Hrs 
1 Rural West Community 1013 7//0/0 Medical Assistants 
5 19 
2 Urban North-
east Hospital 27 1/0/0 
Graduate 
Degree 
1 15.25 
3 Urban Mid-
west Hospital 25 3/0/0 
RN, 
Associate 
Degree 
2 19.25 
4 Urban North-
east Hospital 16 2/1/2 
MSW, Health 
Educators 
2 12.75 
5 Urban South Hospital 17 1/0/0 RN 1 21.5 
6 Rural West Community 8 1/4/1 Bachelor Degree 
4 15.75 
7 Urban West Hospital 117 1/3/0 
LPN, 
Bachelor 
Degree 
4 27.25 
8 Urban North-
east Hospital 590 1/1/0 
High School, 
Bachelor 
Degree 
1 12.7 
9 Urban South Hospital 8 0/0/17 Lay  (survivors) 
6 15.5 
10 Urban West Hospital 8 5/0/0 
RN, 
Bachelor, 
Graduate 
Degrees 
5 20.5 
 
Principles 
Table 4.3 describes the initial and inductive codes used in the analysis 
and documents concordance with each principle. During pilot coding, we 
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operationalized the principle categories, and assigned each principle a single 
corresponding code name. Two principles, Integration of Care and Connection 
between Sites/Specialties were collapsed into one code: Integration of Care. 
Both principles focused on addressing specific patient barriers by bridging a 
disconnected system to facilitate access to appropriate care. Initial attempts to 
differentiate these two codes were based on whether integration occurred within 
or between health systems. The varied structure of each hospital and nature of 
the observations did not permit these concepts to be empirically discerned. After 
detecting significant overlap in coding these two principles, a combined concept 
of integration was determined to be most appropriate.  
In comparing the empirical data across major codes, two discrete 
categories of principles were distinguished. These were established according to 
whether principles captured individual-level or system-level activities. The first 
category, Individual-Level Principles, represented activities focused on single 
patients as part of the one-on-one relationship with the navigator. The second 
category, Program-Level Principles, encompassed principles describing program 
organization and structure. Two principles not originally included in the 
framework were identified inductively during coding and added to the Program-
Level Principles. These two principles were Resource Identification and System 
Improvement. Findings for each principle are described below.  
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Table 4.3: Original and Modified Descriptions of Principles for Patient Navigation by Category 
Code Freeman Definition Modified Description for Coding Concord-
ant 
Discord-
ant 
Not 
Observed 
Individual-Level Principles 
Eliminating 
Barriers to 
Timely Care 
“The core function of patient 
navigation is the elimination of 
barriers to timely care across 
all segments of the healthcare 
continuum.” 
Any action taken by the navigator that 
reduces a barrier to following through on 
care. 
10 0 0 
Providing 
Patient-
Centric Care 
“Patient navigation is a 
patient-centric healthcare 
service delivery model.” 
An action performed that focuses on 
providing a service that intends to move an 
individual through care (attend 
appointments, get treatment, etc.) 
10 0 0 
Integrate 
Fragmented 
System 
“Patient navigation serves to 
virtually integrate a 
fragmented healthcare 
system for the individual 
patient.” 
Navigator actions on behalf of a specific 
patient that serve to keep the patient flowing 
through the process of diagnosis/treatment. 
Integration can be classified in two ways: 1) 
Navigators coordinate with members of the 
clinical team to move patients through care; 
and 2) Navigators contact multiple 
departments, specialties, hospitals and 
clinics to facilitate care coordination for 
patients between these separate entities. 
9 1 0 
Navigate 
Across 
Disconnected 
System 
“There is a need to navigate 
patients across disconnected 
systems of care, such as 
primary care sites and tertiary 
care sites.” 
Program-Level Principles 
Program 
Cost-
Effectiveness 
“Delivery of patient navigation 
services should be cost-
effective and commensurate 
with the training and skills 
necessary to navigate an 
individual through a particular 
phase of the care continuum.” 
Actions taken by navigators that 
demonstrate strategies utilized by programs 
to maintain services in a clinically efficient 
manner. 
4 1 5 
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Level of Skill 
is Defined 
“The determination of who 
should navigate should be 
determined by the level of 
skills required at a given 
phase of navigation.” 
Programs hire navigators into positions with 
a specific skill set defined. This level of skill 
should be matched to the needs of patient in 
the phase on the cancer continuum where 
navigation activities are performed. 
2 8 0 
Defined 
Beginning 
and End of 
Navigation 
“In a given system of care 
there is a need to define the 
point at which navigation 
begins and the point at which 
navigation ends.” 
There are specific points of entry where 
navigators get involved in patient care, and a 
point at which the navigator no longer 
handles the case. 
8 0 2 
Clear Scope 
of Role 
“Patient navigation should be 
defined with a clear scope of 
practice that distinguishes the 
role and responsibilities of the 
navigator from that of all other 
providers.” 
Tasks that demonstrate the defined role of 
the navigator within the team. 5 5 0 
System is 
Coordinated 
“Patient navigation systems 
require coordination.” 
There is a person/group who coordinates 
and/or oversees navigation activities at the 
site. 
6 0 4 
There are defined and established metrics or 
goals that the navigator must meet and/or 
report. Reporting may be to an outside 
agency or internal to the organization.  
4 0 6 
System 
Improvement Not Included 
Any action taken by a navigator that aims to 
improve inefficient systems that create 
barriers for navigator in carrying out their 
role. 
7 1 2 
Resource 
Identification Not Included 
Actions that reflect the unorthodox ways in 
which navigators find and utilize funding and 
resources to provide navigation services. 
10 0 0 
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Individual-Level Principles 
Eliminating Barriers 
The observational data consistently reflect this core concept of navigation: 
Navigators at all ten sites actively sought to eliminate barriers to care faced by 
patients. The type of barrier targeted was based on the navigator’s evaluation of 
individual patient needs and varied according to the community served by the 
program. The following examples from Site 1 represent the variation in the barrier 
elimination tasks that were observed across all sites:  
[Navigator D] starts looking through her file for a form that 
might indicate an MRI option to save the patient $500. 
 
Navigator E offers a special Saturday screening date. Navigator 
offers a free Pap smear too, which Patient 2 accepts.  
While financial and logistic barriers were most commonly documented, social and 
cultural barriers addressed by navigators were also observed as important 
aspects of the one-on-one relationship formed with patients. 
 
Navigator L explains what really scared Patient 4 was that, 
when the local surgeon said the tumor was unusual, and Patient 
4 needed to see a specialist, Patient 4 thought that meant it 
must be very bad and she was going to die. Navigator L 
reframed that interpretation as, “You’re in a good position: 
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you’re going to see a specialist, someone who sees more of 
these tumors. This is a positive step.” [Site 6] 
These examples demonstrate the wide array of skills, networks, and/or systems 
cultivated by navigators in their efforts to eliminate barriers. Identifying and 
eliminating barriers was a key service component in all navigator programs, 
demonstrating concordance with the model definition. 
 
Patient-Centric Care 
 Patient-centric care was observed on numerous occasions in all 10 of the 
programs studied. This principle reinforces the individualized approach to 
addressing patient needs and preferences. While the 9-Principle Model provides 
a very broad definition for providing patient-centric care, it was operationalized 
here as patient-focused activities that promote individual engagement in care. 
For example: 
Navigator I explains that she has tried to maintain a very personal 
relationship with the patient, hoping that if she continues to build 
trust with her, Patient 2 may re-think [doing] radiation.[Site 4] 
 
Navigator K finds a support group that meets tonight… Navigator 
K calls Patient 2 back, tells [patient] about the group, gives the 
date and location and encourages the patient to go. [Site 5] 
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The navigator was observed to be central to providing care that extends beyond 
defined clinical needs. In this manner, patient navigation was observed to bridge 
the gap between social and medical needs experienced by individual patients 
and represented a unique role on the health care team. All programs were 
determined to be concordant with the patient-centered principle proposed in the 
model. 
 
Integration of Care 
 Nine sites were observed integrating care within their health care team 
and across specialties. This principle attempts to capture the manner in which 
navigators work within and between health care systems to create a seamless 
care experience for patients. For example:  
Patient 13 is interacting with a lot of people. She has a social 
worker and a navigator; Navigator BB and [the nurse 
practitioner] discuss how they can coordinate all these 
efforts. [Site 10] 
Navigator BB acts as a conduit between the nurse practitioner and other local 
practitioners to ensure that care is synchronized. When integrating care within 
teams and across sites, it was imperative for the navigator to access internal 
systems, as evidenced below: 
Navigator B works through the list of patients due for annual 
screening mammogram. She checks the EMR for each 
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patient, looking to see whether they are already scheduled 
for a screening mammogram. If not, she fills in and 
addresses a reminder card. [Site 1] 
Navigators at most sites made extensive use of electronic records, charts, and 
other tracking systems to integrate care effectively. The 9 sites observed to use 
these strategies to coordinate care were considered to be concordant with the 
model definition of integration of care. 
 
Program-Level Principles 
Defined Level of Skill 
The level of skill principle showed significant variation between these 10 
sites. As Table 3 exhibits, programs utilized navigators with a broad range of 
education and skills. The 9-principle model definition for level of skill suggests 
that programs should tailor navigators’ skill level to the phase of navigation, 
interpreted operationally as the point along the cancer continuum (described 
below) where navigator activities were focused. 
 Five points along the cancer continuum were represented in these sites: 
Outreach, screening, diagnosis, treatment, and survivorship. Among those 
observed, eight programs participated in at least 3 of these phases. There was 
little evidence that navigator skills were aligned with the phase of navigation. For 
example, there was no evidence of tailoring such that nurses were confined to 
navigating patients in treatment, while lay navigators served patients in screening 
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or survivorship. Instead, other criteria were valued in the selection of navigators: 
“Given the variety of languages spoken by patients at the hospital, most of the 
navigators are bilingual and bicultural, and this is the primary qualification for 
becoming a navigator” [Site 7]. Skills such as language appeared to gain priority 
when the spectrum of services was broad. Only two programs that focused 
narrowly on outreach and survivorship services had very tailored criteria for 
navigator practice and were classified as concordant on this definition. 
 
Scope of Navigator Practice 
The scope of practice principle demonstrated the greatest variation among 
programs. Five sites were categorized as concordant with this principle and 5 
were discordant. Observed tasks included patient-based, administrative, 
financial, and support duties. There were core tasks that were widely represented 
including connecting patients to services, patient contact and tracking, providing 
patient information/education, referral coordination, and identifying patient needs. 
These tasks functioned to support the individual-level principles of providing 
patient-centric, integrated care through the elimination of barriers. While these 
tasks were identified across many of the observed sites, patient navigators 
acknowledged that their role was often dictated by actions they initiated: 
Navigator F tells observer that her job description was vague, and 
that she has been inventing it as she goes along, with few main 
components. [Site 2] 
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Despite expansive definitions of the navigator role, many navigators 
demonstrated the ability to set boundaries in managing this broad job mandate 
while defining their own role in several domains: 
Navigator A explains Patient 2 had felt lumps, so she reminded 
the woman that not all lumps are cancer and that she should talk 
to her doctor. Navigator A adds, “I won’t diagnose.” [Site 1] 
Navigator A, a lay navigator, clearly articulates her inability to make clinical 
decisions to the patients she navigates, a common trend among patient 
navigators without clinical credentials. Generally, the scope of navigator practice 
appeared to be defined broadly, with both navigators and to a lesser degree 
programs, narrowing this scope through defining particular boundaries. 
 
Cost Effectiveness 
The cost-effectiveness principle described by Freeman was identified in 5 
sites, with 4 defined as concordant. The model’s definition of cost effectiveness is 
efficient resource utilization, “commensurate with the training and skills 
necessary to navigate an individual through a particular phase of the care 
continuum” (Freeman and Rodriguez 2011) which is distinct from the traditional 
health service research definition. Some programs used highly compensated 
navigators with clinical or graduate degrees to perform tasks that could be 
accomplished by lay individuals. For example, one navigator who was trained as 
an RN was observed sending reminder letters to all patients overdue for 
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mammograms, followed by calls to schedule mammograms. These tasks would, 
by definition, be considered below the scope of RN practice.  
Three of the programs supplemented employed navigators with volunteers 
who provided clerical or logistic tasks: There’s just one [navigator], so it’s one 
[reminder] call, then a letter. Volunteers help with the mailing [Site 9]. At Site 4: 
Navigator I explains that ACS coordinates volunteer drivers who provide 
transportation for medical visits. While this observational examination of 
navigator activities did not allow for a full exploration of efficiency in delivery of 
navigation services, there was evidence that indicated some programs attempted 
to use volunteer resources to increase cost-effectiveness. 
 
Defined Beginning and End of Navigation 
 Eight of ten sites showed evidence of defined protocols for moving 
patients in and out of navigation. Protocols were partially dictated by the scope of 
navigator practice and range of services provided by the program. Identifying 
patients for navigation through specific protocols was often time intensive: 
She says there are monthly reports from Pathology for all patients 
newly diagnosed here in the past month. Navigator Q reviews 
them and assigns them to navigators. [Site 7] 
This program deemed all patients with newly diagnosed cancer as eligible for 
navigation services. Some sites that navigate all patients defined boundaries 
along the continuum of cancer care: Patient 9 is out of Navigator F’s system now 
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that she’s getting chemo. The patient is now in Chemo-Navigator’s system [Site 
2]. This program defined the end of navigation as the transition to the next phase 
of cancer care.  
Other programs used needs-based protocols: “Social Worker 2 will 
interview all recently diagnosed patients and then refer them to the navigation 
program if they need more help” [Site 3]. While two sites did not establish 
discrete protocols for patients to be navigated, navigators still established ways 
in which they identified patients in need of navigation:  
Navigator K sees Patient 9, female, in the office. She 
recognizes her as a patient she hasn’t met… Navigator K says 
she can tell because “I don’t know their faces.”[Site 5] 
These examples demonstrate the highly variable methods by which programs 
defined processes for moving patients through navigation: Some used broad 
criteria, such as navigating based on the phase of care, while others used 
individual, needs-based methods. 
 
Coordinated System 
 This principle presented challenges in creating an operational definition 
based on the vague conceptualization in the 9-principle model. Coding focused 
on 2 observable aspects of a coordinated system: 1) Evidence of a management 
team guiding navigation; 2) Established metrics or targets to evaluate navigator 
performance. Six of the programs had designated management teams for their 
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navigators, although significant variation was present in their structures. 
Programs had navigator-supervisors, dedicated program directors, or clinically-
based supervisors. An example of a comprehensive management structure was 
observed at Site 2: 
Navigator F attends a monthly meeting with the ‘task force’ which 
includes NP, data people, nutrition, outreach nurse, PA at breast 
institute, radiology people, etc. 
Such programs demonstrated how patient navigators were situated in clinical 
teams functioning to provide a system of navigation beyond the individual.  
The second criteria indicating a coordinated system of navigation was the 
act of patient navigators recording actions taken with patients or targeting 
objective metrics. Four sites were concordant with this definition: 
At 6 months, 1 year, and 18 months, Navigator V fills out a report 
on how the patient is doing. Navigator V describes the Navigator 
Tracking Form navigators use to report their activities to the 
program director. [Site 9] 
This points to how the patient navigator role bridges clinical and administrative 
realms within the health care system. Programs were structured using 
supervisors and navigators in various capacities, with observed differences in 
reporting to clinical and/or administrative stakeholders. Approximately half of 
programs demonstrated structured coordination, but only 2 programs had both 
formalized reporting systems and a management structure. 
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Resource Identification 
 Navigators at all ten sites participated in seeking new resources in order to 
provide services to their patient populations. The resource identification principle 
was inductively added to capture navigator efforts that identify new sources of 
funding and/or resources and aim to improve existing activities. These efforts 
represent a specific type of activity focused on community needs versus 
individual needs not captured in patient-centric care.   
Resource identification aimed to improve both the patient experience and 
the program’s ability to provide quality care: 
She explains that she once got in trouble for giving a patient 
cash. It is against hospital policy for employees to give out cash 
to patients. One way she has gotten around this is by creating 
an Emergency Fund for patients. Navigator H designs and 
makes jewelry, and so, in the past she has held a jewelry sale 
with the proceeds going to the Patient Navigation Emergency 
Fund. That way, money is there for patients if they are really in 
a bad situation or they need something and Navigator H doesn’t 
have a donated service to help them out. [Site 3] 
All sites observed were active in these creative efforts which appeared to aim at 
creating sustainability by anticipating the future needs of patients at the program 
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level. Activities were diverse and highlighted community differences. All sites 
were observed to be concordant with this proposed principle definition.   
 
System Improvement 
Patient navigators in seven programs were observed participating in 
system improvement efforts aimed at reducing systems-level barriers to care or 
improving the ability to navigate patients. These efforts exemplify the importance 
of navigation as situated within the health care system and its ability to integrate 
disparate processes. While the bulk of activity is directed at integrating care for 
patients, navigators were also primed to identify areas for system improvement. 
If the patient gets a mammogram only, with no [clinical breast 
exam], then there’s no record in the chart. This makes it difficult 
for Navigator C, who is responsible for documenting all 
screening mammograms to the [Program]. She thinks a form 
should be developed that would allow the mammogram tech to 
record that a mammogram was done, which could be inserted 
into the patients’ charts. [Site 1] 
 
[Navigator G] explains that she is working with the IT department 
to create a new clinical form to put in the EMR to use instead of 
paper forms, and up until this point she has served as the point-
person for IT. [Site 3] 
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These cases demonstrate the problem-solving skills that navigators apply not 
only to addressing patient barriers, but also to systems barriers they encounter in 
their daily navigation.  
 
Program Comparisons 
 Program characteristics described in Table 4.3 were examined as they 
related to other programs and each of the 9 principles. The use of paid versus 
volunteer navigators was strongly associated with concordance with the principle 
of care integration. Hiring navigators as employees as opposed to volunteers 
allowed access to confidential medical record systems. The one site that did not 
demonstrate integration of care used exclusively volunteer navigators without 
access to medical record or scheduling systems. This appeared to be the 
essential feature driving the ability of navigators to integrate care in a manner 
reflective of the 9-principle model definition of care integration. 
 A second pattern emerged as related to the scope of role principle. The 
sites that were categorized as discordant on this principle were those that 
required clinically-based degree qualifications among navigators. Navigators with 
these types of degrees did not demonstrate concordance with this principle as 
their role often blended with that of their clinical degree. In these sites navigator 
responsibilities were not distinguished from those of an RN or MA. This was also 
true when volunteers were used as navigators. Volunteer navigators often were 
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observed to perform tasks that were normally executed by staff, such as 
retrieving pillows and blankets during chemotherapy infusions. 
 
Discussion 
With the rapid dissemination of patient navigator activities and programs, 
there is an urgent need to understand how programs are organized and to 
characterize the activities they conduct. Our analysis divided the 9 principle 
model into individual level and program level principles through empirical 
assessment. Evaluating ten breast cancer navigation programs using published 
principles of navigation indicated that programs were broadly consistent in the 
application of individual-level principles. Individual-level principles reflect other 
authors’ conceptions of the instrumental and relational interventions performed 
by navigators in a variety of settings (Jean-Pierre et al., 2011). In contrast, 
program-level principles demonstrated considerable variation in practice, a 
phenomenon reflected in other research (Jean-Pierre et al., 2011; Wells et al., 
2008; Wilcox & Bruce, 2010). In addition to the 9 core principles previously put 
forth, we distinguished two new components of patient navigator activities; 
System Improvement and Resource Identification. 
  Despite encouragement for institutions to implement patient navigation in 
hospitals and clinics (Fashoyin-Aje, Martinez, & Dy, 2012), there is little 
consensus on how navigation should be implemented. The observed variation in 
local implementation was not unexpected given the body of literature on 
  
 155
innovation diffusion. When new care delivery systems like patient navigation are 
implemented, the process is often non-linear and disorderly. The process of 
diffusion “proliferates into complex bundles of innovation ideas, and divergent 
activities by different organizational units” (Van de Ven, Polley, Garud, & 
Venkataraman, 1999). This is similar to the variation seen across these 10 
programs.  
Patient navigation is a complex innovation, attempting to integrate a new 
role that interacts with several different professional groups. Ferlie and 
colleagues have documented the additional challenges associated with 
implementing innovations that change practices across groups of professionals 
(Ferlie, Fitzgerald, Wood, & Hawkins, 2003). The navigator role, without a clear 
focus, may be adapted by each professional group with which the navigator 
interacts, expanding the scope of the navigator role as we observed in this data. 
This may be particularly true when nurse navigators are perceived to be part of 
the nursing team. A clear scope of the navigator role is an essential principle in 
supporting navigators to meet the goal of integrating care in a patient-centric 
manner. These considerations are important in implementing and sustaining 
navigation programs that provide meaningful improvements in patient care for 
populations as well as individuals. 
Zapka and colleagues published a model in 2010 documenting a set of 
transitions and interfaces representing multi-level gaps in the pathway from 
cancer screening to diagnosis and treatment (Zapka, Taplin, Price, Cranos, & 
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Yabroff, 2010). This framework identifies processes that are amenable to patient 
navigation interventions applying Freeman’s principles. For example, referrals for 
diagnostic evaluations require both physician coordination and patient 
acceptance. Navigator tasks related to the principles of integrating care within the 
system and eliminating patient barriers represent aspects of navigation that may 
close this identified gap. The coordinated system of navigation principle further 
applies across Zapka’s continuum, which provides a systematic and 
complementary framework to aid navigators in targeting gaps in processes of 
care associated with cancer screenings. 
Navigators provide a unique role in health care: They aid patients in 
negotiating disjointed processes of care, crossing boundaries imposed by 
specialization. Our findings suggest that a key program feature that allowed 
navigators to bridge professional and organizational boundaries was the use of 
paid navigators who have access to medical records, practice schedules, and 
other protected health information. There has been little systematic investigation 
of the role of the volunteer navigator in the United States. Canadian policy has 
drawn attention to the different roles that staff and volunteer navigators hold 
(Cancer Journey Portfolio, 2012; Lorhan et al., 2013). The distinction between 
the capacity of these two roles and their impact on the delivery of navigation 
warrants further examination and consideration. 
Although it is imperative that programs address local disparities, there 
remains an inherent tension in balancing worker capacity with community needs. 
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Navigators may be hired based on skills that serve the target population, which 
need to be balanced with concerns of efficiency in navigation practice. The 
development of specific program goals may aid in balancing these concerns. 
Others similarly support navigation as a goal-oriented intervention, encouraging 
programs to employ navigation services to improve specific outcomes of interest 
(Paskett, Harrop, & Wells, 2011). Producing goal-oriented navigation programs 
holds promise for creating inclusive navigation models that allow for varied 
implementation according to specifically defined prevention or disease outcomes.  
A major strength of this analysis is the direct observation of navigator 
activity measured independently of program intent. There are several limitations 
to our analysis. First, this study is an exploratory analysis of the Freeman 9-
principle framework within 10 breast cancer navigation programs, and as such is 
not representative of patient navigation nationally. There was the potential for 
similarities in these programs as they were supported by the same funding 
agency and therefore shared requirements for reporting. Even within this context, 
we observed significant variation in program implementation. The imputing of 
intent based on the observational data represents a limitation of this project’s 
scope and could be overcome by a comprehensive program analysis. Future 
work could involve more detailed analysis of how navigation spans health 
systems and types of care (i.e. primary vs. tertiary). Finally, our data are not 
linked to outcomes; therefore we cannot comment on which principles or 
activities are associated with best practices.  
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This research assesses one framework for defining the navigator role as 
focused on eliminating barriers through the provision of patient centric-care that 
integrates the fragmented health care system. The set of programs observed in 
this sample reflected navigation as described by others as facilitating care 
through identifying specific needs of patients in the community. This was 
evidenced by the varied approaches to implementing programs that were tailored 
to local context and focused on community needs. The diversity of 
implementation in these programs provides an argument for broad consensus 
criteria around creating targeted, context-specific program goals addressing 
population needs. Creating these contextually driven goals will provide programs 
with the opportunity to measure navigation effectiveness, which is needed to 
provide support for the navigator role. Lastly, creating guidance for program 
development around goal setting and navigator management may increase the 
ability of navigators to effectively manage their role that bridges program and 
community interests.  
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CHAPTER 5 : CONCLUSION 
As we re-design our healthcare systems to deliver patient-centered and 
personalized care, it is critical that we understand the multi-level implications of 
adopting the current approaches to screening and risk assessment. Recently 
there have been calls for an end to routine screening mammography (Topol, 
2015), with the Swiss medical board recommending the abolishment of their 
screening program (Biller-Andorno & Jüni, 2014). Despite the ongoing 
professional debate over the utility of widespread, routine breast cancer 
screening, women continue to feel overly optimistic about the benefits they gain 
from mammography in terms of saving lives (Davidson et al., 2011; 
Domenighetti, D’Avanzo, Egger, & al., 2003). The varied beliefs and attitudes of 
providers and patients regarding screening and risk assessment as tools for 
prevention may contribute to some of the differences in perception and behaviors 
observed in women at risk for breast cancer throughout the course of this 
dissertation.  
Three studies examined utilization in the setting of screening and 
prevention for breast cancer, using the lens of several intersecting contexts: the 
patient’s social and cultural context, the health system context, and public 
discourse. Qualitative interviews with women at risk for breast cancer suggested 
that women’s explanatory models of risk contribute to their perceptions of risk 
and control, which in turn drive decision-making about prevention. Explanatory 
models were closely tied to elements of social contexts, as we observed women 
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describing their perceptions and decisions through a lens of social comparisons. 
Examining medical record data demonstrated that the occurrence of an abnormal 
mammogram increases utilization of health services. The increase in rates of 
both outpatient visits and referrals suggest that utilization may be driven by both 
patient care-seeking and health system means. The final study examined the 
health system’s use of patient navigators as a means to engage at risk women in 
care, showing that navigation programs focus on addressing community needs to 
keep women engaged in follow up care. 
There is an urgent need to align evidence produced by the health system, 
public discourse, and the social/cultural contexts of the lay public to provide 
appropriate screening and prevention. A major challenge is establishing 
consensus about appropriate care among these different stakeholder contexts. 
The most striking example of misalignment in these contexts as they relate to 
breast cancer screening is the current trend of informing women of their breast 
density. As of April 2015, 22 states have mandated radiology providers to inform 
women if they have dense breasts on mammography, and indicate that density is 
a risk factor for cancer. These laws have been driven by patient advocacy and 
lay people, with medical providers more cautious about their utility (Slanetz, 
Freer, & Birdwell, 2015). This legislation has expanded the source of messages 
about increased risk beyond the one-on-one medical encounter and may 
heighten perceptions of risk among women who receive these communications. 
Many of these notifications suggest that women discuss the potential for 
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supplemental screening with ultrasound, MRI or 3D mammography, despite little 
evidence that these modalities are beneficial (United States Preventive Services 
Task Force, 2015). Despite insufficient evidence to support the use of these 
modalities, a recent study of MRI utilization among women with dense breasts 
demonstrated a 23-fold increase in the use of MRI following the enactment of this 
legislation in Texas (Mason, Yokubaitis, Howard, Shah, & Wang, 2015). This 
example further displays how personal perceptions about risk factors such as 
density can drive advocacy and public discourse that leads to the implementation 
of policies and practice that are not supported by medical evidence.  
In an era of shared-decision making and emphasis on patient centered 
care, it is important to illuminate relationships between provider and patient 
assessment of risk. How patients and providers discuss and negotiate behavioral 
and medical options in a risk context is important and we know little about both 
the content and form of these medical encounters. The medical encounter brings 
together at least two of the contexts where perceptions and beliefs can be 
negotiated to produce behaviors that are supported by evidence and aligned with 
the values of the individual. Future research is needed to document how 
academic and community practitioners communicate about risk and what options 
for prevention are presented to women who are at high risk for developing 
cancer. There is an urgent need to develop evidence-based tools to guide both 
clinicians and patients in their discussions about risk and risk-reduction 
opportunities (Ozanne, Howe, Omer, & Esserman, 2014) especially in light of 
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these new disclosures about breast density that may heighten risk perceptions 
further.  
One theme that runs throughout this dissertation is the inherent 
uncertainty associated with risk. It can be difficult for physicians to communicate 
about the uncertainty that resides within risk assessments, with the result that 
women may overestimate their risk and seek additional testing and treatment that 
may not be warranted. It has been shown that when physicians disclose 
uncertainty, patients may experience ambiguity aversion. Ambiguity aversion is 
the phenomenon whereby the communication of uncertainty related to risk 
information leads to outcomes such as heightened risk perceptions, negative 
affective responses (i.e. worry), and avoidance of decision-making in situations 
involving choice (Han, Moser, & Klein, 2006). Ambiguity aversion can be 
moderated by both personal factors such as optimism, and communication 
factors, such as visual representation of risk (Han et al., 2011). Nonetheless, 
uncertainty and feelings of ambiguity are important constructs that should be 
considered by providers in relaying risk information and engaging women in 
shared decision-making given their impact on risk perceptions and decision-
making. It highlights the dual importance of form and content in risk 
communication. Vogel suggests that risk discussions focus on aligning patient 
perceptions with objective risk estimates, including women’s personal 
experiences with breast cancer among families, as well as addressing beliefs 
and fears concerning cancer etiology and treatment (Vogel, 2003). This 
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suggested approach speaks to many of the elements represented in this 
dissertation that relate to engagement in health service use.  Etiology and 
treatment were two of the explanatory model domains that were integral in 
shaping women’s perceptions and decision making about risk reduction in 
Chapter 2, indicating that assessing these and other aspects of explanatory 
models and social context may be one way to understand patient perceptions 
and behaviors. Communications may then be designed to address influential 
elements of explanatory models so that patient perceptions can be aligned more 
closely with calculated risk estimates. 
Another future direction for this work is in jointly examining the multi-level 
effects of implementing health services designed to engage at risk patients in 
screening and prevention. As women become engaged in the health system as 
patients, it is important to further understand how they come to conceptualize 
themselves either as at risk or not. This dissertation has highlighted the important 
role that the social and cultural context plays in forming a risk identity, which 
enhances previous work focused on the role of cognitive and affective 
evaluations in producing risk perceptions. Future interventions may help identify 
those women who have risk perceptions that differ greatly from evaluated risk 
and then intervene to help align perceptions. Lay workers such as patient 
navigators, who often share the social and cultural context of the patient 
population, may be one alternative to merely providing knowledge as an 
intervention. Past work has shown that particularly for higher risk women, 
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information provision is insufficient in producing accurate risk perceptions and 
allowing for informed decisions (Green, Peterson, Baker, & et al., 2004). Lay 
health workers with specialized training may be able to target socially-rooted 
constructions of risk perception that are not addressed in medical encounters. 
Future research is needed to first understand how the multiple domains of 
explanatory models contribute to perceptions of risk in order to identify elements 
that might be amenable to intervention. Secondly, establishing evidence-based 
guidelines for appropriate care and incorporating meaningful shared decision 
making for screening and risk assessment is warranted. 
This dissertation has examined the multiple influences on risk perceptions 
and participation in care among women who undergo screening or engage in 
prevention using three different perspectives. Further work is needed to 
investigate how each of these uniquely contributes to individual perceptions and 
decision-making. In conjunction with understanding the patient perspective, 
providers require evidence-based support to better counsel women and 
understand personal preferences for engagement in care among a population 
that may otherwise be healthy. The current approach of diagnosing risk as if it 
were disease has been shown to have multiple effects at the level of the patient 
and provider in terms of engagement in care. However, a more complete 
understanding of how women come to see themselves at risk and negotiate the 
health system context within their social milieu is imperative for providing 
personalized and patient-centered care. 
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APPENDIX A: CHAPTER 2 INTERVIEW GUIDE 
 
Introduction Topic Details 
Study Aims • Study aims from 
Participant 
• Gaps filled by 
interviewer 
Notes: 
Study 
Structure: 
Three Parts 
• Consultation session  
 
How you experienced the consultation session, 
what you took away from it and what was 
important to you about it. 
• Being at risk for 
breast cancer & 
general health 
concerns 
 
We also will talk more generally about your 
health concerns, being at risk for breast cancer, 
and how you came to this particular clinic to talk 
to the HCP. 
• video of the 
consultation session  
 
We are also going to watch the video of the 
consultation session you had with the doctor 
and I would like you to comment on how you felt 
during the consultation, what happened, why 
you did what you did, and how you felt when the 
HCP told you certain things, and how you feel 
now that you watch the video.  
 
Interview Questions: Consultation Session 
 
Consultation 
session 
• Can you tell me 
what you talked 
about during the 
consultation 
session? 
 
• How did you feel about the information you 
received? 
• Did you feel comfortable with amount of 
information you received? 
• Did you feel you understood the information? 
• Would you have liked to have had different 
information? 
• Were there any problems in understanding what 
the HCP talked about? 
• What did the health care provider recommend to 
reduce your breast cancer risk? 
• Would you have liked to have had more time to 
talk about your breast cancer risk and options or 
how to manage the risk? 
Consultation 
session 
• What topics in 
the consultation 
session were 
most important 
to you? 
• Of all the topics that were discussed, which felt the 
most important to you? 
Consultation 
session 
• If you think back 
to the session, 
what do you 
• Is there anything that was said, referenced or 
discussed that made a particular impression on 
you during the consultation? 
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Interview Questions: Consultation Session 
 
remember most 
about it? 
Consultation 
session 
• How did you 
experience the 
consultation 
session, HCP and 
clinic? 
• How long have you known this HCP? How did you 
first come into contact with this health care 
provider? 
• Do you trust this HCP? 
• Did you leave the consultation session satisfied? 
Less worried? More worried? 
• When was the first time you talked to clinic staff 
about risk for breast cancer? Who first told you 
that you were at risk for breast cancer? How were 
you told this information? 
• When was the first time someone talked to you 
about your being at risk for breast cancer?  
• What was it like hearing that information for the 
first time? 
• How did you come to this particular clinic? 
• Did getting a measurement of your risk in the form 
of a number help you understand your risk? 
• What was it like when the doctor described that 
the x-ray result today was okay? 
Consultation 
session 
• Did the HCP talk 
about the option 
for you to take a 
medication 
(SERM) to reduce 
your breast 
cancer risk? 
• Did the HCP ask you if you have considered 
taking medication to reduce your risk of breast 
cancer (SERM)? 
• If so, how strongly did the HCP recommend a 
SERM? Was there a specific SERM that was 
recommended? 
• Are you interested in taking SERM? (reassure the 
patient that in our view it is totally fine not to take a 
SERM) 
• Why or why not?  
 
Interview Questions: Experience of breast cancer risk & general health 
Experiencing 
breast cancer 
risk 
• Do you feel at 
risk for 
developing 
breast cancer? 
 
• Why/ Why not? 
• When you talked to the HCP about it, were you 
shocked? Was it a relief?  
• Are you now concerned about your situation as 
being at risk for breast cancer?  
• Are you o.k. with what the HCP told you? 
• Do you feel like you will get breast cancer? Why? 
Why not?  
• How did you feel when they told you that your 
mammogram found something?   
General 
health 
stances 
 
• How do you deal 
with health more 
generally, risk 
prevention 
• What health conditions/topics do you worry about 
most for yourself? 
• How do you generally treat health information? 
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Interview Questions: Experience of breast cancer risk & general health 
illness and risk of 
disease? 
 
• Have you experienced other health concerns 
where prevention options given to you or those 
close to you? How have you dealt with or felt in 
these situations?  
• Where do you go to obtain health information? 
• Who do you involve in making health decisions 
and how are these people/is this person involved?  
• Tell me about your blood clot episodes.  Do you 
still worry about this problem? 
• Tell me how you manage your heart condition. 
• Have you always disliked taking pills?  Did the 
heart condition change things for you? 
• Your mother came with you – does she come to 
all of your medical appointments?  
• Do you find it helpful to have your mother at your 
appointments? 
• What do you think in general about breast cancer 
and breast cancer risk? 
• What do you think of options to deal with breast 
cancer risk such as screening, healthy eating, 
physical activity, smoking cessation? 
• What do you generally think about taking 
medications (in general and for prevention)?  
• Do you use/ practice any alternative health 
approaches or treatments (such as vitamins, TCM, 
homeopathy, aromatherapy, etc.)?  
• Are you having regular mammograms right now?   
Cancer 
experience 
• What types of 
cancers exist in 
your family and 
circle of friends? 
 
• Have you had personal contact with a woman who 
has had breast cancer (a family member, friend)? 
• Are there any types of breast cancer or other 
types of cancer known in your family? 
• How was it for your family member or friend to be 
diagnosed with cancer and how did she/ he deal 
with it? 
• How did you deal with the disease of your family 
member/friend? 
• How involved were you with the care of your 
family member or friend with cancer? 
• Do you know someone who died of breast cancer/ 
other types of cancer? 
• (How was and is the relationship between you and 
breast cancer patients in your family?)  
 
Missing 
Pieces 
• Is there anything 
else that is 
important for you 
that you’d like to 
share? 
Notes: 
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Viewing Video 
Video 
Introduction 
• Reassurance and 
aim 
Now we’ll watch the video of your meeting with the 
HCP. Like I have said before, I would like to run 
through the video and talk about the consultation 
session and your feelings and impressions. I have 
watched the video myself and I also have some 
questions about it that I‘ll ask you. Sometimes 
people feel uncomfortable watching themselves on 
video.  Try not to focus on that, it’s very helpful for 
us to get your perspective after the fact and see if 
your thoughts about it are different while watching it 
as opposed to being in the session.   
Video 
viewing 
structure 
• Task during video 
viewing 
I’d like you to pay attention to what you see on the 
screen and if there is something in the consultation 
that you don’t remember or something that you think 
is important, please speak up. 
Video 
viewing 
structure 
• Video viewing 
format 
We will stop the video at any point and discuss what 
you see, or it is also o.k. to just watch the entire 
video without any comments if there is nothing that 
strikes you. 
Video 
viewing 
questions 
• Video viewing 
Questions 
• When you watched the video what did you think? 
• Was it as you remembered it? Or did you get 
more or less information than you remembered?  
• Did the HCP make stronger or different 
recommendations than you remember?  
• Or did she make no recommendation even 
though you thought she did? 
• Can you explain any of these differences? 
Video 
Questions 
• Individualized 
Video Questions 
Questions based on video pre-viewing: 
o Video question: the provider tells you that you 
two are going to get to know each other and 
you will come back and talk about risk with her 
overall several visits – is this something that 
you are interested in doing? 
o Do you think 1.5% risk is high? Low? 
o Video question (6:06) - The HCP days that 
you came to this visit because you had a spot 
on an x-ray - can you tell me what happened? 
o Video question (2:30) – you have a long 
conversation about your mixed race.  How 
does the information the doctor gives you on 
race and risk make you feel? More/Less sure 
of your risk? 
o Video question – (9:15) When she’s writing 
down those three options – lifestyle, pills, and 
surgery, what were you thinking?  What was 
your first impression? 
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Viewing Video 
o Video Question (9:37) - Tell me about your 
recent weight loss. What made you decide to 
lose weight? 
o Video question (13:49) – you say “I know what 
I’m dealing with” – can you describe what you 
mean when you say that? 
o Video question (15:09) – You say you would 
get a second opinion – is this your normal 
approach when a doctor suggests something 
new?  
o Video question - What prompted you to get 
breast reduction surgery?  Were you 
concerned about getting keloids (as you 
mention in the video) like the doctors said you 
might? 
o Video question – you mention that you 
advised your mother not to take tamoxifen 
when she had breast cancer.  What made you 
suggest this?  How involved are you in making 
decisions about your mother’s care? 
o The doctor thinks it might be helpful to get 
genetic testing – are you considering this? Do 
you think genetic testing would be helpful? 
Post video 
summary 
• Summary of 
themes after 
watching the video 
Notes: 
 
 
Post video 
wrap up 
• Interview wrap up Is there anything else you would like to add? 
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APPENDIX B: SUPPLEMENTAL TABLES 
 
Correlation Matrix for Independent Variables 
Spearman Correlation Coefficients (N=3,920) 
 
Age Race Language Education Primary Insurance 
Risk 
Category 
Age 1 0.040 (p=0.012) 
0.130 
(p<0.001) 
-0.071 
(p<0.001) 
0.139 
(p<0.001) 
-0.029 
(p<0.001) 
Race 0.040 (p=0.012) 1 
0.309 
(p<0.001) 
-0.084 
(p<0.001) 
0.178 
(p<0.001) 
-0.031 
(p=0.051) 
Language 0.130 (p<0.001) 
0.309 
(p<0.001) 1 
-0.179 
(p<0.001) 
0.254 
(p<0.001) 
-0.005 
(p=0.747) 
Education -0.071 (p<0.001) 
-0.084 
(p<0.001) 
-0.179 
(p<0.001) 1 
-0.171 
(p<0.001) 
-0.028 
(p=0.08) 
Primary 
Insurance 
0.139 
(p<0.001) 
0.178 
(p<0.001) 
0.254 
(p<0.001) 
-0.171 
(p<0.001) 1 
-0.004 
(p=0.827) 
Risk 
Category 
-0.029 
(p<0.001) 
-0.031 
(p=0.051) 
-0.005 
(p=0.747) 
-0.028 
(p=0.08) 
-0.004 
(p=0.827) 1 
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Negative Binomial Models 
Negative Binomial Model for Outpatient Visits 
Variables IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.92 (0.84, 1.00) 
Intermediate 1.00 (0.93, 1.09) 
Time 
(ref=1 year pre-index) 
Post-index 1.00 (0.96, 1.04) 
2 Years pre-index 0.69 (0.66, 0.72) 
Time x Risk Category High x. Post-Index 1.38 (1.24, 1.55) 
Intermediate x Post-Index 0.74 (0.68, 0.80) 
Age group (ref= 50-
64) 
<50 1.02 (0.96, 1.08) 
65-75 0.97 (0.90, 1.05) 
Race  
(ref=White) 
Black 1.12 (1.03, 1.21) 
Hispanic 1.22 (1.06, 1.41) 
Other 1.14 (1.03, 1.26) 
Language 
(ref=English) 
Haitian Creole 0.85 (0.79, 0.92) 
Spanish 0.94 (0.81, 1.09) 
Other 0.95 (0.87, 1.03) 
Education 
(ref=College) 
<High school 1.20 (1.11, 1.30) 
High School/GED 1.31 (1.21, 1.42) 
Some College/Voc./Tech/Assoc 1.19 (1.07, 1.31) 
Other/missing 0.95 (0.84, 1.06) 
Primary Insurance 
(ref=Private) 
Public 1.24 (1.16, 1.33) 
Other 0.98 (0.91, 1.06) 
Comorbidities 
Congestive Heart Failure 1.43 (1.22, 1.67) 
Cardiac Arrhythmias 1.44 (1.22, 1.71) 
Valvular Disease 1.20 (0.99, 1.46) 
Pulmonary Circulation Disorders 1.86 (1.54, 2.26) 
Peripheral vascular disorders 1.30 (1.12, 1.51) 
Hypertension, uncomplicated 1.17 (1.11, 1.23) 
Hypertension, complicated 1.28 (0.96, 1.72) 
Paralysis 0.88 (0.67, 1.17) 
Other neurological disorders 1.34 (1.15, 1.55) 
Chronic pulmonary disease 1.23 (1.14, 1.32) 
Diabetes, uncomplicated 1.47 (1.32, 1.63) 
Diabetes, complicated 1.70 (1.53, 1.88) 
Hypothyroidism 1.23 (1.12, 1.34) 
Renal failure 1.80 (1.46, 2.21) 
Liver disease 1.38 (1.15, 1.66) 
Peptic ulcer disease, excluding 
bleeding 1.19 (1.01, 1.41) 
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Variables IRR (95% CI) 
Rheumatoid arthritis/collagen 
vascular disorders 1.39 (1.22, 1.58) 
Coagulopathy 1.36 (1.08, 1.72) 
Obesity 1.28 (1.16, 1.41) 
Weight loss 1.13 (0.98, 1.31) 
Fluid and electrolyte disorders 1.35 (1.13, 1.61) 
Deficiency anemias 1.28 (1.17, 1.40) 
Alcohol abuse 1.00 (0.84, 1.19) 
Drug abuse 1.36 (1.21, 1.53) 
Psychoses 1.37 (1.16, 1.62) 
Depression 1.38 (1.30, 1.46) 
Index date Index in 2011 0.96 (0.91, 1.01) 
 
Negative Binomial Model for Referrals  
Variables IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.98 (0.88, 1.11) 
Intermediate 0.88 (0.79, 0.98) 
Time 
(ref=1 year pre-index) 
Post-index 0.85 (0.80, 0.90) 
2 Years pre-index 0.69 (0.65, 0.73) 
Time x Risk Category High x. Post-Index 1.33 (1.15, 1.54) 
Intermediate x Post-Index 0.84 (0.74, 0.96) 
Age group (ref= 50-
64) 
<50 0.95 (0.89, 1.01) 
65-75 0.91 (0.84, 1.00) 
Race  
(ref=White) 
Black 1.11 (1.01, 1.22) 
Hispanic 1.23 (1.04, 1.45) 
Other 1.14 (1.01, 1.28) 
Language 
(ref=English) 
Haitian Creole 0.82 (0.75, 0.89) 
Spanish 0.95 (0.80, 1.13) 
Other 0.99 (0.90, 1.09) 
Education 
(ref=College) 
<High school 1.04 (0.95, 1.14) 
High School/GED 1.19 (1.08, 1.31) 
Some 
College/Voc./Tech/Assoc 1.05 (0.93, 1.18) 
Other/missing 0.93 (0.82, 1.06) 
Primary Insurance 
(ref=Private) 
Public 1.19 (1.10, 1.29) 
Other 1.02 (0.93, 1.11) 
Comorbidities 
Congestive Heart Failure 0.99 (0.82, 1.20) 
Cardiac Arrhythmias 1.01 (0.85, 1.19) 
Valvular Disease 1.02 (0.79, 1.32) 
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Variables IRR (95% CI) 
Pulmonary Circulation 
Disorders 1.43 (1.11, 1.85) 
Peripheral vascular disorders 1.29 (1.07, 1.54) 
Hypertension, uncomplicated 1.11 (1.05, 1.18) 
Hypertension, complicated 0.80 (0.60, 1.08) 
Paralysis 1.10 (0.85, 1.42) 
Other neurological disorders 1.45 (1.22, 1.73) 
Chronic pulmonary disease 1.16 (1.07, 1.26) 
Diabetes, uncomplicated 1.39 (1.25, 1.55) 
Diabetes, complicated 1.61 (1.43, 1.81) 
Hypothyroidism 1.16 (1.06, 1.26) 
Renal failure 1.23 (1.04, 1.45) 
Liver disease 1.55 (1.26, 1.92) 
Peptic ulcer disease, excluding 
bleeding 0.97 (0.74, 1.27) 
Rheumatoid arthritis/collagen 
vascular disorders 1.34 (1.11, 1.62) 
Coagulopathy 1.28 (0.97, 1.68) 
Obesity 1.34 (1.20, 1.50) 
Weight loss 1.13 (0.98, 1.31) 
Fluid and electrolyte disorders 1.15 (0.97, 1.35) 
Deficiency anemias 1.35 (1.22, 1.49) 
Alcohol abuse 0.90 (0.76, 1.06) 
Drug abuse 1.16 (1.03, 1.31) 
Psychoses 1.00 (0.79, 1.27) 
Depression 1.42 (1.33, 1.51) 
Index date Index date 0.95 (0.90, 1.01) 
 
Negative Binomial Model for Rate of Missed Appointments 
Variables IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.94 (0.86, 1.03) 
Intermediate 1.06 (0.99, 1.14) 
Time 
(ref=1 year pre-index) 
Post-index 1.24 (1.20, 1.29) 
2 Years pre-index 0.79 (0.75, 0.82) 
Time x Risk Category High x. Post-Index 1.14 (1.03, 1.25) 
Intermediate x Post-Index 0.86 (0.80, 0.93) 
Age group (ref= 50-64) <50 0.98 (0.95, 1.01) 
65-75 0.94 (0.88, 1.00) 
Race  
(ref=White) 
Black 0.86 (0.77, 0.96) 
Hispanic 0.97 (0.90, 1.04) 
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Variables IRR (95% CI) 
Other 0.87 (0.81, 0.92) 
Language (ref=English) 
Haitian Creole 0.98 (0.88, 1.10) 
Spanish 0.93 (0.88, 0.99) 
Other 0.98 (0.92, 1.05) 
Education 
(ref=College) 
<High school 1.00 (0.93, 1.07) 
High School/GED 1.03 (0.95, 1.11) 
Some 
College/Voc./Tech/Assoc 0.99 (0.90, 1.09) 
Other/missing 1.04 (0.99, 1.10) 
Primary Insurance 
(ref=Private) 
Public 0.96 (0.90, 1.02) 
Other 0.85 (0.74, 0.99) 
Comorbidities 
Congestive Heart Failure 0.81 (0.71, 0.92) 
Cardiac Arrhythmias 1.14 (0.98, 1.32) 
Valvular Disease 0.66 (0.53, 0.82) 
Pulmonary Circulation 
Disorders 0.85 (0.73, 0.99) 
Peripheral vascular 
disorders 1.08 (1.03, 1.12) 
Hypertension, uncomplicated 0.99 (0.69, 1.43) 
Hypertension, complicated 0.98 (0.74, 1.28) 
Paralysis 0.98 (0.86, 1.13) 
Other neurological disorders 1.02 (0.96, 1.08) 
Chronic pulmonary disease 0.92 (0.83, 1.02) 
Diabetes, uncomplicated 0.80 (0.73, 0.89) 
Diabetes, complicated 1.04 (0.98, 1.11) 
Hypothyroidism 0.70 (0.59, 0.84) 
Renal failure 0.94 (0.79, 1.12) 
Liver disease 1.05 (0.86, 1.28) 
Peptic ulcer disease, 
excluding bleeding 1.13 (1.01, 1.27) 
Rheumatoid 
arthritis/collagen vascular 
disorders 
0.99 (0.83, 1.18) 
Coagulopathy 1.00 (0.93, 1.08) 
Obesity 1.04 (0.93, 1.16) 
Weight loss 0.89 (0.76, 1.06) 
Fluid and electrolyte 
disorders 1.00 (0.93, 1.07) 
Deficiency anemias 0.91 (0.80, 1.05) 
Alcohol abuse 1.01 (0.92, 1.10) 
Drug abuse 0.93 (0.80, 1.07) 
Psychoses 1.15 (1.10, 1.20) 
Depression 1.01 (0.97, 1.05) 
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Models Stratified by Age 
Age Stratified Model for Outpatient Visits 
 
Age < 50  Age 50-75 
IRR (95% CI) IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.99 (0.88, 1.11) 0.89 (0.79, 1.01) 
Intermediate 1.08 (0.94, 1.24) 0.96 (0.87, 1.05) 
Time 
(ref=1 year pre-index) 
Post-index 0.95 (0.89, 1.00) 1.00 (0.95, 1.04) 
2 Years pre-index 0.77 (0.72, 0.82) 0.71 (0.67, 0.75) 
Time x Risk Category High x. Post-Index 1.34 (1.17, 1.54) 1.41 (1.20, 1.65) 
Intermediate x Post-Index 0.79 (0.71, 0.89) 0.81 (0.73, 0.90) 
Age  1.01 (0.99, 1.02) 1.00 (1.00, 1.01) 
Race 
(ref=White) 
Black 1.08 (0.95, 1.23) 1.07 (0.96, 1.18) 
Hispanic 1.24 (1.00, 1.54) 1.01 (0.84, 1.21) 
Other 1.06 (0.91, 1.24) 1.14 (1.00, 1.31) 
Language (ref=English) 
Haitian Creole 0.92 (0.82, 1.03) 0.86 (0.78, 0.95) 
Spanish 0.85 (0.69, 1.04) 1.10 (0.91, 1.31) 
Other 1.11 (0.98, 1.26) 0.88 (0.79, 0.97) 
Education 
(ref=College) 
<High school 1.09 (0.97, 1.22) 1.24 (1.10, 1.41) 
High School/GED 1.20 (1.07, 1.35) 1.39 (1.23, 1.58) 
Some 
College/Voc./Tech/Assoc 1.16 (0.99, 1.36) 1.18 (1.02, 1.37) 
Other/missing 0.82 (0.66, 1.01) 1.02 (0.88, 1.19) 
Primary Insurance 
(ref=Private) 
Public 1.35 (1.24, 1.47) 1.19 (1.08, 1.32) 
Other 1.15 (1.03, 1.28) 0.96 (0.86, 1.07) 
Comorbidities 
Congestive Heart Failure 1.40 (1.00, 1.96) 1.32 (1.10, 1.59) 
Cardiac Arrhythmias 1.11 (0.87, 1.42) 1.58 (1.32, 1.90) 
Valvular Disease 1.52 (0.93, 2.49) 1.00 (0.81, 1.22) 
Pulmonary Circulation 
Disorders 2.11 (1.56, 2.84) 1.62 (1.31, 1.99) 
Peripheral vascular 
disorders 1.36 (1.03, 1.79) 1.37 (1.15, 1.63) 
Hypertension, 
uncomplicated 1.12 (1.03, 1.22) 1.17 (1.08, 1.25) 
Hypertension, 
complicated 1.29 (0.79, 2.09) 1.25 (0.82, 1.91) 
Paralysis 0.81 (0.56, 1.18) 0.98 (0.70, 1.37) 
Other neurological 
disorders 1.31 (1.01, 1.68) 1.32 (1.10, 1.59) 
Chronic pulmonary 
disease 1.23 (1.11, 1.36) 1.21 (1.11, 1.33) 
Diabetes, uncomplicated 1.63 (1.30, 2.05) 1.40 (1.23, 1.60) 
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Age < 50  Age 50-75 
IRR (95% CI) IRR (95% CI) 
Diabetes, complicated 1.80 (1.47, 2.19) 1.55 (1.38, 1.73) 
Hypothyroidism 1.19 (1.05, 1.35) 1.23 (1.10, 1.38) 
Renal failure 1.74 (1.26, 2.41) 1.66 (1.35, 2.04) 
Liver disease 1.02 (0.74, 1.39) 1.78 (1.39, 2.28) 
Peptic ulcer disease, 
excluding bleeding 1.39 (1.16, 1.66) 1.10 (0.84, 1.43) 
Rheumatoid 
arthritis/collagen vascular 
disorders 
1.14 (0.88, 1.48) 1.29 (1.10, 1.53) 
Coagulopathy 1.57 (1.15, 2.16) 1.25 (0.96, 1.63) 
Obesity 1.29 (1.12, 1.47) 1.23 (1.09, 1.40) 
Weight loss 1.05 (0.86, 1.28) 1.09 (0.89, 1.32) 
Fluid and electrolyte 
disorders 1.36 (1.02, 1.82) 1.24 (1.02, 1.51) 
Deficiency anemias 1.29 (1.15, 1.45) 1.25 (1.10, 1.41) 
Alcohol abuse 1.03 (0.81, 1.31) 0.99 (0.79, 1.23) 
Drug abuse 1.35 (1.17, 1.56) 1.20 (1.02, 1.42) 
Psychoses 1.63 (1.30, 2.06) 1.26 (1.01, 1.57) 
Depression 1.36 (1.25, 1.48) 1.26 (1.17, 1.35) 
Index date Index in 2011 1.00 (0.92, 1.07) 0.96 (0.89, 1.03) 
 
Age Stratified Model for Referrals 
 
Age < 50 Age 50-75 
IRR (95% CI) IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.97 (0.81, 1.16) 0.95 (0.81, 1.10) 
Intermediate 0.80 (0.67, 0.96) 0.95 (0.83, 1.08) 
Time 
(ref=1 year pre-index) 
Post-index 0.81 (0.74, 0.89) 0.84 (0.78, 0.90) 
2 Years pre-index 0.71 (0.65, 0.78) 0.72 (0.67, 0.78) 
Time x Risk Category High x. Post-Index 1.33 (1.09, 1.63) 1.36 (1.10, 1.68) 
Intermediate x Post-Index 0.91 (0.74, 1.12) 0.88 (0.77, 1.02) 
Age  1.00 (0.99, 1.02) 0.99 (0.99, 1.00) 
Race  
(ref=White) 
Black 1.08 (0.92, 1.26) 1.13 (1.02, 1.26) 
Hispanic 1.18 (0.95, 1.48) 1.25 (0.97, 1.60) 
Other 1.07 (0.89, 1.30) 1.12 (0.98, 1.28) 
Language (ref=English) 
Haitian Creole 0.83 (0.72, 0.95) 0.84 (0.75, 0.94) 
Spanish 0.93 (0.76, 1.14) 0.93 (0.72, 1.20) 
Other 1.13 (0.96, 1.32) 0.95 (0.85, 1.06) 
Education 
(ref=College) 
<High school 1.05 (0.93, 1.20) 1.06 (0.93, 1.20) 
High School/GED 1.16 (1.01, 1.33) 1.25 (1.10, 1.42) 
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Age < 50 Age 50-75 
IRR (95% CI) IRR (95% CI) 
Some 
College/Voc./Tech/Assoc 1.03 (0.88, 1.22) 1.08 (0.91, 1.28) 
Other/missing 0.88 (0.70, 1.10) 1.01 (0.86, 1.19) 
Primary Insurance 
(ref=Private) 
Public 1.22 (1.10, 1.37) 1.18 (1.07, 1.31) 
Other 1.11 (0.97, 1.27) 0.99 (0.88, 1.12) 
Comorbidities 
Congestive Heart Failure 1.04 (0.73, 1.48) 0.97 (0.78, 1.20) 
Cardiac Arrhythmias 0.98 (0.68, 1.42) 1.03 (0.86, 1.24) 
Valvular Disease 1.04 (0.70, 1.56) 0.93 (0.72, 1.21) 
Pulmonary Circulation 
Disorders 1.44 (0.94, 2.20) 1.39 (1.07, 1.82) 
Peripheral vascular 
disorders 1.61 (1.07, 2.44) 1.22 (1.01, 1.47) 
Hypertension, 
uncomplicated 1.09 (0.99, 1.19) 1.12 (1.03, 1.21) 
Hypertension, 
complicated 0.52 (0.29, 0.94) 0.89 (0.64, 1.23) 
Paralysis 0.98 (0.68, 1.41) 1.37 (1.05, 1.79) 
Other neurological 
disorders 1.17 (0.93, 1.47) 1.50 (1.20, 1.87) 
Chronic pulmonary 
disease 1.11 (0.99, 1.25) 1.18 (1.07, 1.31) 
Diabetes, uncomplicated 1.33 (1.07, 1.65) 1.35 (1.18, 1.54) 
Diabetes, complicated 1.70 (1.30, 2.20) 1.54 (1.36, 1.75) 
Hypothyroidism 1.19 (1.02, 1.38) 1.14 (1.02, 1.26) 
Renal failure 1.36 (1.00, 1.83) 1.20 (1.00, 1.43) 
Liver disease 1.22 (0.94, 1.59) 1.86 (1.42, 2.43) 
Peptic ulcer disease, 
excluding bleeding 0.92 (0.45, 1.89) 0.83 (0.59, 1.16) 
Rheumatoid 
arthritis/collagen vascular 
disorders 
1.21 (0.93, 1.56) 1.21 (0.96, 1.52) 
Coagulopathy 1.68 (1.20, 2.35) 1.05 (0.77, 1.44) 
Obesity 1.40 (1.18, 1.65) 1.27 (1.11, 1.46) 
Weight loss 1.18 (0.97, 1.45) 1.05 (0.87, 1.25) 
Fluid and electrolyte 
disorders 1.01 (0.72, 1.43) 1.05 (0.86, 1.28) 
Deficiency anemias 1.41 (1.23, 1.62) 1.28 (1.11, 1.47) 
Alcohol abuse 1.00 (0.80, 1.23) 0.84 (0.66, 1.08) 
Drug abuse 1.31 (1.12, 1.52) 0.97 (0.80, 1.18) 
Psychoses 1.39 (1.01, 1.90) 0.69 (0.53, 0.91) 
Depression 1.46 (1.33, 1.60) 1.32 (1.21, 1.43) 
Index date Index in 2011 0.97 (0.89, 1.06) 0.96 (0.89, 1.03) 
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Age Stratified Model for Rate of Missed Appointments 
 
Age < 50 Age 50-75 
IRR (95% CI) IRR (95% CI) 
Risk Category 
(ref=low) 
High 0.93 (0.81, 1.06) 0.94 (0.82, 1.07) 
Intermediate 1.04 (0.90, 1.20) 1.11 (0.99, 1.24) 
Time 
(ref=1 year pre-index) 
Post-index 1.19 (1.11, 1.27) 1.26 (1.18, 1.34) 
2 Years pre-index 0.81 (0.75, 0.87) 0.81 (0.76, 0.86) 
Time x Risk Category High x Post-Index 1.01 (0.85, 1.20) 1.15 (0.98, 1.37) 
Intermediate x Post-Index 0.90 (0.80, 1.02) 0.77 (0.68, 0.88) 
Age  1.00 (0.98, 1.01) 1.00 (0.99, 1.01) 
Race 
(ref=White) 
Black 0.84 (0.74, 0.96) 0.91 (0.83, 1.00) 
Hispanic 0.82 (0.67, 1.01) 0.94 (0.79, 1.11) 
Other 0.87 (0.75, 1.00) 0.92 (0.81, 1.03) 
Language (ref=English) 
Haitian Creole 0.88 (0.78, 0.99) 0.87 (0.79, 0.95) 
Spanish 1.04 (0.85, 1.28) 0.89 (0.75, 1.05) 
Other 0.98 (0.86, 1.11) 0.96 (0.86, 1.07) 
Education 
(ref=College) 
<High school 1.02 (0.90, 1.16) 0.96 (0.86, 1.07) 
High School/GED 1.12 (0.99, 1.26) 1.10 (0.98, 1.22) 
Some 
College/Voc./Tech/Assoc 0.95 (0.80, 1.13) 1.18 (1.04, 1.34) 
Other/missing 1.07 (0.87, 1.33) 1.00 (0.88, 1.15) 
Primary Insurance 
(ref=Private) 
Public 1.09 (0.99, 1.19) 1.10 (1.01, 1.20) 
Other 0.97 (0.83, 1.13) 1.00 (0.91, 1.11) 
Comorbidities 
Congestive Heart Failure 1.13 (0.76, 1.66) 1.01 (0.87, 1.18) 
Cardiac Arrhythmias 0.98 (0.74, 1.30) 0.90 (0.78, 1.03) 
Valvular Disease 1.12 (0.79, 1.58) 1.15 (0.99, 1.33) 
Pulmonary Circulation 
Disorders 0.43 (0.18, 1.01) 0.87 (0.68, 1.09) 
Peripheral vascular 
disorders 1.09 (0.79, 1.50) 0.93 (0.81, 1.06) 
Hypertension, 
uncomplicated 1.17 (1.07, 1.28) 1.15 (1.07, 1.23) 
Hypertension, 
complicated 0.44 (0.15, 1.31) 1.05 (0.79, 1.41) 
Paralysis 1.33 (1.01, 1.76) 0.70 (0.39, 1.24) 
Other neurological 
disorders 0.93 (0.72, 1.20) 1.10 (0.96, 1.27) 
Chronic pulmonary 
disease 1.08 (0.96, 1.21) 1.00 (0.92, 1.09) 
Diabetes, uncomplicated 0.70 (0.49, 1.02) 0.91 (0.77, 1.09) 
Diabetes, complicated 0.89 (0.72, 1.11) 0.98 (0.87, 1.12) 
Hypothyroidism 1.19 (1.07, 1.33) 1.03 (0.88, 1.21) 
Renal failure 0.55 (0.31, 0.99) 0.86 (0.71, 1.05) 
Liver disease 1.20 (0.90, 1.60) 0.81 (0.57, 1.16) 
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Age < 50 Age 50-75 
IRR (95% CI) IRR (95% CI) 
Peptic ulcer disease, 
excluding bleeding 1.17 (0.82, 1.65) 0.85 (0.65, 1.10) 
Rheumatoid 
arthritis/collagen vascular 
disorders 
1.41 (1.12, 1.77) 1.29 (1.13, 1.48) 
Coagulopathy 0.76 (0.44, 1.34) 1.18 (1.00, 1.38) 
Obesity 1.06 (0.92, 1.23) 1.20 (1.09, 1.34) 
Weight loss 1.12 (0.90, 1.41) 0.88 (0.74, 1.05) 
Fluid and electrolyte 
disorders 1.01 (0.75, 1.36) 0.97 (0.81, 1.16) 
Deficiency anemias 1.00 (0.88, 1.13) 1.08 (0.94, 1.23) 
Alcohol abuse 0.74 (0.48, 1.12) 0.84 (0.63, 1.12) 
Drug abuse 1.01 (0.84, 1.20) 1.01 (0.86, 1.19) 
Psychoses 1.05 (0.82, 1.36) 0.93 (0.76, 1.15) 
Depression 1.15 (1.06, 1.25) 1.26 (1.18, 1.36) 
Index date Index in 2011 1.04 (0.96, 1.13) 1.05 (0.99, 1.12) 
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